



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

The efficacy of low-load blood flow restricted resistance EXercise in patients with Knee osteoarthritis scheduled for total knee replacement (EXKnee). A multicenter, randomized controlled trial.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-034376
Article Type:	Protocol
Date Submitted by the Author:	17-Sep-2019
Complete List of Authors:	Jørgensen, Stian; Regional Hospital Horsens, Department of occupational and physical therapy; Horsens Sygehus, H-HIP Aagaard, Per; Institute for Sports Science and Clinical Biomechanics, University of Southern Denmark, Bohn, Marie; Horsens Sygehus, Department of Orthopedic Surgery Mechlenburg, Inger; Aarhus University Hospital, Department of Orthopedics; Aarhus University, Clinical Medicine
Keywords:	blood flow restriction exercise, knee osteoarthritis, total knee replacement surgery, preconditioning, functional capacity

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

The efficacy of low-load blood flow restricted resistance EXercise in patients with Knee osteoarthritis scheduled for total knee replacement (EXKnee). A multicenter, randomized controlled trial.

Stian Langgård Jørgensen^{1,2,5}, Marie Bagger Bohn², Per Aagaard³, Inger Mechlenburg^{4,5}

¹Department of Occupational and Physical Therapy. Regional Hospital Horsens, Denmark

²H-HIP, Department of Orthopedic Surgery, Regional Hospital Horsens, Denmark

³Department of Sports Science and Clinical Biomechanics, University of Southern Denmark

⁴ Department of Orthopedic Surgery , Aarhus University Hospital, Denmark

⁵Department of clinical Medicine, Aarhus University, Denmark

Corresponding Author:

Name: PhD student Stian Langgård Jørgensen

Address: Regional Hospital Horsens, Sundvej 30C, DK-8700 Horsens

E-mail: stiajo@rm.dk

Phone: +45 22 71 17 82

Word count: 2.648

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction

Up to 20% of patients undergoing total knee replacement (TKR) surgery report no or suboptimal pain relief after TKR. Moreover, despite chances of recovering to preoperative functional levels, patients receiving TKR have demonstrated persistent deficits in quadriceps strength and functional performance compared to healthy aged-matched adults. We intend to examine if low-load blood flow restricted exercise (BFRE) is an effective preoperative method to increase functional capacity, lower limb muscle strength and self-reported outcomes after TKR. In addition we seek to investigate to which extent preoperative BFRE will protect against surgery-related atrophy 3 months after TKR. Specifically, the primary aim of this trial is to examine the efficacy 8 weeks of low-load BFRE prior to a scheduled TKR on changes in 30-seconds Chair stand test from baseline to 3 months after TKR. As a secondary aim, the effect of preoperative BFRE on maximal knee extensor strength (MVC), functional capacity, patient-reported outcome (Knee Injury and Osteoarthritis Outcome Score) and selected myofiber properties (fiber CSA, myogenic stem cell content, myonuclei density) also will be examined also.

Method and analysis

The trial is a multicenter, randomized controlled and assessor blinded trial, where patients scheduled for TKR will be randomized to either 8 weeks of preoperative BFRE or serve as a control group following usual care before TKR. Data will be collected at baseline, in the week of TKR, 6 weeks (questionnaires only), 3 months, and 12 months after TKR.

Ethical approval and dissemination

The trial has been accepted by Central Denmark Region Committee on Biomedical Research Ethics (Journal No 10-72-19-19) and by The Danish Data Protection Agency (Journal No 652164). All results from the trial will be published in international peer-reviewed scientific journals regardless of whether the results are positive, negative or inconclusive.

Trial registration

The trial is registered at Clinical Trial (NCT04081493)

Article Summary

Strengths and limitations of this study

- The trial is a multicenter, randomized controlled assessor blinded trial.
- This is the first clinical trial to investigate the effect of low-load ischemic resistance training as a preconditioning method prior to elective knee replacement surgery.
- Patients will not be blinded to their allocation into intervention groups (BFR vs. control)

Key words

Blood flow restricted exercise, knee osteoarthritis, total knee replacement surgery, preconditioning

INTRODUCTION

Knee OA is a degenerative joint disease associated with pain, reduced physical activity, and quality of life affecting almost 40% of all individuals ≥ 60 years of age¹⁻⁵. Approaching end-stage knee OA, total knee replacement (TKR) is often the preferred treatment choice to reduce pain and regain functional capacity. However, despite TKR patients typically demonstrate long-lasting deficits in quadriceps strength and functional performance^{2, 4}. This failure to return to “normal” strength levels has been suggested to be associated with preoperatively lower limb muscle strength and function².

Preconditioning exercise, designed to prepare the musculoskeletal system to better tolerate the stressful events such as the impact of invasive surgery has been suggested to be applicable prior to elective TKR⁶. Muscle atrophy is known to occur postoperatively, which may explain the marked functional deficits reported to persist for years^{6, 7}. Previous research on exercise-based intervention prior to TKR has demonstrated mixed results⁶⁻¹², as a likely result of insufficient exercise intensity, training volume, and/or lack of effective progression strategies⁹. Heavy-resistance strength training (HRST) is an often-used method for improving, skeletal muscle strength, hypertrophy and functional capacity in healthy and clinical populations^{4, 7, 12-15}. However joint pain resulting from the high mechanical loads associated with HRST often represents a barrier to this type of training in knee OA patients^{1, 16}. Resistance training with low exercise loads ($\sim 30\%$ 1 repetition maximum) performed with concurrent partial blood flow restriction to the working limb (Blood flow restricted exercise: BFRE) has received increasing clinical interest during the last decade^{1, 16-34}. The application of low muscle/tendon/joint forces in BFRE has been documented to increase human skeletal muscle size and to cause substantial strength gains in healthy young and old individuals¹⁷, despite the low magnitude of mechanical stress imposed on the trained tissue. The adaptive mechanisms evoked by BFRE seem to involve accumulation of metabolites, ischemia (transient

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

tissue hypoxia) and activation of myogenic muscle stem cells (satellite cells: SC) ^{17, 24, 35}. When applied in the clinical setting, BFRE has demonstrated positive effects on skeletal muscle hypertrophy, strength, and functional capacity in mild-degree knee OA patients ^{1, 16, 33, 34}, although not observed in all studies ³³. Importantly, BFRE appears to be feasible with a high training adherence in knee OA patients ^{1, 33, 34}.

Satellite cells (SC) are quiescent myogenic stem cells positioned between the sarcolemma and the myofiber basal lamina ^{24, 36}. SC plays an important role in human skeletal muscle growth due to their ability to donate new myonuclei to the muscle fibers ^{24, 37-41}. The human skeletal muscle fibers are multinucleated cells with each myonucleus controlling the protein synthesis of a certain cytoplasmatic area in the muscle fiber ^{37-39, 41, 42}. Myonuclei transcriptional activity can be fully maximized with exercise, hence requiring new myonuclei to support further muscle tissue accretion ³⁸⁻⁴³. Furthermore, exercise-induced increases in SC and myonuclei content by means of preconditioning BFRE might represent an effective atrophy-protective mechanism ^{24, 44}. Previous studies applying short term (10 days) preoperative BFRE before an anterior cruciate ligament rupture-reconstruction demonstrated no atrophy protective effect nor higher postoperative muscle strength compared to performing a low-load exercise without blood flow restriction (placebo) .

Aim and hypothesis of the trial

The primary aim of this trial is to investigate the efficacy of 8 weeks of BFRE compared to receiving usual care prior to TKR on postoperative chair stand performance. We hypothesize that 8 weeks of preoperative BFRE will lead to increased performance 30 seconds chair stand performance (30-seconds Chair Stand Test: 30-s CST) when assessed 3 months postoperatively. Secondary aims are to investigate the efficacy of preoperative BFRE on lower limb muscle strength 3 months after TKR and investigate the potential relationship to functional capacity and quality of

life. Furthermore, it will be investigated to which extent 8 weeks of BFRE induces myofiber hypertrophy and gains in satellite cell number and myonuclei content in the knee extensor musculature.

MATERIAL & METHODS

Design

The trial is designed as a multicenter (2 sites), randomized, assessor blinded, controlled trial following the CONSORT guidelines⁴⁵. Primary endpoint will be 3 months after TKR. Additional and secondary endpoints will be evaluated during the week of TKR, 6 weeks after TKR (questionnaires only) and 12 months after TKR. Muscle biopsies will be obtained from all patients undergoing surgery at Horsens Regional Hospital at baseline, during surgery and 3 months after TKR.

Participants

Patient will be recruited from the Orthopedic Departments at Horsens and Silkeborg Regional Hospitals.

Inclusion criteria: 1) Patients ≥ 50 years scheduled for TKR at Horsens- or Silkeborg Regional Hospital.

Exclusion criteria: 1) Severe cardiovascular diseases (New York Heart Association (NYHA) class III and IV), previous stroke incident, thrombosis incident; 2) Traumatic nerve injury in affected limb 3) Unregulated hypertension (Systolic ≥ 180 or diastolic ≥ 110 mmHg) 4) Spinal cord injury; 5) Planned other lower limb surgery within 12 months; 6) Cancer diagnosis and currently undergoing chemo-, immuno-, or radiotherapy; 7) Inadequacy in written and spoken Danish; 8) an existing

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

prosthesis in the index limb; 9) living more than 45 minutes from either Horsens Regional Hospital or Silkeborg Regional Hospital; 10) Pregnancy.

The orthopedic surgeon will perform the initial inclusion of study participants. In case the patient agrees to participate in the trial, the patient will be baseline-tested at the hospital by a blinded (to group allocation) assessor. Patients declining to participate in the RCT will be offered the option of participating in a parallel observational cohort trial.

Randomization

After baseline assessment, patients will be randomized (1:1) using Research Electronic Data Capture (REDCap) randomization system to either the training (BFRE) group or the control (CON) group. Prior to randomization, all patients will be booked for follow-up test sessions and surgery. All randomization procedures will be performed by the physiotherapists in charge of the BFRE training. Assessors performing the tests will be blinded to group allocation until completion of the trial. A flow chart of the patient allocation procedures is depicted in Figure 1.

CON group: Participants in the CON group will follow usual care before a TKR and be encouraged to continue their usual lifestyle up until TKR.

BFRE group: Will perform supervised BFRE sessions 3 times per week for 8 weeks supervised by a physiotherapist educated in administering BFRE. All BFRE sessions will be performed at either Horsens Regional Hospital or Silkeborg Regional Hospital.

Insert figure 1 here

Intervention procedures

BFRE

Each BFRE session will consist of a 10-min warm up (ergometer cycling) followed by two different unilateral lower-limb resistance training exercises: 1) leg press and 2) knee extension performed in standard strength training machines. Each exercise will be performed with the affected lower limb only and consist of 4 rounds interspaced by 30 seconds of rest. 1st round: 30 repetitions (reps); 2nd round: 15 reps; 3rd round: 15 reps; 4th round: until exhaustion. If patients can perform more than 15 repetitions in the 4th exercise set, the exercise load will be increased with the minimum extra load possible²⁵. Participants will be instructed to perform both the eccentric and concentric contraction phases using a steady 2-sec pace duration. The 4th and final exercise set will be performed to the point of exhaustion defined as being unable to complete the final concentric contraction phase in 2 seconds. During the 30 sec rest period, patients will rest in a standardized resting position while maintaining the initial cuff-pressure. Between each exercise patients will have a 5-min "free-flow" rest period. The cuff will be released immediately after completion of the final exercise set.

The occlusion pressure during both exercises will be set at 60% of total limb occlusion pressure (LOP) and starting load intensity will be 30% 1 repetition maximum (1RM) in both exercises.

Individual LOP will be determined using a pneumatic, conically shaped, 12 cm wide, rigid cuff (Occlude Aps, Denmark) attached to the patient's most proximal area of the thigh on the affected side. While sitting on an examination table with the ankle and 1/3 of the lower limb off the table, a vascular Doppler probe (EDAN Instruments, inc., China) will be placed posterior to the medial malleolus over the posterior tibial artery to capture the auscultatory pulse. To determine the cuff

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

pressure (mmHg) needed for total blood flow occlusion, the cuff will gradually be inflated in 20 mmHg steps until reaching the pressure where the auscultatory pulse is interrupted (LOP). First time the auscultatory pulse is interrupted the examiner releases 10-20 mmHg pressure from the cuff until the auscultatory pulse is present again. When the auscultatory pulse reappears the cuff is inflated with 10 mmHg until LOP is found again. If the second LOP is identical to the first it will be defined as LOP for that specific patient. Otherwise, the procedure will be repeated until determining an identical LOP two consecutive times.

Insert table 1 here

Outcome variables

Outcome assessments will be performed at baseline, in the week of surgery, 6 weeks after TKR, 3 months after TKR, and 12 months after TKR. Six weeks after TKR only questionnaires will be completed. Two testers (the PhD-stipendiate and a trained physiotherapist) blinded to group allocation will perform all baseline and follow-up measurements. Bergström needle muscle biopsies⁴⁶ will be taken from vastus lateralis of the quadriceps in both lower limbs from patients included at Regional Hospital Horsens only at baseline, during surgery, and 3 months after TKR by doctors trained in performing the procedure. An overview of the data collection parameters is presented in Table 2.

Primary outcome variable

The primary outcome measure will be the change from baseline to 3 months follow-up in 30s-CST. The 30s-CST measures the number of sit-to-stand repetitions completed within 30 seconds^{47, 48} and is a part of the OARSI-recommended minimum outcome core set representing the ability to perform

a sit-to-stand activity⁴⁹. The 30s-CST is considered a valid and sensitive measure of lower-extremity sit-to-stand function with good to excellent intra- and inter-observer reliability⁴⁷⁻⁵⁰.

Secondary outcome variables

Secondary outcome measures comprise The Timed Up and Go test⁵⁰⁻⁵², 40-m fast-paced walk test⁵⁰, maximal isometric knee extensor and knee flexor strength assessed with hand-held dynamometry⁵³,⁵⁴, knee extensor (VL) myofiber area, fibertype composition, satellite cell content, myonuclei number¹⁴, the Knee disability and Osteoarthritis Outcome Score^{55, 56}, EuroQol Group 5-dimensions⁵⁷, Numeric Ranking Scale for pain (NRS)⁵⁸, and adverse events/postponement of TKR.

Explorative outcome variables

Type of postoperative rehabilitation received, medication, knee joint range of motion

Demographic data

Gender, age, height, weight, civil status, level of educational, employment status, substance use (alcohol and smoking), duration of knee symptoms, pain medication during past week due to knee-related pain, and co-morbidities.

Adherence

Adherence to training will be registered by the physiotherapists in charge of the exercise sessions.

High compliance is defined as attendance to the supervised BFRE of $\geq 80\%$.

Insert table 2 here

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Sample size

The power and sample size calculation is based on the expected differences between the two subject groups from baseline to 3 months follow up ⁸. Skoffler et al. ⁸ investigated the efficacy of 4 weeks of preoperative and 4 weeks postoperative HRST (intervention group) compared to 4 weeks of postoperative HRST only (control group) on 30-s CST 3 months after TKR ⁸. The authors found a between-group difference of 3-4 repetition difference (14.7 ± 4.7 repetitions versus 11.0 ± 4.4 repetitions) 3 months after TKR ⁸.

To reduce the probability of type I errors and be able to detect a between-group difference also, α -level is set at 0.05 ($p < 0.05$) and β -level is set at 0.20 (80% power). Expecting a 3-repetitions between-group difference 3 months postoperatively and assuming a SD of 4.7 in both groups, 39 patients are required in each group (yielding a total of 78 patients). With an anticipated dropout rate of 10%, a total of 84 patients will be recruited for the trial.

Statistical considerations

The primary efficacy analysis will be assessment of the between group difference in change in the 30-S CST from baseline to 3 months follow up (primary end point).

All descriptive statistics and tests will be reported in accordance with the recommendations of the “Enhancing the QUALity and Transparency Of health Research” (EQUATOR) network⁵⁹ and the CONSORT statement⁴⁵. Intention-to-treat principle (i.e. all patients as randomized independent of departures from allocation treatment, compliance and/or withdrawals) and per protocol analysis will be conducted. A one-way analysis of variance (one-way ANOVA) model will be used to analyze between group mean changes in continuous outcome measures ²⁴. The model includes changes from baseline to 12 months follow-up. Between-intervention comparison from baseline to 3 months after surgery will be analyzed using a mixed linear model with patient ID as a random

effect and time and group as fixed effects^{24, 60}. Also, to gain insights into the potential pre-to-post training differences within the respective training or control groups, paired student t-tests will be performed. Level of statistical significance is $P < 0.05$. *Secondary outcome variables*: Between-intervention comparison from baseline to the week of surgery, 6 weeks after surgery, 3 and 12 months after surgery will be analyzed as described for the primary outcome. Regression analysis will be used to analyze the potential associations between preoperative strength and postoperative lower extremity function and self-reported outcome as well as between preoperative functional capacity and postoperative functional capacity. Additionally, regression analysis will be used to analyze the association between preoperative number of satellite cells and myonuclei on postoperative isometric knee extensor muscle strength, muscle fiber cross sectional area, and functional capacity. All statistical analysis will be performed using Stata.

Ethical aspects and dissemination

The trial has been accepted by Central Denmark Region Committee on Biomedical Research Ethics (Journal No 10-72-19-19) and by The Danish Data Protection Agency (Journal No 652164). The trial is registered at Clinicaltrial.gov (NCT04081493). Before inclusion, all patients will provide their written informed consent in accordance with the Helsinki Declaration. All data and information collected in regard to this trial will be treated confidentially (blinded and encrypted) by the researchers and staff connected to the trial.

All results from the trial will be published in international peer-reviewed scientific journals regardless of the results being considered positive, negative or inconclusive.

Patient and public involvement

Before developing this clinical trial, a pilot project was performed to determine feasibility and

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

efficacy of BFRE in patients suffering from lower limb injuries. The experiences with the training modality and also the verbal feedback from patients on training duration, frequency, and intensity resulted in useful knowledge that certainly have improved the development of the present clinical trial.

DISCUSSION

To our best knowledge, this is the first trial to investigate the effect of preoperative BFRE on functional capacity, self-reported outcome, lower limb muscle strength and myofiber morphology/stem cell abundance in patients scheduled for TKR. Only few studies have investigated (short term (10 days)) preoperative BFRE without finding an atrophy protective effect or difference in muscle strength compared to a control group performing a placebo intervention (SHAM group)⁶¹. However, patients performing short term preoperative BFRE before ACL-R demonstrated higher muscle endurance compared to a SHAM group⁶². Therefore, results of this trial are expected to provide novel information on longer periods of BFRE that will enable to design effective exercise-based preconditioning protocols for elective TKR patients.

The trial is designed as an assessor blinded randomized controlled trial, thus representing the highest evidence level. However, the nature of the trial does not allow blinding of the participants which is an inherent limitation of the trial. The trial is conducted at two hospitals that consistently perform a high number TKR procedures annually (225 and 460, respectively), thus securing a strong expertise in terms of surgery and infrastructure. Both hospitals have all equipment needed available for surgery, post-operative hospitalization, training and testing. All outcome variables are considered valid and reliable measures and consist of both objective outcomes and self-reported patient outcomes.

No adverse health-related events have been reported in previous studies applying BFRE in patients' suffering from knee OA or in healthy older adults^{1, 16, 17, 27, 33, 34}. Further, in a recent review and meta-analysis it was stated that exercise with concurrent blood-flow restriction is a safe exercise modality when occlusion procedures are applied correctly¹⁷. The inherent invasive procedure of muscle biopsies may cause adverse events in rare occasions. Therefore, all muscle biopsy samples will be collected by trained medical doctors and performed following administration of local anesthesia and in fully sterile conditions. The needle muscle biopsy protocol have been applied in a large number of previous investigations including very old frail subjects (97 years of age) without any reporting of adverse events besides occasional muscle soreness^{15, 24, 46, 63, 64}.

Author contributions

All authors contributed to the design of the trial as well as to the writing of the manuscript and approved the final version of the protocol.

Data statement

All obtained data will be stored in anonymized form at the Danish National Archives and deleted after 10 years.

Funding

This work trial is supported by Aase og Ejnar Danielsens Foundation (100.000 dkk) and The Foundation for health research of Central Denmark Region (99.658 dkk).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Competing interest

None to be declared

Ethics approval

The trial has been accepted by Central Denmark Region Committee on Biomedical Research Ethics (Journal No 10-72-19-19) and by The Danish Data Protection Agency (Reference No 652164).

Word count

2.648 words

References

1. Ferraz RB, Gualano B, Rodrigues R, Kurimori CO, Fuller R, Lima FR, De Sá-Pinto AL, Roschel H. Benefits of resistance training with blood flow restriction in knee osteoarthritis. *Med Sci Sports Exerc* 2018.
2. Bade MJ, Kohrt WM, Stevens-Lapsley J. Outcomes before and after total knee arthroplasty compared to healthy adults. *J Orthop Sports Phys Ther* 2010.
3. Fransen M, McConnell S, Harmer AR, Van de, Simic M, Bennell KL. Exercise for osteoarthritis of the knee. *Cochrane Database of Systematic Reviews* 2015.
4. Skoffler B, Dalgas U, Mechlénburg I. Progressive resistance training before and after total hip and knee arthroplasty: A systematic review. *Clin Rehabil* 2015.
5. Sundhedsstyrelsen. Knæartrose - nationale kliniske retningslinjer og faglige visitationsretningslinjer. ; 2012. .
6. Franz A, Queitsch FP, Behringer M, Mayer C, Krauspe R, Zilkens C. Blood flow restriction training as a prehabilitation concept in total knee arthroplasty: A narrative review about current preoperative interventions and the potential impact of BFR. *Med Hypotheses* 2018.
7. Suetta C. Training-induced changes in muscle CSA, muscle strength, EMG, and rate of force development in elderly subjects after long-term unilateral disuse. *J Appl Physiol* 2004;97(5):1954-61.
8. Skoffler B, Maribo T, Mechlénburg I, Hansen PM, Søballe K, Dalgas U. Efficacy of preoperative progressive resistance training on postoperative outcomes in patients undergoing total knee arthroplasty. *Arthritis Care & Research* 2016.
9. Chesham RA, Shanmugam S. Does preoperative physiotherapy improve postoperative, patient-based outcomes in older adults who have undergone total knee arthroplasty? A systematic review. *Physiotherapy Theory and Practice* 2017.
10. Jagers JR, Simpson CD, Frost KL, Quesada PM, Topp RV, Swank AM, Nyland JA. Prehabilitation before knee arthroplasty increases postsurgical function: A case study. *Journal of Strength and Conditioning Research* 2007.
11. Rooks DS, Huang J, Bierbaum BE, Bolus SA, Rubano J, Connolly CE, Alpert S, Iversen MD, Katz JN. Effect of preoperative exercise on measures of functional status in men and women undergoing total hip and knee arthroplasty. *Arthritis Care and Research* 2006.
12. Calatayud J, Casaña J, Ezzatvar Y, Jakobsen MD, Sundstrup E, Andersen LL. High-intensity preoperative training improves physical and functional recovery in the early post-operative periods after total knee arthroplasty: A randomized controlled trial. *Knee Surgery, Sports Traumatology, Arthroscopy : Official Journal of the ESSKA* 2016.
13. Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM, Nieman DC, Swain DP. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: Guidance for prescribing exercise. *Med Sci Sports Exerc* 2011;43(7):1334-59.
14. Aagaard P, Andersen JL, Dyhre-Poulsen P, Leffers AM, Wagner A, Peter Magnusson S, Halkjær-Kristensen J, Simonsen EB. A mechanism for increased contractile strength of human pennate muscle in response to strength training: Changes in muscle architecture. *J Physiol (Lond)* 2001;534(2):613-23.
15. Andersen J, Aagaard P. Myosin heavy chain IIX overshoot in human skeletal muscle. *Muscle Nerve* 2000;23:1095-104.
16. Bryk FF, dos Reis AC, Fingerhut D, Araujo T, Schutzer M, Cury RdPL, Duarte A, Fukuda TY. Exercises with partial vascular occlusion in patients with knee osteoarthritis: A randomized clinical trial. *Knee Surgery, Sports Traumatology, Arthroscopy* 2016;24(5):1580-6.
17. Hughes L, Paton B, Rosenblatt B, Gissane C, Patterson SD. Blood flow restriction training in clinical musculoskeletal rehabilitation: A systematic review and meta-analysis. *Br J Sports Med* 2017.
18. Loenneke JP, Wilson JM, Balapur A, Thrower AD, Barnes JT, Pujol TJ. Time under tension decreased with blood flow-restricted exercise. *Clin Physiol Funct Imaging* 2012 Jul;32(4):268-73.
19. Loenneke JP, Thrower AD, Balapur A, Barnes JT, Pujol TJ. Blood flow-restricted walking does not result in an accumulation of metabolites. *Clin Physiol Funct Imaging* 2012 Jan;32(1):80-2.
20. Loenneke JP, Fahs CA, Rossow LM, Sherk VD, Thiebaud RS, Abe T, Bemben DA, Bemben MG. Effects of cuff width on arterial occlusion: Implications for blood flow restricted exercise. *Eur J Appl Physiol* 2012 Aug;112(8):2903-12.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

21. Loenneke JP, Young KC, Fahs CA, Rossow LM, Bembien DA, Bembien MG. Blood flow restriction: Rationale for improving bone. *Med Hypotheses* 2012 Apr;78(4):523-7.

22. Loenneke JP, Kim D, Fahs CA, Thiebaud RS, Abe T, Larson RD, Bembien DA, Bembien MG. The influence of exercise load with and without different levels of blood flow restriction on acute changes in muscle thickness and lactate. *Clinical Physiology and Functional Imaging* 2017.

23. Ozaki H, Loenneke JP, Abe T. Blood flow-restricted walking in older women: Does the acute hormonal response associate with muscle hypertrophy? *Clin Physiol Funct Imaging* 2017 Jul;37(4):379-83.

24. Nielsen JL, Aagaard P, Bech RD, Nygaard T, Hvid LG, Wernbom M, Suetta C, Frandsen U. Proliferation of myogenic stem cells in human skeletal muscle in response to low-load resistance training with blood flow restriction. *J Physiol (Lond)* 2012;590(17):4351-61.

25. Jørgensen AN, Aagaard P, Nielsen JL, Frandsen U, Diederichsen LP. Effects of blood-flow-restricted resistance training on muscle function in a 74-year-old male with sporadic inclusion body myositis: A case report. *Clinical Physiology and Functional Imaging* 2016;36(6):504-9.

26. Kubo K, Komuro T, Ishiguro N, Tsunoda N, Sato Y, Ishii N, Kanehisa H, Fukunaga T. Effects of low-load resistance training with vascular occlusion on the mechanical properties of muscle and tendon. *Journal of Applied Biomechanics* 2006;22(2):112-9.

27. Ozaki H, Sakamaki M, Yasuda T, Fujita S, Ogasawara R, Sugaya M, Nakajima T, Abe T. Increases in thigh muscle volume and strength by walk training with leg blood flow reduction in older participants. *J Gerontol A Biol Sci Med Sci* 2011 Mar;66(3):257-63.

28. Ozaki H, Loenneke JP, Thiebaud RS, Stager JM, Abe T. Possibility of leg muscle hypertrophy by ambulation in older adults: A brief review. *Clin Interv Aging* 2013;8:369-75.

29. TAKARADA Y, TAKAZAWA H, ISHII N. Applications of vascular occlusion diminish disuse atrophy of knee extensor muscles. *Med Sci Sports Exerc* 2000;32(12):2035-9.

30. Takarada Y, Takazawa H, Sato Y, Takebayashi S, Tanaka Y, Ishii N. Effects of resistance exercise combined with moderate vascular occlusion on muscular function in humans. *Journal of Applied Physiology (Bethesda, Md.: 1985)* 2000;88(6):2097-106.

31. Takarada Y, Nakamura Y, Aruga S, Onda T, Miyazaki S, Ishii N. Rapid increase in plasma growth hormone after low-intensity resistance exercise with vascular occlusion. *J Appl Physiol (1985)* 2000 Jan;88(1):61-5.

32. Yamanaka T, Farley RS, Caputo JL. Occlusion training increases muscular strength in division IA football players. *J Strength Cond Res* 2012 Sep;26(9):2523-9.

33. Segal N, Davis MD, Mikesky AE. Efficacy of blood flow-restricted low-load resistance training for quadriceps strengthening in men at risk of symptomatic knee osteoarthritis. *Geriatr Orthop Surg Rehabil* 2015 Sep;6(3):160-7.

34. Segal NA, Williams GN, Davis MC, Wallace RB, Mikesky AE. Efficacy of blood flow-restricted, low-load resistance training in women with risk factors for symptomatic knee osteoarthritis. *PM R* 2015 Apr;7(4):376-84.

35. Scott BR, Loenneke JP, Slaterry KM, Dascombe BJ. Exercise with blood flow restriction: An updated evidence-based approach for enhanced muscular development. *Sports Med* 2015 Mar;45(3):313-25.

36. Mauro A. Satellite cell of skeletal muscle fibers. *The Journal of Biophysical and Biochemical Cytology* 1961.

37. Kadi F, Charifi N, Denis C, Lexell J. Satellite cells and myonuclei in young and elderly women and men. *Muscle and Nerve* 2004.

38. Olsen S, Aagaard P, Kadi F, Tufekovic G, Verney J, Olesen JL, Suetta C, Kjær M. Creatine supplementation augments the increase in satellite cell and myonuclei number in human skeletal muscle induced by strength training. *J Physiol (Lond)* 2006.

39. Francaux M, Deldicque L. Exercise and the control of muscle mass in human. *Pflügers Archiv - European Journal of Physiology* 2018 10.

40. Kadi F, Schjerling P, Andersen LL, Charifi N, Madsen J, Christensen LR, Andersen JL. The effects of heavy resistance training and detraining on satellite cells in human skeletal muscles. *J Physiol (Lond)* 2004.

41. Bazgir B, Fathi R, Valojerdi MR, Mozdziak P, Asgari A. Satellite cells contribution to exercise mediated muscle hypertrophy and repair. *Cell Journal* 2016.

42. Kadi F, Thornell LE. Concomitant increases in myonuclear and satellite cell content in female trapezius muscle following strength training. *Histochem Cell Biol* 2000.

43. Petrella JK, Kim J-, Mayhew DL, Cross JM, Bamman MM. Potent myofiber hypertrophy during resistance training in humans is associated with satellite cell-mediated myonuclear addition: A cluster analysis. *J Appl Physiol* 2008.
44. Bruusgaard JC, Johansen IB, Egner IM, Rana ZA, Gundersen K. Myonuclei acquired by overload exercise precede hypertrophy and are not lost on detraining. *Proceedings of the National Academy of Sciences* 2010.
45. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG, CONSORT. CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials. *Int J Surg* 2012;10(1):28-55.
46. Suetta C, Andersen JL, Dalgas U, Berget J, Koskinen S, Aagaard P, Magnusson SP, Kjaer M. Resistance training induces qualitative changes in muscle morphology, muscle architecture, and muscle function in elderly postoperative patients. *Journal of Applied Physiology* (Bethesda, Md.: 1985) 2008;105(1):180-6.
47. Gill S, McBurney H. Reliability of performance-based measures in people awaiting joint replacement surgery of the hip or knee. *Physiother Res Int* 2008 Sep;13(3):141-52.
48. Jones CJ, Rikli RE, Beam WC. A 30-s chair-stand test as a measure of lower body strength in community-residing older adults. *Res Q Exerc Sport* 1999 Jun;70(2):113-9.
49. Dobson F, Bennell KL, Hinman RS, Abbott JH, Roos EM. Recommended performance - based tests to assess physical function in people diagnosed with hip or knee osteoarthritis. OARSI - Osteoarthritis Research Society International 2013.
50. Wright AA, Cook CE, Baxter GD, Dockerty JD, Abbott JH. A comparison of 3 methodological approaches to defining major clinically important improvement of 4 performance measures in patients with hip osteoarthritis. *J Orthop Sports Phys Ther* 2011 May;41(5):319-27.
51. Bloch ML, Jonsson LR, Kristensen MT. Introducing a third timed up & go test trial improves performances of hospitalized and community-dwelling older individuals. *J Geriatr Phys Ther* 2017 Jul/Sep;40(3):121-6.
52. Alghadir A, Anwer S, Brismée J. The reliability and minimal detectable change of timed up and go test in individuals with grade 1-3 knee osteoarthritis. *BMC Musculoskeletal Disorders* 2015.
53. C. N, V.A.B. S, Y. L, I. K, M V, Der Hulst, R.H.H. E, R.W. P. Reliability of hand-held dynamometry in patients awaiting total knee arthroplasty. *Physiotherapy (United Kingdom)* 2011.
54. Koblauer IFH, Lambrecht Y, Van DH, Neeter C, Engelbert RHH, Poolman RW, Scholtes VA. Reliability of maximal isometric knee strength testing with modified hand-held dynamometry in patients awaiting total knee arthroplasty: Useful in research and individual patient settings? A reliability study. *BMC Musculoskeletal Disorders* 2011.
55. Lyman S, Lee YY, McLawhorn AS, Islam W, MacLean CH. What are the minimal and substantial improvements in the HOOS and KOOS and JR versions after total joint replacement? *Clin Orthop Relat Res* 2018 Dec;476(12):2432-41.
56. Roos EM, Lohmander LS. The knee injury and osteoarthritis outcome score (KOOS): From joint injury to osteoarthritis. *Health and Quality of Life Outcomes* 2003.
57. Wittrup-Jensen KU, Lauridsen J, Gudex C, Pedersen KM. Generation of a danish TTO value set for EQ-5D health states. *Scand J Public Health* 2009 Jul;37(5):459-66.
58. Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual analog scale for pain (VAS pain), numeric rating scale for pain (NRS pain), McGill pain questionnaire (MPQ), short-form McGill pain questionnaire (SF-MPQ), chronic pain grade scale (CPGS), short form-36 bodily pain scale (SF-36 BPS), and measure of intermittent and constant osteoarthritis pain (ICOAP). *Arthritis Care Res (Hoboken)* 2011 Nov;63 Suppl 11:S240-52.
59. Christensen R, Bliddal H, Henriksen M. Enhancing the reporting and transparency of rheumatology research: A guide to reporting guidelines. *Arthritis Res Ther* 2013 Feb 28;15(1):109.
60. Malcata RM, Hopkins WG, Pearson SN. Tracking career performance of successful triathletes. *Med Sci Sports Exerc* 2014 Jun;46(6):1227-34.
61. Grapar Zargi T, Drobic M, Jkoder J, Strazar K, Kacin A. The effects of preconditioning with ischemic exercise on quadriceps femoris muscle atrophy following anterior cruciate ligament reconstruction: A quasi-randomized controlled trial. *Eur J Phys Rehabil Med* 2016 Jun;52(3):310-20.
62. Zargi T, Drobic M, Strazar K, Kacin A. Short-term preconditioning with blood flow restricted exercise preserves quadriceps muscle endurance in patients after anterior cruciate ligament reconstruction. *Front Physiol* 2018 Aug 24;9:1150.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

63. Malm C, Nyberg P, Engstrom M, Sjodin B, Lenkei R, Ekblom B, Lundberg I. Immunological changes in human skeletal muscle and blood after eccentric exercise and multiple biopsies. *J Physiol* 2000 Nov 15;529 Pt 1:243-62.

64. Ekblom B. The muscle biopsy technique. historical and methodological considerations. *Scand J Med Sci Sports* 2017 May;27(5):458-61.

For peer review only

Tables

Table 1. Exercise variables for the blood-flow restricted exercise (BFRE) protocol

Exercise variable	Week 1-8
Level of LOP	60% LOP
Sets	4
Load intensity	30% 1RM
Repetitions 1 st set	30
Repetitions 2 nd & 3 rd set	15
Repetitions 4 th set	To volitional failure
Contraction modes per repetition	
Concentric	2 seconds
Isometric	0 seconds
Eccentric	2 seconds
Rest between repetitions	0 seconds
Time under tension per repetition	4 seconds
Range of movement	maximum
Rest between sets	30 seconds
Rest between sessions	≥36 hours
Progression	The minimal possible load (5 kilo) is added when patients perform >15 repetitions in 4 th set

Table 2. Outcome measures to be collected.

Outcome measures	Data collection instrument	Time-points of assessment
Primary outcome		
Sit-to-stand function	30 seconds chair stand test	B, S, 3 and 12 months
Secondary outcomes		
Isometric Knee extensor muscle strength	Handheld Dynamometer	B, S, 3 and 12 months
Isometric Knee flexion muscle strength	Handheld Dynamometer	B, S, 3 and 12 months
Gait speed	4x10-meter walk test	B, S, 3 and 12 months
Ambulatory capacity	Timed Up & Go	B, S, 3 and 12 months
Muscle morphology and biology	Muscle Biopsies	B, D, 3 months
Pain	KOOS	B, S, 6 weeks, 3 and 12 months
Symptoms	KOOS	B, S, 6 weeks, 3 and 12 months
Activities of daily living	KOOS	B, S, 6 weeks, 3 and 12 months
Sports & Recreation	KOOS	B, S, 6 weeks, 3 and 12 months
Quality of life	KOOS	B, S, 6 weeks, 3 and 12 months
Socioeconomic costs	EQ-5D	B, S, 6 weeks, 3 and 12 months
Adverse Events	Questionnaire and medical records	S, 3 months
Patient characteristics and related measurements		
Gender	Questionnaire	B
Age	Questionnaire	B
Height	Tape measure	B
Body mass	Electronic body mass scale	B
Civil Status	Questionnaire	B
Educational Level	Questionnaire	B
Employment Status	Questionnaire	B
Substance Use (alcohol, smoking)	Questionnaire	B
Duration of knee symptoms	Questionnaire	B
Pain medication during the last week	Questionnaire	B

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Com-morbidities	Questionnaire	B
Blood pressure	Electronic upper limb blood pressure monitor	During the exercise period
Postoperative supervised physiotherapy	Questionnaire	B, S, at each BBFRE session, 3
Exercise compliance and progression	Physiotherapist records	and 12 months
NRS	PhD-stipendiate and physiotherapist records	

For peer review only

```
graph TD
    A[Patients scheduled for a TKR at Horsens Regional Hospital and Silkeborg Regional Hospital  
Assessed for eligibility (n)] --> B[Enrolment]
    A --> C[Excluded (n)  
- Not meeting inclusion criteria (n)  
- Declining to participate  
- Other reasons (n)]
    B --> D[Baseline assessments and randomization]
    D --> E[BFRE group (n=42)]
    D --> F[CON Group (n=42)]
    E --> G[Lost to follow-up (n)  
Did not complete the intervention (n)  
Declining TKA (n)]
    F --> H[Lost to follow-up (n)  
Declining TKA (n)]
    G --> I[Lost to follow-up (n)]
    H --> J[Lost to follow-up (n)]
    I --> K[Lost to follow-up (n)]
    J --> L[Lost to follow-up (n)]
    K --> M[Lost to follow-up (n)]
    L --> N[Lost to follow-up (n)]
    G --> O[Surgery follow-up]
    H --> O
    O --> I
    O --> J
    O --> L
    O --> N
    I --> P[6 weeks follow-up]
    J --> P
    P --> I
    P --> J
    P --> L
    P --> N
    I --> Q[3 months primary Endpoint]
    J --> Q
    Q --> I
    Q --> J
    Q --> L
    Q --> N
    I --> R[12 months follow-up]
    J --> R
    R --> I
    R --> J
    R --> L
    R --> N
```


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table and figure legends

Table 1. LOP = Limb occlusion pressure; RM = Repetition maximum

Table 2. KOOS = Knee disability and Osteoarthritis Outcome Score; B = Baseline; S = 0-2 days before surgery; D = during surgery; 3 months = 3 months after TKR; 12 months = 12 after TKR; NRS = Numeric Ranking Scale of pain

Figure 1. Flow chart of the enrollment, treatment, and follow-up phases. TKR: Total Knee Replacement, BFRE: Low-load blood-flow restricted exercise

For peer review only

Figure and figure legend

EXKnee project

Figure 1. Patient flow




Figure 1. Flow chart of the enrollment, treatment, and follow-up phases. TKR: Total Knee Replacement, BFE: Low-load blood-flow restricted exercise

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

Tables

Table 1. Exercise variables for the blood-flow restricted exercise (BFRE) protocol

Exercise variable	Week 1-8
Level of LOP	60% LOP
Sets	4
Load intensity	30% 1RM
Repetitions 1 st set	30
Repetitions 2 nd & 3 rd set	15
Repetitions 4 th set	To volitional failure
Contraction modes per repetition	
Concentric	2 seconds
Isometric	0 seconds
Eccentric	2 seconds
Rest between repetitions	0 seconds
Time under tension per repetition	4 seconds
Range of movement	maximum
Rest between sets	30 seconds
Rest between sessions	≥36 hours
Progression	The minimal possible load (5 kilo) is added when patients perform >15 repetitions in 4 th set

Table 2. Outcome measures to be collected.

Outcome measures	Data collection instrument	Time-points of assessment
Primary outcome		
Sit-to-stand function	30 seconds chair stand test	B, S, 3 and 12 months
Secondary outcomes		
Isometric Knee extensor muscle strength	Handheld Dynamometer	B, S, 3 and 12 months
Isometric Knee flexion muscle strength	Handheld Dynamometer	B, S, 3 and 12 months
Gait speed	4x10-meter walk test	B, S, 3 and 12 months
Ambulatory capacity	Timed Up & Go	B, S, 3 and 12 months
Muscle morphology and biology	Muscle Biopsies	B, D, 3 months
Pain	KOOS	B, S, 6 weeks, 3 and 12 months
Symptoms	KOOS	B, S, 6 weeks, 3 and 12 months
Activities of daily living	KOOS	B, S, 6 weeks, 3 and 12 months
Sports & Recreation	KOOS	B, S, 6 weeks, 3 and 12 months
Quality of life	KOOS	B, S, 6 weeks, 3 and 12 months
Socioeconomic costs	EQ-5D	B, S, 6 weeks, 3 and 12 months
Adverse Events	Questionnaire and medical records	S, 3 months
Patient characteristics and related measurements		
Gender	Questionnaire	B
Age	Questionnaire	B
Height	Tape measure	B
Body mass	Electronic body mass scale	B
Civil Status	Questionnaire	B
Educational Level	Questionnaire	B
Employment Status	Questionnaire	B
Substance Use (alcohol, smoking)	Questionnaire	B
Duration of knee symptoms	Questionnaire	B
Pain medication during the last week	Questionnaire	B

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Com-morbidities	Questionnaire	B
Blood pressure	Electronic upper limb blood pressure monitor	During the exercise period
Postoperative supervised physiotherapy	Questionnaire	B, S, at each BBFRE session, 3
Exercise compliance and progression	Physiotherapist records	and 12 months
NRS	PhD-stipendiate and physiotherapist records	

For peer review only

Table legends

Table 1. LOP = Limb occlusion pressure; RM = Repetition maximum

Table 2. KOOS = Knee disability and Osteoarthritis Outcome Score; B = Baseline; S = 0-2 days before surgery; D = during surgery; 3 months = 3 months after TKR; 12 months = 12 after TKR; NRS = Numeric Ranking Scale of pain

For peer review only

BMJ Open

The efficacy of low-load blood flow restricted resistance EXercise in patients with Knee osteoarthritis scheduled for total knee replacement (EXKnee). Protocol for a multicenter, randomized controlled trial.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-034376.R1
Article Type:	Protocol
Date Submitted by the Author:	03-Mar-2020
Complete List of Authors:	Jørgensen, Stian; Regional Hospital Horsens, Department of occupational and physical therapy; Horsens Sygehus, H-HIP Aagaard, Per; Institute for Sports Science and Clinical Biomechanics, University of Southern Denmark, Bohn, Marie; Horsens Sygehus, Department of Orthopedic Surgery Mechlenburg, Inger; Aarhus University Hospital, Department of Orthopedics; Aarhus University, Clinical Medicine
Primary Subject Heading:	Sports and exercise medicine
Secondary Subject Heading:	Rehabilitation medicine
Keywords:	blood flow restriction exercise, knee osteoarthritis, total knee replacement surgery, preconditioning, functional capacity

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

The efficacy of low-load blood flow restricted resistance EXercise in patients with Knee osteoarthritis scheduled for total knee replacement (EXKnee). Protocol for a multicenter, randomized controlled trial.

Stian Langgård Jørgensen^{1,2,5}, Marie Bagger Bohn², Per Aagaard³, Inger Mechlenburg^{4,5}

¹Department of Occupational and Physical Therapy, Horsens Regional Hospital, Denmark

²H-HIP, Department of Orthopedic Surgery, Horsens Regional Hospital, Denmark

³Department of Sports Science and Clinical Biomechanics, University of Southern Denmark

⁴Department of Orthopedic Surgery, Aarhus University Hospital, Denmark

⁵Department of Clinical Medicine, Aarhus University, Denmark

Corresponding Author:

Name: PhD student Stian Langgård Jørgensen

Address: Horsens Regional Hospital, Sundvej 30C, DK-8700 Horsens

E-mail: stiajo@rm.dk

Phone: +45 22 71 17 82

Word count: 5.650

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction

Up to 20% of patients undergoing total knee replacement (TKR) surgery report no or suboptimal pain relief after TKR. Moreover, despite chances of recovering to preoperative functional levels, patients receiving TKR have demonstrated persistent deficits in quadriceps strength and functional performance compared to healthy aged-matched adults. We intend to examine if low-load blood flow restricted exercise (BFRE) is an effective preoperative method to increase functional capacity, lower limb muscle strength and self-reported outcomes after TKR. In addition, the study aims to investigate to which extent preoperative BFRE will protect against surgery-related atrophy 3 months after TKR.

Methods

In this multicenter, randomized controlled and assessor blinded trial, 84 patients scheduled for TKR will be randomized to receive usual care and 8 weeks of preoperative BFRE or to follow usual care-only. Data will be collected at baseline, in the week of TKR, 6 weeks, 3 months, and 12 months after TKR. Primary outcome will be the change in 30-seconds chair stand test from baseline to 3 months follow-up. Key secondary outcomes will be Timed Up & Go, 40-meter fast-paced walk test, isometric knee extensor and flexor strength, patient-reported outcome, and selected myofiber properties. Intention-to-treat principle and per protocol analyses will be conducted. A one-way analysis of variance model will be used to analyze between group mean changes. Between-intervention comparison will be analyzed using a mixed linear model. Also, paired student t-tests will be performed and regression analysis will be used for analyzation of associations between selected outcomes.

49

50 **Ethical approval**

51 The trial has been accepted by Central Denmark Region Committee on Biomedical Research Ethics
52 (Journal No 10-72-19-19) and The Danish Data Protection Agency (Journal No 652164). All results
53 will be published in international peer-reviewed scientific journals regardless of positive, negative
54 or inconclusive results.

56 **Trial registration**

57 The trial is registered at Clinical Trial (NCT04081493)

59 **Article Summary**

60 **Strengths and limitations of this study**

- 61 • The trial is a multicenter, randomized controlled assessor blinded trial.
- 62 • This is the first clinical trial to investigate the effect of low-load ischemic resistance training
63 as a preconditioning method prior to elective knee replacement surgery.
- 64 • Patients will not be blinded to their allocation into intervention groups (BFR vs. control)

66 **Key words**

67 Blood flow restricted exercise, knee osteoarthritis, total knee replacement surgery, preconditioning

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

68 **INTRODUCTION**

69 Knee OA is a degenerative joint disease associated with pain, reduced physical activity, and quality
70 of life and affects almost 40% of all individuals ≥ 60 years of age (1-5). Approaching end-stage knee
71 OA, total knee replacement (TKR) is often the preferred treatment choice to reduce pain and regain
72 functional capacity. That is, TKR is considered a highly successful treatment to improve quality of
73 life and long-term function (6). However, despite being considered highly successful approximately
74 20% of the patients undergoing TKA experience a suboptimal outcome (6), which has been
75 suggested often to be related to incomplete restoration of physical function (7). In addition, TKR
76 patients typically demonstrate long-lasting deficits in quadriceps strength and functional
77 performance (2, 4). This failure to return to “normal” strength levels has been suggested to be
78 associated with preoperatively lower limb muscle strength and function (2) .

79 Preconditioning exercise designed to prepare the musculoskeletal system to better tolerate
80 stressful events such as the impact of invasive surgery has been suggested to be applicable prior to
81 elective TKR (6). This is supported by the results of two randomized controlled trials indicating that
82 preoperative heavy resistance strength training (HRST) may enhance functional capacity and knee
83 extensor muscle strength 3 months postoperatively (7, 8). However, joint pain resulting from the
84 high mechanical loads associated with HRST may represent a barrier to this type of training in some
85 patients suffering from severe knee OA (1, 9). Therefore, a more tolerable, yet effective, alternative
86 is needed for this population. Also, 3 recent systematic reviews investigating the topic of
87 preoperative physiotherapy-based exercise before TKR have suggested high quality, well-powered
88 evidence to investigate the efficacy of preoperative physiotherapy before TKR (10-12). Resistance
89 training with low exercise loads ($\sim 30\%$ 1 repetition maximum) performed with concurrent partial
90 blood flow restriction to the working limb (Blood flow restricted exercise: BFRE) has received
91 increasing clinical interest during the last decade (1, 13-32). The application of low

muscle/tendon/joint forces in BFRE has been documented to increase human skeletal muscle size and to cause substantial strength gains in healthy young and old individuals, as well as some patient populations (13, 25, 26), despite the low magnitude of mechanical stress imposed on the trained tissue. The adaptive mechanisms evoked by BFRE seem to involve accumulation of metabolites, ischemia (transient tissue hypoxia) and activation of myogenic muscle stem cells (satellite cells: SC) (13, 26, 31). When applied in the clinical setting, BFRE has demonstrated positive effects on skeletal muscle hypertrophy, strength, and functional capacity in mild-degree knee OA patients (1, 9, 33, 34) although not observed in all studies (33). Importantly, BFRE appears to be feasible with a high training adherence in knee OA patients (1, 33, 34). Furthermore, the use of different restrictive pressures (absolute restrictive pressures: 160-200 mmHg and individualized pressure of 70% the pressure needed to provide complete blood flow restriction) have been applied without any adverse events in mild-degree knee OA (1, 33, 34). This is in line Hughes et al. (13), who suggested that when BFRE is performed correctly it has been demonstrated to be as safe as free-flow exercise methods (13).

Satellite cells (SC) are quiescent myogenic stem cells positioned between the sarcolemma and the myofiber basal lamina (31, 35). SC plays an important role in human skeletal muscle growth due to their ability to donate new myonuclei to the muscle fibers (31, 36-40). That is, the human skeletal muscle fibers are multinucleated cells with each myonucleus controlling the protein synthesis of a certain cytoplasmic area in the muscle fiber (36-38, 41). Myonuclei transcriptional activity can be fully maximized with exercise, hence requiring new myonuclei to support further muscle tissue accretion (37, 38, 40). It has been suggested that exercise-related addition of SCs and myonuclei by means of BFRE might reduce the muscle atrophy related to bedrest and/or prolonged inactivity (31, 42). Previous studies applying short term (10 days) preoperative BFRE before an anterior cruciate ligament rupture-reconstruction found no atrophy protective effect or higher

1
2
3
4 116 postoperative muscle strength compared to performing a low-load exercise without blood flow
5
6 117 restriction (placebo). However, it might be questionable if the applied training frequency, intensity
7
8
9 118 and training period have been sufficient to promote SC and myonuclei addition. Thus, longer
10
11 119 periods of intensive training might be necessary to promote the desired muscle morphological
12
13 120 adaptations (addition of myonuclei and increased SC content).
14
15

16 121
17
18 122 **Aim and hypothesis of the trial**
19

20 123 The primary aim of this trial is to investigate the efficacy of 8 weeks of BFRE compared to
21
22
23 124 receiving usual care prior to TKR on postoperative chair stand performance. We hypothesize that 8
24
25 125 weeks of preoperative BFRE will lead to increased 30 seconds chair stand performance (30-seconds
26
27 126 Chair Stand Test: 30-s CST) when assessed 3 months postoperatively. Secondary aims are to
28
29
30 127 investigate the efficacy of preoperative BFRE on lower limb muscle strength 3 months after TKR
31
32 128 and investigate the potential relationship to functional capacity and quality of life. Furthermore, it
33
34 129 will be investigated to which extent 8 weeks of BFRE induces myofiber hypertrophy and gains in
35
36 130 satellite cell number and myonuclei content in the knee extensor musculature.
37
38

39 131
40
41 132 **MATERIAL & METHODS**
42

43 133 **Design**
44

45
46 134 The trial is designed as a multicenter (2 sites), randomized, assessor blinded, controlled trial
47
48 135 following the CONSORT guidelines (43). Primary endpoint will be 3 months after TKR. Additional
49
50 136 and secondary endpoints will be evaluated during the week of TKR, 6 weeks after TKR
51
52
53 137 (questionnaires only) and 12 months after TKR. Muscle biopsies will be obtained from all patients
54
55 138 undergoing surgery at Horsens Regional Hospital at baseline, during surgery and 3 months after
56
57 139 TKR.
58
59
60

Participants

Patient will be recruited from the Orthopedic Departments at Horsens and Silkeborg Regional Hospitals in Denmark. Patient enrollment will start September 2nd 2019 at Horsens Regional Hospital and October 1st 2019 at Silkeborg Regional Hospital. Patient recruitment is expected to be completed in June 2021. All patients are expected to have completed baseline testing ultimo June 2021 and have performed 3 months follow-up during September 2021. Thus, at the end of June 2022 all patients are expected to have completed 12 months follow-up testing.

Inclusion criteria: 1) Patients ≥ 50 years scheduled for TKR due to knee OA at Horsens- or Silkeborg Regional Hospital.

Exclusion criteria: 1) Severe cardiovascular diseases (New York Heart Association (NYHA) class III and IV), previous stroke incident, thrombosis incident; 2) Traumatic nerve injury in affected limb 3) Unregulated hypertension (Systolic ≥ 180 or diastolic ≥ 110 mmHg) 4) Spinal cord injury; 5) Planned other lower limb surgery within 12 months; 6) Cancer diagnosis and currently undergoing chemo-, immuno-, or radiotherapy; 7) Inadequacy in written and spoken Danish; 8) an existing prosthesis in the index limb; 9) living more than 45 minutes from either Horsens Regional Hospital or Silkeborg Regional Hospital; 10) Pregnancy.

All patients will be screened for eligibility by orthopedic surgeons at Horsens Regional Hospital and Silkeborg Regional Hospital who will perform the initial inclusion of study participants and hand out written project information. All patients accepting to participate will be asked to complete a written informed consent allowing the physiotherapist (at Horsens Regional Hospital and

Silkeborg Regional Hospital) to contact the patients by phone for a final eligibility and exclusion criteria-screening, and book an appointment for baseline testing. In case the patient agrees to participate in the trial, the patient will sign a written informed consent to participate in the project. Subsequently, the patient will be baseline-tested at the hospital by a blinded (to group allocation) assessor. Patients declining to participate in the RCT will be offered the option of participating in a parallel observational cohort trial. All patients included in the project will be scheduled for a TKR and receive a standard multimodal surgical program with standard preoperative care (usual care). Specifically, 2-3 weeks before surgery all patients will be invited to a preoperative information meeting where nurses, surgeons, and physiotherapists will provide detailed information on pain management, nutrition, the surgical procedure, physical activity, postoperative home-based rehabilitation, load management, etc. (44) On the day of surgery, patients will be hospitalized at Horsens Regional Hospital or Silkeborg Regional Hospital where an orthopedic surgeon will perform the TKR procedure. The day after surgery all patients will be trained once or twice per day by a physiotherapist towards fulfilling the following discharge criteria: a minimum knee flexion range of motion (ROM) of 60/90 degree and maximally a knee extension ROM deficit of 15/5 degree knee extension (Horsens Region Hospital/ Silkeborg Regional Hospital), independency in in-and-out of bed and sit-to-stand activities, independency in walking and stair-negotiation with crutches, ADL activities, and sufficient understanding of the home-based exercises during the hospitalization period (44). Patients will generally be discharged within ~1-2 days after fulfilling all the above discharge criteria. After discharge, all patients will as standard receive a standard home-based rehabilitation program focusing on improving knee joint mobility, increasing the tolerance for standing without assistive devices (i.e. crutches), and lower extremity muscle strength. Small variations in the selection of exercises in the standard home-based rehabilitation program exists between hospitals, however, the purpose of the programs is identical. However, if the patients do

not fulfill the discharge criteria the patient will be offered supervised knee-specific exercise therapy at municipal rehabilitation centers, or specialized hospital-based rehabilitation after discharge from the Hospital.

Randomization

After baseline assessment, patients will be randomized (1:1) using Research Electronic Data Capture (REDCap) randomization system to either the training (BFRE) group or the control (CON) group. Prior to randomization, all patients will be booked for follow-up test sessions and surgery. All randomization procedures will be performed by the physiotherapists in charge of the BFRE training. Assessors performing the tests will be blinded to group allocation until completion of the trial. A flow chart of the patient allocation procedures is depicted in Figure 1.

CON group: Participants in CON will receive usual care (see above) prior to TKR and be encouraged to continue their usual lifestyle up until TKR.

BFRE group: In addition to receiving usual care (cf. above), participants in the BFRE group will perform supervised BFRE sessions 3 times per week for 8 weeks supervised by a physiotherapist educated in administering BFRE. All BFRE training will be performed at Horsens Regional Hospital and Silkeborg Regional Hospital.

Please insert Figure 1 about here

Intervention procedures

BFRE

1
2
3
4 212 Each BFRE session will consist of a 10-min warm up (ergometer cycling) followed by two different
5
6 213 unilateral lower-limb resistance training exercises: 1) leg press and 2) knee extension performed in
7
8 214 standard strength training machines. Each exercise will be performed with the affected lower limb
9
10
11 215 only and consist of 4 rounds interspaced by 30 seconds of rest. 1st round: 30 repetitions (reps); 2nd
12
13 216 round: 15 reps; 3rd round: 15 reps; 4th round: until exhaustion (Table 1). If patients can perform
14
15
16 217 more than 15 repetitions in the 4th exercise set, the exercise load will be increased with the
17
18 218 minimum extra load possible (30). Participants will be instructed to perform both the eccentric and
19
20 219 concentric contraction phases using a steady 2-sec pace duration. The 4th and final exercise set will
21
22
23 220 be performed to the point of exhaustion defined as being unable to complete the final concentric
24
25 221 contraction phase in 2 seconds. During the 30 sec rest period, patients will rest in a standardized
26
27 222 resting position while maintaining the initial cuff-pressure. Between each exercise, patients will
28
29
30 223 have a 5-min "free-flow" rest period. The cuff will be released immediately after completion of the
31
32 224 final exercise set.

33
34 225 The occlusion pressure during both exercises will be set at 60% of total limb occlusion pressure
35
36 226 (LOP) and starting load intensity will be 30% 1 repetition maximum (1RM) in both exercises.

37
38
39 227 Individual LOP will be determined using a pneumatic, conically shaped, 12 cm wide, rigid cuff
40
41 228 (Occlude Aps, Denmark) attached to the patient's most proximal area of the thigh on the affected
42
43 229 side. While sitting on an examination table with the ankle and 1/3 of the lower limb off the table, a
44
45
46 230 vascular Doppler probe (EDAN Instruments, inc., China) will be placed posterior to the medial
47
48 231 malleolus over the posterior tibial artery to capture the auscultatory pulse. To determine the cuff
49
50 232 pressure (mmHg) needed for total blood flow occlusion, the cuff will gradually be inflated in 20
51
52 233 mmHg steps until reaching the pressure where the auscultatory pulse is interrupted (LOP). First
53
54
55 234 time the auscultatory pulse is interrupted the examiner releases 10-20 mmHg pressure from the cuff
56
57 235 until the auscultatory pulse is present again. When the auscultatory pulse reappears the cuff is

inflated with 10 mmHg until LOP is found again. If the second LOP is identical to the first it will be defined as LOP for that specific patient. Otherwise, the procedure will be repeated until determining an identical LOP two consecutive times.

Please insert Table 1 about here

Outcome variables

Outcome assessments will be performed at baseline, in the week of surgery, 6 weeks after TKR, 3 months after TKR, and 12 months after TKR. To reduce the number of postoperative visits only questionnaires; The Knee disability and Osteoarthritis Outcome Score (KOOS), EuroQol Group 5-dimensions (EQ-5D-L5), and reporting of adverse event or receiving supervised physiotherapy postoperatively will sent via email 6 weeks after surgery. Two testers (two trained physiotherapists) blinded to group allocation will perform all baseline and follow-up measurements. Bergström needle muscle biopsies (45) will be taken from vastus lateralis of the quadriceps muscle in both lower limbs from patients included at Horsens Regional Hospital only at baseline, during surgery, and 3 months after TKR by doctors trained in performing the procedure. An overview of the data collection parameters is presented in Table 2.

Before starting the baseline testing, all assessors will be thoroughly trained in performing the tests according to the standardized test procedures for each test method. To maintain fidelity of testing during the study period, assessors will be retrained every 3rd month. Also, the physiotherapist in charge of LL-BFRE will be thoroughly trained in performing the exercise on healthy subjects before applying LL-BFRE on study-patients. The primary investigator will be in weekly contact with the physiotherapists supervising the LL-BFRE at Horsens Regional Hospital and Silkeborg Regional Hospital where day-to-day-retraining and supervision can be arranged.

1
2
3
4 260 Furthermore, physiotherapists supervising the LL-BFRE will receive in-depth retraining every 3rd
5
6 261 month.
7
8

9 262
10
11 263 **Data management**
12

13
14 264 All data from the physical function tests will be entered into RedCap by the assessors, using double
15
16 265 data entry to ensure data quality. All patient-reported outcome data (KOOS, NRS Pain, EQ-5D-5L)
17
18 266 will be entered directly into RedCap by the patients, and usage of the “required fields” will ensure
19
20 267 no missing items from the completed questionnaires. To reduce missing data, a reminder email will
21
22
23 268 be sent automatically from the RedCap-system. All patient data will be anonymized by assigning
24
25 269 study numbers to each patient (coding). Personal data about the patient will be located separately
26
27 270 from the main dataset to protect confidentiality during all trial phases.

28
29
30 271 The raw dataset will be maintained for ten years after completion of the trial, with indefinite
31
32 272 restricted access due to sensitive date. After publication of the trial, a fully anonymized patient-level
33
34 273 dataset and corresponding statistical description will be made publicly available if required by the
35
36
37 274 scientific journal, in which the results are published.
38

39 275
40
41 276 Primary outcome variable
42

43
44 277 The primary outcome measure will be the change in 30s-CST from baseline to 3 months follow-up.
45

46 278
47
48 279 Secondary outcome variables
49

50
51 280 Secondary outcome measures comprises The Timed Up and Go test (46-48), 40-m fast-paced walk
52
53 281 test (46), maximal isometric knee extensor and knee flexor strength assessed with hand-held
54
55 282 dynamometry (49, 50), knee extensor (VL) myofiber cross sectional area, muscle fibertype
56
57
58 283 composition, satellite cell content, myonuclei number (51), the Knee disability and Osteoarthritis
59
60

Outcome Score (52, 53), EuroQol Group 5-dimensions (54), Numeric Ranking Scale for pain (NRS) (55), and adverse events/postponement of TKR.

Explorative outcome variables

Type of postoperative rehabilitation received, medication and knee joint range of motion.

Demographic data

Gender, age, height, weight, civil status, level of educational, employment status, substance use (alcohol and smoking), duration of knee symptoms, pain medication during past week due to knee-related pain, and co-morbidities.

Adherence

Adherence to training will be registered by the physiotherapists in charge of the exercise sessions.

High compliance is defined as attendance to the supervised BFRE of $\geq 80\%$.

Please insert Table 2 about here

Elaborated description of outcome measures

Primary outcome

The 30s-CST will be assessed using a 44 cm (seat height) chair with armrests. The 30s-CST measures the number of sit-to-stand repetitions completed within 30 seconds. The 30s-CST is considered a valid and sensitive measure of lower-extremity sit-to-stand function with good to excellent intra- and inter-observer reliability (46, 56, 57).

1
2
3
4 308 Secondary outcomes

6 309 **The Timed Up & Go test (TUG)** assesses the time required for patients to stand from a 44 cm
8
9 310 (seat height) chair walk around a tape mark 3 meters away and sit into the chair at return. The
10
11 311 patients will be instructed to walk as fast and safely as possible towards the tape mark (and touch
12
13 312 the tape mark (with at least one foot), turn around and return to the chair and sit down. Use of
14
15
16 313 armrests are allowed. The fastest of two trials will be used for further analysis. Up to one minute of
17
18 314 rest will be allowed between trials (47, 58). Good inter-rater reliability has been demonstrated with
19
20 315 the TUG test (46).

22
23 316
24
25 317 **4x10 meter walk test meter walk test (40m-FWT)** measures the total time taken to walk 4 x 10 m
26
27 318 excluding turns (meter/sec) (46). Patients will be instructed to walk as quickly and as safely as
28
29
30 319 possible without running to a visible mark 10 m away, return and repeat for a total distance of 40 m
31
32 320 (46). Prior to the test one practice trial will be provided to check understanding. The 40m-FWT is a
33
34 321 valid and responsive measure for assessing short distance maximum walking speed with excellent
35
36 322 inter-rater reliability (46).

38
39 323
40
41 324 **1RM leg press strength** will be estimated from a 5-8RM leg press test. Patients perform 3 low-load
42
43 325 warm-up sets. 1st and 2nd warm-up set consists of 12 repetitions, and the 3rd warm-up set consist of 8
44
45 326 repetitions. The load of each warm-up set will be increased with 10 kilos. After warm-up, the load
46
47
48 327 will be increased to determine the 5RM. If the 5RM cannot be determined within 3 trials, an 4th all-
49
50 328 out trial (as many repetitions as possible) will be performed. The 1RM will be calculated as [1RM =
51
52 329 load (kg)/1.0278-0.0278·number of repetitions)] (59).

54
55 330

56
57
58
59
60

1RM knee extension strength will be estimated from 5-8RM knee extension test as described above for the estimation of 1RM leg press test (59).

Maximal isometric voluntary contraction (MVC) of the knee will be measured using a hand held dynamometer (HHD). The patients will be seated on an examination table with knees and hips positioned at 90° flexion. The patients will be instructed to remain seated in an upright position and place both hands on the shoulder to avoid compensation. The HHD will be fixed with a rigid belt to the examination table. Adjustable straps will be used to allow MVCs of the knee extensors to be performed at 90° knee flexion in all patients. The HDD will be positioned 5 cm above the medial malleolus (50). The patients will be instructed to produce as much force as possible into the HHD as possible. Good to excellent inter- and intra-rater reliability has previously been demonstrated on group-level in patients suffering from knee OA for maximum knee extensor muscle strength testing with HDD (49, 50). Patients will receive 4 trials. For analysis, the mean maximal strength of the 2nd, 3rd, and 4th measures will be calculated and corrected for bodyweight (50)

MVC of the knee flexors will be measured will be performed using HHD at 90° knee flexion with the patients seated identically as during MVC for the knee extensors (50). The HHD will be positioned posterior aspect of calcaneus (50) and patients will be instructed to produce as much force as possible into the HHD. Good to excellent inter- and intra-rater reliability has previously been demonstrated on group-level in patients suffering from knee OA for maximum knee flexor muscle strength testing with HDD (50). Patients will receive 4 trials. For analysis, the mean maximal strength of the 2nd, 3rd, and 4th measures will be calculated and corrected for bodyweight (50)

1
2
3
4 355 **Myofiber cross sectional area (CSA), muscle fiber type composition, satellite cell content, and**
5
6 356 **myonuclei number** will be assessed by obtaining needle biopsies (100-150 mg) from all patients
7
8
9 357 enrolled at Horsens Regional Hospital. The biopsies will be obtained bilaterally from the middle
10
11 358 portion of the vastus lateralis muscle utilizing the percutaneous needle biopsy technique of
12
13 359 Bergström (45, 60, 61). Biopsies will be performed by two experienced orthopedic surgeons (chief
14
15
16 360 physicians) trained in performing the needle muscle biopsy technique at Horsens Regional Hospital.
17
18 361 Efforts will be made to extract tissue from the same region (2-3 cm apart) and depth (~1-2 cm.)
19
20 362 (45). The tissue samples will be dissected of all visible blood, adipose tissue, and connective tissue
21
22
23 363 and mounted in Tissue-Tec (4583, Sakura Finetek, Alphen aan den Rijn, The Netherlands), frozen
24
25 364 in isopentane pre-cooled with liquid nitrogen, and stored at -80°C (31, 45, 51). All muscle samples
26
27 365 will be analyzed as previously described by Nielsen et al. (31) using immunofluorescence
28
29
30 366 microscopy. Transverse serial sections (8 µm) of the embedded muscle biopsy specimen will be cut
31
32 367 at -22°C using a cryostat (HM560; Microm, Walldorf, Germany) and will be mounted on glass
33
34 368 slides for subsequent analysis as described in detail elsewhere (31). Myogenic stem cells (satellite
35
36
37 369 cells (SC)) will be visualized with an antibody against Pax7 (31). Type I (stained) and Type II
38
39 370 (unstained) myofibers will be differentiated, and muscle fiber area will be determined (31): MSC-
40
41 371 derived nuclei will stain positive for Pax7 and be within the basal lamina; nuclei (DAPI stained)
42
43
44 372 with a sublaminar placement will be considered myonuclei (31).

45
46 373
47
48 374 **Knee disability and Osteoarthritis Outcome Score (KOOS)** is a patient-administered knee
49
50 375 specific questionnaire comprising five subscales Pain; Symptoms; Activities of daily living; Sport
51
52
53 376 & Recreation; and Knee-Related Quality of Life. Each item is scored from 0 to 4 (53). The raw
54
55 377 score for each of the five subscales is the total sum of the associated item scores. Scores can be
56
57 378 transformed to a 0 to 100 scale. The scores of the five subscales can be expressed as a composite
58
59
60

outcome profile, higher scores indicating fewer problems (62). The KOOS questionnaire is valid and reliable in patients suffering from knee OA and patients on the waiting list for TKA for knee OA (52, 53, 63).

EuroQol Group 5-dimension (EQ-5D-5L) is a self-completion questionnaire consisting of two parts; first part of the EQ-5D-5L comprises five dimensions involving mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. All dimensions have five response categories (no problems, slight problems, moderate problems, severe problems, and extreme problems) resulting in a five digit descriptive health state (64), which will be converted into a summary index ranging from -0.624 (worst) to 1.000 (best), using a Danish value set (54). The second part, EQ-VAS rates the overall current health status from 0 (worst imaginable health) to 100 (best imaginable health) (64). The EQ-5D-5L is reliable and valid in patients with knee osteoarthritis eligible for TKA, (65, 66)

Adverse events will be defined as unpredicted or unintended events, signs, or disease occurring during the period from inclusion until the 3-month follow-up (primary end-point) resulting in contact with the healthcare system (hospital or general practitioner) independent of whether or not the event is related to the intervention or outcome assessments. Adverse events will be recorded and categorized in accordance with the definitions established by the United States Food and Drug Administration [88]. Continuous registration of adverse events will be performed and a short open-ended questionnaire will be administered at 3-months and 12 months follow-up.

Other Outcome Measures

Blood pressure will be measured by the orthopedic surgeon when patients are visiting the outpatient clinic. Blood pressure will be used to determine eligibility to participate in the project.

1
2
3
4 404
5
6
7 405 **Exercise compliance and progression** will be obtained by the physiotherapist in charge of the
8
9 406 training sessions and entered directly into the REDCap-system. The progression will be monitored
10
11 407 as the total load lifted by the patient for exercise session.
12
13
14 408
15
16 409 **Declining to be operated** will be measured at 3 months follow up, where patients will be asked
17
18 410 whether they decided to be operated or not. Patients who declined to be operated will be invited to
19
20 411 participate will be invited to participate in all prescheduled follow-up assessments.
21
22
23 412
24
25 413 **Postoperative supervised physiotherapy** will be measured at 6 weeks, 3 months, and 12 months
26
27 414 follow-up by answering a questionnaire. If patients have participated in postoperative supervised
28
29
30 415 physiotherapy, the patient must specify whether the treatment was related to the TKR or due to
31
32 416 other circumstances.
33
34 417
35
36 418 **Knee joint active range of motion** will be measured with a 360° plastic goniometer (scale 1°) with
37
38
39 419 16.5 cm moveable arms at baseline, in the week of surgery, 3 months, and 12 months after surgery.
40
41 420 Laying supine on an examination table, the knee joint flexion and knee joint extension will be
42
43 421 measured separately (67). The tester then identifies the most prominent part of the trochanter, the
44
45 422 lateral epicondyle of the femur, the lateral head of fibula, and the lateral malleolus. When identified,
46
47
48 423 the patient is asked to flex the knee as much as possible with the heel maintaining contact to the
49
50 424 surface at all time (67). Secondly, the patients will be asked to extend the knee joint as much as
51
52 425 possible. To allow the knee to extend as much as possible a firm quadratic box (height: 5 cm, width:
53
54
55 426 8 cm, length: 15 cm) will be placed under the heel of the patient. The procedure of measuring knee
56
57 427 extension will be similar to knee flexion, as the patients increases the degree of knee extension
58
59
60

maximally (67) The fulcrum of the goniometer will correspond visually to the trans-epicondylar axis of the knee joint. The moveable arms of the goniometer will be pointed towards the greater trochanter and the lateral malleolus while (67).

Sample size

The power and sample size calculation is based on the expected differences between the two subject groups from baseline to 3 months follow up (8). Skoffler et al. (8) investigated the efficacy of 4 weeks of preoperative and 4 weeks postoperative HRST (intervention group) compared to 4 weeks of postoperative HRST only (control group) on 30-s CST 3 months in patients receiving a TKR (8). The authors found a between-group difference of 3-4 repetition difference (14.7 ± 4.7 repetitions versus 11.0 ± 4.4 repetitions) 3 months after TKR surgery (8).

To reduce the probability of type I errors and be able to detect a between-group difference also, α -level is set at 0.05 ($p < 0.05$) and β -level is set at 0.20 (80% power). Expecting a 3-repetitions between-group difference 3 months postoperatively and assuming a SD of 4.7 in both groups, 39 patients are required in each group (yielding 78 patients in total). With an anticipated dropout rate of 10%, 84 patients will be recruited for the trial in total.

Statistical considerations

The primary efficacy analysis will be assessment of the between group difference in change in the 30-S CST from baseline to 3 months follow up (primary endpoint).

All descriptive statistics and tests will be reported in accordance with the recommendations of the “Enhancing the QUALity and Transparency Of health Research” (EQUATOR) network (68) and the CONSORT statement (43). Intention-to-treat principle (i.e. all patients as randomized independent of departures from allocation treatment, compliance and/or withdrawals) and per

1
2
3
4 452 protocol analysis will be conducted. A one-way analysis of variance (one-way ANOVA) model will
5
6 453 be used to analyze between group mean changes in continuous outcome measures (31). The model
7
8
9 454 includes changes from baseline to 12 months follow-up. Between-intervention comparison from
10
11 455 baseline to 3 months after surgery will be analyzed using a mixed linear model with patient ID as a
12
13 456 random effect and time and group as fixed effects (31, 69). Also, to gain insights into the potential
14
15
16 457 pre-to-post training differences within the respective training or control groups, paired student t-
17
18 458 tests will be performed. Level of statistical significance is $P < 0.05$. *Secondary outcome variables:*
19
20 459 Between-intervention comparison from baseline to the week of surgery, 6 weeks after surgery, 3
21
22
23 460 and 12 months after surgery will be analyzed as described for the primary outcome. Regression
24
25 461 analysis will be used to analyze the potential associations between preoperative strength and
26
27 462 postoperative lower extremity function and self-reported outcome as well as between preoperative
28
29
30 463 functional capacity and postoperative functional capacity. Additionally, regression analysis will be
31
32 464 used to analyze the association between preoperative number of satellite cells and myonuclei on
33
34 465 postoperative isometric knee extensor muscle strength, muscle fiber cross sectional area, and
35
36 466 functional capacity. All statistical analysis will be performed by the primary investigator using
37
38
39 467 Stata.

40
41 468
42
43 469 **Ethical aspects and dissemination**

44
45
46 470 The trial has been accepted by Central Denmark Region Committee on Biomedical Research Ethics
47
48 471 (Journal No 10-72-19-19) and by The Danish Data Protection Agency (Journal No 652164). The
49
50 472 trial is registered at Clinicaltrial.gov (NCT04081493). Before inclusion, all patients will provide
51
52
53 473 their written informed consent in accordance with the Helsinki Declaration. All data and
54
55 474 information collected in regard to this trial will be treated confidentially (blinded and encrypted) by
56
57 475 the researchers and staff connected to the trial.
58
59
60

All results from the trial will be published in international peer-reviewed scientific journals regardless of the results being considered positive, negative or inconclusive.

Patient and public involvement

Before developing this clinical trial, a pilot project was performed to determine feasibility and efficacy of BFRE in patients suffering from lower limb injuries. The experiences with the training modality and the verbal feedback from patients on training duration, frequency, and intensity resulted in useful knowledge that certainly have improved the development of the present clinical trial.

DISCUSSION

To our best knowledge, this is the first trial to investigate the effect of preoperative BFRE on functional capacity, self-reported outcome, lower limb muscle strength and myofiber morphology/stem cell abundance in patients scheduled for TKR. Only few studies have investigated (short term (10 days)) preoperative BFRE without finding an atrophy protective effect or difference in muscle strength compared to a control group performing a placebo intervention (SHAM group) (70). However, patients performing short term preoperative BFRE before ACL-R demonstrated higher muscle endurance compared to a SHAM group (71). Therefore, results of this trial are expected to provide novel information on longer periods of BFRE that will enable to design effective exercise-based preconditioning protocols for elective TKR patients. The LL-BFRE protocol applied in the present project is widely used and follows the recommendations from a recent position stand by Patterson et al. (72). The authors suggested that exercising 2-3 times per week at 20-40% of 1RM in 2-4 sets (e.g. 30-15-15-15 or sets to failure) using pressures between 40

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

to 80% of LOP has demonstrated to be effective when aiming at increasing muscle strength and promoting muscle hypertrophy (72).

The trial is designed as an assessor blinded randomized controlled trial, thus representing the highest evidence level. However, the nature of the trial does not allow blinding of the participants which is an inherent limitation of the trial. The trial is conducted at two hospitals that consistently perform a high number TKR procedures annually (225 and 460, respectively), thus securing a strong expertise in terms of surgery and infrastructure. Both hospitals have all equipment needed available for surgery, post-operative hospitalization, training, and testing. All outcome variables are considered valid and reliable measures and consist of both objective outcomes and self-reported patient outcomes.

No adverse health-related events have been reported in previous studies applying BFRE in patients' suffering from knee OA or in healthy older adults (1, 9, 13, 23, 33, 34). Further, in a recent review and meta-analysis it was stated that exercise with concurrent blood-flow restriction is a safe exercise modality when occlusion procedures are applied correctly (13). The inherent invasive procedure of muscle biopsies may cause adverse events in rare occasions. Therefore, all muscle biopsy samples will be collected by trained medical doctors and performed following administration of local anesthesia and in fully sterile conditions. The needle muscle biopsy protocol have been applied in a large number of previous investigations including very old frail subjects (97 years of age) without any reporting of adverse events besides occasional muscle soreness(31, 45, 60, 73, 74).

There are some limitations of the project that must be taken into account. First, our primary end point is 3 months postoperatively. The (uncontrolled) period discharge to 3 months postoperatively renders the project vulnerable to external variabilities. However, from a pragmatic point of view, this uncontrolled period from discharge to 3 months follow-up reflects the reality that Danish patients faces postoperatively. Thus, the results at 3 months follow-up will, indeed, reflect the

1
2
3
4 523 impact of performing preoperative LL-BFRE on the postoperative outcome regardless of the
5
6 524 external variable that can hamper the results. Secondly, the discharge criteria at Horsens Regional
7
8
9 525 Hospital and Silkeborg Regional Hospital withhold slight differences. That is, the acceptable knee
10
11 526 joint ROM at discharge differs between the sites, thus it can be speculated that more patients from
12
13 527 Silkeborg Regional Hospital will be offered a postoperative, supervised rehabilitation program. This
14
15
16 528 might affect the number of patient receiving supervised physiotherapy after discharge between sites.
17
18 529 However, all patients included in present project will report whether they have received
19
20 530 postoperative supervised physiotherapy at all follow-up assessment. Thus, we will be able to
21
22
23 531 determine (and normalize?) a potential between-site difference in patients receiving supervised
24
25 532 physiotherapy after TKR.
26
27 533

29 534 **Author contributions**

31
32 535 SLJ, PAA, MBB, and IM were all part of designing the trial and approved the final version of the
33
34 536 protocol. Also, SLJ, PAA, MBB, and IM wrote and revised the protocol.
35
36 537

38 538 **Data statement**

40
41 539 All obtained data will be stored in anonymized form at the Danish National Archives and deleted
42
43 540 after 10 years.
44
45 541

48 542 **Funding**

50 543 This work trial is supported by Aase og Ejnar Danielsens Foundation (100.000 dkk), Nis-Hanssens
51
52 544 Mindeslegat (163.883 dkk) and The Foundation for health research of Central Denmark Region
53
54
55 545 (99.658 dkk), Hede-Nielsen Foundation (8.000,00 dkk).
56
57 546
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

547 **Competing interest**

548 None to be declared

550 **Ethics approval**

551 The trial has been accepted by Central Denmark Region Committee on Biomedical Research Ethics
552 (Journal No 10-72-19-19) and by The Danish Data Protection Agency (Reference No 652164).

554 **Word count**

555 5.650 words

For peer review only

REFERENCES

1. Ferraz RB, Gualano B, Rodrigues R, Kurimori CO, Fuller R, Lima FR, et al. Benefits of Resistance Training with Blood Flow Restriction in Knee Osteoarthritis. *Medicine and science in sports and exercise*. 2018.
2. Bade MJ, Kohrt WM, Stevens-Lapsley J. Outcomes before and after total knee arthroplasty compared to healthy adults. *The Journal of orthopaedic and sports physical therapy*. 2010.
3. Fransen M, McConnell S, Harmer AR, Van dE, Simic M, Bennell KL. Exercise for osteoarthritis of the knee. 2015.
4. Skoffier B, Dalgas U, Mechlenburg I. Progressive resistance training before and after total hip and knee arthroplasty: A systematic review. 2015.
5. Sundhedsstyrelsen. Knæartrose - nationale kliniske retningslinjer og faglige visitationsretningslinjer 2012.
6. Franz A, Queitsch FP, Behringer M, Mayer C, Krauspe R, Zilkens C. Blood flow restriction training as a prehabilitation concept in total knee arthroplasty: A narrative review about current preoperative interventions and the potential impact of BFR. *Medical hypotheses*. 2018.
7. Calatayud J, Casaña J, Ezzatvar Y, Jakobsen MD, Sundstrup E, Andersen LL. High-intensity preoperative training improves physical and functional recovery in the early post-operative periods after total knee arthroplasty: a randomized controlled trial. *Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA*. 2016.
8. Skoffier B, Maribo T, Mechlenburg I, Hansen PM, Søballe K, Dalgas U. Efficacy of Preoperative Progressive Resistance Training on Postoperative Outcomes in Patients Undergoing Total Knee Arthroplasty. *Arthritis Care & Research*. 2016.
9. Bryk FF, dos Reis AC, Fingerhut D, Araujo T, Schutzer M, Cury RdPL, et al. Exercises with partial vascular occlusion in patients with knee osteoarthritis: a randomized clinical trial. *Knee Surgery, Sports Traumatology, Arthroscopy*. 2016;24(5):1580-6.
10. Wang L, Lee M, Zhang Z, Moodie J, Cheng D, Martin J. Does preoperative rehabilitation for patients planning to undergo joint replacement surgery improve outcomes? A systematic review and meta-analysis of randomised controlled trials. *BMJ open*. 2016;6(2):e009857-2015-.
11. Chesham RA, Shanmugam S. Does preoperative physiotherapy improve postoperative, patient-based outcomes in older adults who have undergone total knee arthroplasty? A systematic review. 2017.
12. Kwok IH, Paton B, Haddad FS. Does Pre-Operative Physiotherapy Improve Outcomes in Primary Total Knee Arthroplasty? - A Systematic Review. *The Journal of arthroplasty*. 2015;30(9):1657-63.
13. Hughes L, Paton B, Rosenblatt B, Gissane C, Patterson SD. Blood flow restriction training in clinical musculoskeletal rehabilitation: A systematic review and meta-analysis. 2017.
14. Counts BRDSJBBEKDGMJAKMTRSATBMGLJP. Influence of Relative Blood Flow Restriction Pressure on Muscle Activation and Muscle Adaptation. *Muscle & nerve*. 2016;53:438-45.
15. Kim D, Loenneke JP, Ye X, Bemben DA, Beck TW, Larson RD, et al. Low-load resistance training with low relative pressure produces muscular changes similar to high-load resistance training. *Muscle & nerve*. 2017;56(6):E126-E33.
16. Loenneke JP, Fahs CA, Rossow LM, Sherk VD, Thiebaud RS, Abe T, et al. Effects of cuff width on arterial occlusion: implications for blood flow restricted exercise. *European journal of applied physiology*. 2012;112(8):2903-12.

17. Loenneke JP, Kim D, Fahs CA, Thiebaud RS, Abe T, Larson RD, et al. The influence of exercise load with and without different levels of blood flow restriction on acute changes in muscle thickness and lactate. *Clinical Physiology and Functional Imaging*. 2017.
18. Loenneke JP, Kim D, Fahs CA, Thiebaud RS, Abe T, Larson RD, et al. Effects of exercise with and without different degrees of blood flow restriction on torque and muscle activation. *Muscle & nerve*. 2015.
19. Loenneke JP, Thrower AD, Balapur A, Barnes JT, Pujol TJ. Blood flow-restricted walking does not result in an accumulation of metabolites. *Clinical physiology and functional imaging*. 2012;32(1):80-2.
20. Loenneke JP, Wilson JM, Balapur A, Thrower AD, Barnes JT, Pujol TJ. Time under tension decreased with blood flow-restricted exercise. *Clinical physiology and functional imaging*. 2012;32(4):268-73.
21. Loenneke JP, Wilson JM, Wilson GJ, Pujol TJ, Bembien MG. Potential safety issues with blood flow restriction training. 2011. p. 510-8.
22. Loenneke JP, Young KC, Fahs CA, Rossow LM, Bembien DA, Bembien MG. Blood flow restriction: rationale for improving bone. *Medical hypotheses*. 2012;78(4):523-7.
23. Ozaki H, Loenneke JP, Abe T. Blood flow-restricted walking in older women: does the acute hormonal response associate with muscle hypertrophy? *Clinical physiology and functional imaging*. 2017;37(4):379-83.
24. Ozaki H, Loenneke JP, Thiebaud RS, Stager JM, Abe T. Possibility of leg muscle hypertrophy by ambulation in older adults: a brief review. *Clinical interventions in aging*. 2013;8:369-75.
25. Scott BR, Loenneke JP, Slattery KM, Dascombe BJ. Blood flow restricted exercise for athletes: A review of available evidence. *Journal of science and medicine in sport*. 2016;19(5):360-7.
26. Scott BR, Loenneke JP, Slattery KM, Dascombe BJ. Exercise with blood flow restriction: an updated evidence-based approach for enhanced muscular development. *Sports medicine (Auckland, NZ)*. 2015;45(3):313-25.
27. Takarada Y, Nakamura Y, Aruga S, Onda T, Miyazaki S, Ishii N. Rapid increase in plasma growth hormone after low-intensity resistance exercise with vascular occlusion. *Journal of applied physiology (Bethesda, Md: 1985)*. 2000;88(1):61-5.
28. Takarada Y, Sato Y, Ishii N. Effects of resistance exercise combined with vascular occlusion on muscle function in athletes. *European journal of applied physiology*. 2002;86:308-14.
29. Takarada Y, Takazawa H, Ishii N. Applications of vascular occlusion diminish disuse atrophy of knee extensor muscles. *Medicine and science in sports and exercise*. 2000;32(12):2035-9.
30. Jørgensen AN, Aagaard P, Nielsen JL, Frandsen U, Diederichsen LP. Effects of blood-flow-restricted resistance training on muscle function in a 74-year-old male with sporadic inclusion body myositis: a case report. *Clinical Physiology and Functional Imaging*. 2016;36(6):504-9.
31. Nielsen JL, Aagaard P, Bech RD, Nygaard T, Hvid LG, Wernbom M, et al. Proliferation of myogenic stem cells in human skeletal muscle in response to low-load resistance training with blood flow restriction. *The Journal of physiology*. 2012;590(17):4351-61.
32. Nielsen JL, Aagaard P, Prokhorova TA, Nygaard T, Bech RD, Suetta C, et al. Blood-flow restricted training leads to myocellular macrophage infiltration and upregulation of heat-shock proteins, but no apparent muscle damage. *The Journal of physiology*. 2017;14:4857-73.

33. Segal N, Davis MD, Mikesky AE. Efficacy of Blood Flow-Restricted Low-Load Resistance Training For Quadriceps Strengthening in Men at Risk of Symptomatic Knee Osteoarthritis. *Geriatric orthopaedic surgery & rehabilitation*. 2015;6(3):160-7.
34. Segal NA, Williams GN, Davis MC, Wallace RB, Mikesky AE. Efficacy of blood flow-restricted, low-load resistance training in women with risk factors for symptomatic knee osteoarthritis. *PM & R : the journal of injury, function, and rehabilitation*. 2015;7(4):376-84.
35. Mauro A. Satellite cell of skeletal muscle fibers. *The Journal of biophysical and biochemical cytology*. 1961.
36. Kadi F, Charifi N, Denis C, Lexell J. Satellite cells and myonuclei in young and elderly women and men. *Muscle and Nerve*. 2004.
37. Olsen S, Aagaard P, Kadi F, Tufekovic G, Verney J, Olesen JL, et al. Creatine supplementation augments the increase in satellite cell and myonuclei number in human skeletal muscle induced by strength training. *Journal of Physiology*. 2006.
38. Francaux M, Deldicque L. Exercise and the control of muscle mass in human. *Pflügers Archiv - European Journal of Physiology*. 2018.
39. Kadi F, Schjerling P, Andersen LL, Charifi N, Madsen J, Christensen LR, et al. The effects of heavy resistance training and detraining on satellite cells in human skeletal muscles. *The Journal of physiology*. 2004.
40. Bazgir B, Fathi R, Valojerdi MR, Mozdziak P, Asgari A. Satellite cells contribution to exercise mediated muscle hypertrophy and repair. 2016.
41. Covinsky KE, Lindquist K, Dunlop DD, Gill TM, Yelin E. Effect of arthritis in middle age on older-age functioning. *Journal of the American Geriatrics Society*. 2008;56(1):23-8.
42. Bruusgaard JC, Johansen IB, Egner IM, Rana ZA, Gundersen K. Myonuclei acquired by overload exercise precede hypertrophy and are not lost on detraining. *Proceedings of the National Academy of Sciences*. 2010.
43. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *International journal of surgery (London, England)*. 2012;10(1):28-55.
44. M B. Knæalloplastik - fysioterapeutisk instruks <https://e-dok.rm.dk/edok/admin/GUI.nsf/Desktop.html?Open&login>; e-dok; 2019 [updated 03.04.19. 4:[1].
45. Suetta C, Andersen JL, Dalgas U, Berget J, Koskinen S, Aagaard P, et al. Resistance training induces qualitative changes in muscle morphology, muscle architecture, and muscle function in elderly postoperative patients. *Journal of applied physiology (Bethesda, Md: 1985)*. 2008;105(1):180-6.
46. Wright AA, Cook CE, Baxter GD, Dockerty JD, Abbott JH. A comparison of 3 methodological approaches to defining major clinically important improvement of 4 performance measures in patients with hip osteoarthritis. *The Journal of orthopaedic and sports physical therapy*. 2011;41(5):319-27.
47. Bloch ML, Jonsson LR, Kristensen MT. Introducing a Third Timed Up & Go Test Trial Improves Performances of Hospitalized and Community-Dwelling Older Individuals. *Journal of geriatric physical therapy (2001)*. 2017;40(3):121-6.
48. Alghadir A, Anwer S, Brismée J-m. The reliability and minimal detectable change of Timed Up and Go test in individuals with grade 1-3 knee osteoarthritis. *BMC musculoskeletal disorders*. 2015.
49. C N, V.A.B S, Y L, I K, M VDH, R.H.H E, et al. Reliability of hand-held dynamometry in patients awaiting total knee arthroplasty. *Physiotherapy (United Kingdom)*. 2011.
50. Koblbauer IFH, Lambrecht Y, Van DH, Neeter C, Engelbert RHH, Poolman RW, et al. Reliability of maximal isometric knee strength testing with modified hand-held dynamometry in

- patients awaiting total knee arthroplasty: Useful in research and individual patient settings? A reliability study. *BMC Musculoskeletal Disorders*. 2011.
51. Aagaard P, Andersen JL, Dyhre-Poulsen P, Leffers AM, Wagner A, Peter Magnusson S, et al. A mechanism for increased contractile strength of human pennate muscle in response to strength training: Changes in muscle architecture. *Journal of Physiology*. 2001;534(2):613-23.
 52. Lyman S, Lee YY, McLawhorn AS, Islam W, MacLean CH. What Are the Minimal and Substantial Improvements in the HOOS and KOOS and JR Versions After Total Joint Replacement? *Clinical orthopaedics and related research*. 2018;476(12):2432-41.
 53. Roos EM, Lohmander LS. The Knee injury and Osteoarthritis Outcome Score (KOOS): From joint injury to osteoarthritis. 2003.
 54. Wittrup-Jensen KU, Lauridsen J, Gudex C, Pedersen KM. Generation of a Danish TTO value set for EQ-5D health states. *Scandinavian Journal of Public Health*. 2009;37(5):459-66.
 55. Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). *Arthritis care & research*. 2011;63 Suppl 11:S240-52.
 56. Gill S, McBurney H. Reliability of performance-based measures in people awaiting joint replacement surgery of the hip or knee. *Physiotherapy Research International : The Journal for Researchers and Clinicians in Physical Therapy*. 2008;13(3):141-52.
 57. Jones CJ, Rikli RE, Beam WC. A 30-s chair-stand test as a measure of lower body strength in community-residing older adults. *Research quarterly for exercise and sport*. 1999;70(2):113-9.
 58. Kristensen MT, Ekdahl C, Kehlet H, Bandholm T. How many trials are needed to achieve performance stability of the Timed Up & Go test in patients with hip fracture? *Archives of Physical Medicine and Rehabilitation*. 2010;91(6):885-9.
 59. Hansen H. RM-testmanal. *Danish Physiotherapy Society: Danish Physiotherapy Society*; 2012. p. 2.
 60. Ekblom B. The muscle biopsy technique. Historical and methodological considerations. *Scandinavian Journal of Medicine & Science in Sports*. 2017;27(5):458-61.
 61. Bergstrom J. Muscle electrolytes in man determined by neutron activation analysis on needle biopsy specimens. *Scandinavian Journal of Clinical and Laboratory Investigation (England)*. 1962;14(Suppl 68).
 62. Nilsson AK, Lohmander LS, Klassbo M, Roos EM. Hip disability and osteoarthritis outcome score (HOOS)--validity and responsiveness in total hip replacement. *BMC musculoskeletal disorders*. 2003;4:10-2474-4-10. Epub 003 May 30.
 63. Collins NJ, Prinsen CA, Christensen R, Bartels EM, Terwee CB, Roos EM. Knee Injury and Osteoarthritis Outcome Score (KOOS): systematic review and meta-analysis of measurement properties. *Osteoarthritis and cartilage*. 2016;24(8):1317-29.
 64. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation*. 2011;20(10):1727-36.
 65. Bilbao A, Garcia-Perez L, Arenaza JC, Garcia I, Ariza-Cardiel G, Trujillo-Martin E, et al. Psychometric properties of the EQ-5D-5L in patients with hip or knee osteoarthritis: reliability, validity and responsiveness. *Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation*. 2018;27(11):2897-908.

66. Buchholz I, Janssen MF, Kohlmann T, Feng YS. A Systematic Review of Studies Comparing the Measurement Properties of the Three-Level and Five-Level Versions of the EQ-5D. *Pharmacoeconomics*. 2018;36(6):645-61.
67. Jakobsen TL, Christensen M, Christensen SS, Olsen M, Bandholm T. Reliability of knee joint range of motion and circumference measurements after total knee arthroplasty: does tester experience matter? *Physiotherapy Research International*. 2010;15(3):126-34.
68. Christensen R, Bliddal H, Henriksen M. Enhancing the reporting and transparency of rheumatology research: a guide to reporting guidelines. *Arthritis research & therapy*. 2013;15(1):109.
69. Malcata RM, Hopkins WG, Pearson SN. Tracking career performance of successful triathletes. *Medicine and science in sports and exercise*. 2014;46(6):1227-34.
70. Grapar Zargi T, Drobic M, Jkoder J, Strazar K, Kacin A. The effects of preconditioning with ischemic exercise on quadriceps femoris muscle atrophy following anterior cruciate ligament reconstruction: a quasi-randomized controlled trial. *European journal of physical and rehabilitation medicine*. 2016;52(3):310-20.
71. Zargi T, Drobic M, Strazar K, Kacin A. Short-Term Preconditioning With Blood Flow Restricted Exercise Preserves Quadriceps Muscle Endurance in Patients After Anterior Cruciate Ligament Reconstruction. *Frontiers in physiology*. 2018;9:1150.
72. Patterson SD, Hughes L, Warmington S, Burr J, Scott BR, Owens J, et al. Blood Flow Restriction Exercise Position Stand: Considerations of Methodology, Application, and Safety. *Frontiers in physiology*. 2019;10:533.
73. Andersen J, Aagaard P. Myosin heavy chain IIX overshoot in human skeletal muscle. *Muscle & nerve*. 2000;23:1095-104.
74. Malm C, Nyberg P, Engstrom M, Sjodin B, Lenkei R, Ekblom B, et al. Immunological changes in human skeletal muscle and blood after eccentric exercise and multiple biopsies. *The Journal of physiology*. 2000;529 Pt 1:243-62.

774 *Table 1. Exercise variables for the blood-flow restricted exercise (BFRE) protocol*

Exercise variable	Week 1-8
Level of LOP	60% LOP
Sets	4
Load intensity	30% 1RM
Repetitions 1 st set	30
Repetitions 2 nd & 3 rd set	15
Repetitions 4 th set	To volitional failure
Contraction modes per repetition	
Concentric	2 seconds
Isometric	0 seconds
Eccentric	2 seconds
Rest between repetitions	0 seconds
Time under tension per repetition	4 seconds
Range of movement	maximum
Rest between sets	30 seconds
Rest between sessions	≥36 hours
Progression	The minimal possible load (5 kilo) is added when patients perform >15 repetitions in 4 th set


776 *Table 2. Outcome measures to be collected.*

Outcome measures	Data collection instrument	Time-points of assessment
Primary outcome		
Sit-to-stand function	30 seconds chair stand test	B, S, 3 and 12 months
Secondary outcomes		
Isometric Knee extensor muscle strength	Handheld Dynamometer	B, S, 3 and 12 months
Isometric Knee flexion muscle strength	Handheld Dynamometer	B, S, 3 and 12 months
Gait speed	4x10-meter walk test	B, S, 3 and 12 months
Ambulatory capacity	Timed Up & Go	B, S, 3 and 12 months
Muscle morphology and biology	Muscle Biopsies	B, D, 3 months
Pain	KOOS	B, S, 6 weeks, 3 and 12 months
Symptoms	KOOS	B, S, 6 weeks, 3 and 12 months
Activities of daily living	KOOS	B, S, 6 weeks, 3 and 12 months
Sports & Recreation	KOOS	B, S, 6 weeks, 3 and 12 months
Quality of life	KOOS	B, S, 6 weeks, 3 and 12 months
Socioeconomic costs	EQ-5D	B, S, 6 weeks, 3 and 12 months
Adverse Events	Questionnaire and medical records	S, 3 months
Patient characteristics and related measurements		
Gender	Questionnaire	B
Age	Questionnaire	B
Height	Tape measure	B
Body mass	Electronic body mass scale	B
Civil Status	Questionnaire	B
Educational Level	Questionnaire	B
Employment Status	Questionnaire	B
Substance Use (alcohol, smoking)	Questionnaire	B
Duration of knee symptoms	Questionnaire	B
Pain medication during the last week	Questionnaire	B
Co-morbidities	Questionnaire	B
Blood pressure	Electronic upper limb blood pressure monitor	At doctor's visit

Postoperative supervised physiotherapy	Questionnaire	6 weeks, 3 and 12 months
Exercise compliance and progression	Physiotherapist records	B, S, at each BBFRE session, 3
NRS Pain	PhD-stipendiate and physiotherapist records	and 12 months

For peer review only

Figure 1. Patient flow





SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description
Administrative information		
Title (p 1, I 1-3)	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym
Trial registration A: p 2, I 56-57 B:	2a	Trial identifier and registry name. If not yet registered, name of intended registry
	2b	All items from the World Health Organization Trial Registration Data Set
Protocol version P 1, I 22	3	Date and version identifier
Funding P 21, I 494-496	4	Sources and types of financial, material, and other support
Roles and responsibilities A: P 1, I 5-11 B: P 1, I 15-20	5a	Names, affiliations, and roles of protocol contributors
	5b	Name and contact information for the trial sponsor
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)
Introduction		
Background and rationale P 3, I 67-133	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention
P 3, I 70-76	6b	Explanation for choice of comparators
Objectives P 5, I 129-136	7	Specific objectives or hypotheses
Trial design P 6, I 140-145	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)

Methods: Participants, interventions, and outcomes

Study setting P6, I 148-149	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained
Eligibility criteria P6, I 155-163	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)
Interventions A: p7, I 164-240 C: p12, 283-285	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)
Outcomes P 10, I 245-384	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial
	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)
Table 1		
Sample size P 17, I 391-401	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations
Recruitment P 6, I 148-151	15	Strategies for achieving adequate participant enrolment to reach target sample size

Methods: Assignment of interventions (for controlled trials)

Allocation:

Sequence generation P8, I 196-201	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions
--------------------------------------	-----	--

Allocation concealment mechanism P8, I 196-201	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned
Implementation P8, I 196-201	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions
Blinding (masking) P8, I 200	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how
	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial

Methods: Data collection, management, and analysis

Data collection methods P 10, I 245-420	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols
Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol
Statistical methods P 17, I 400-420	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)
P 17, I 400-420	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)

Methods: Monitoring

Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed
-----------------	-----	---

	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor
Ethics and dissemination		
Research ethics approval P 18, I 423-424	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)
Consent or assent P7, I 164-173	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable
Confidentiality P 11, I 265-275	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial
Declaration of interests P 22, I 514	28	Financial and other competing interests for principal investigators for the overall trial and each study site
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation
Dissemination policy P 18, 442-444 P 21, I 501-502	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions
	31b	Authorship eligibility guidelines and any intended use of professional writers

- 31c Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code

Appendices

Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.

BMJ Open

The efficacy of low-load blood flow restricted resistance EXercise in patients with Knee osteoarthritis scheduled for total knee replacement (EXKnee). Protocol for a multicenter, randomized controlled trial.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-034376.R2
Article Type:	Protocol
Date Submitted by the Author:	11-May-2020
Complete List of Authors:	Jørgensen, Stian; Regional Hospital Horsens, Department of occupational and physical therapy; Horsens Sygehus, H-HIP Bohn, Marie; Horsens Sygehus, Department of Orthopedic Surgery Aagaard, Per; Institute for Sports Science and Clinical Biomechanics, University of Southern Denmark, Mechlenburg, Inger; Aarhus University Hospital, Department of Orthopedics; Aarhus University, Clinical Medicine
Primary Subject Heading:	Sports and exercise medicine
Secondary Subject Heading:	Rehabilitation medicine
Keywords:	blood flow restriction exercise, knee osteoarthritis, total knee replacement surgery, preconditioning, functional capacity

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

The efficacy of low-load blood flow restricted resistance EXercise in patients with Knee osteoarthritis scheduled for total knee replacement (EXKnee). Protocol for a multicenter randomized controlled trial.

Stian Langgård Jørgensen^{1,2,5}, Marie Bagger Bohn², Per Aagaard³, Inger Mechlenburg^{4,5}

¹Department of Occupational and Physical Therapy, Horsens Regional Hospital, Denmark

²H-HIP, Department of Orthopedic Surgery, Horsens Regional Hospital, Denmark

³Department of Sports Science and Clinical Biomechanics, University of Southern Denmark

⁴Department of Orthopedic Surgery, Aarhus University Hospital, Denmark

⁵Department of Clinical Medicine, Aarhus University, Denmark

Corresponding Author:

Name: PhD student Stian Langgård Jørgensen

Address: Horsens Regional Hospital, Sundvej 30C, DK-8700 Horsens

E-mail: stiajo@rm.dk

Phone: +45 22 71 17 82

Word count: 5.650

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction

Up to 20% of patients undergoing total knee replacement (TKR) surgery report no or suboptimal pain relief after TKR. Moreover, despite chances of recovering to preoperative functional levels, patients receiving TKR have demonstrated persistent deficits in quadriceps strength and functional performance compared to healthy aged-matched adults. We intend to examine if low-load blood flow restricted exercise (BFRE) is an effective preoperative method to increase functional capacity, lower limb muscle strength and self-reported outcomes after TKR. In addition, the study aims to investigate to which extent preoperative BFRE will protect against surgery-related atrophy three months after TKR.

Methods

In this multicenter, randomized controlled and assessor blinded trial, 84 patients scheduled for TKR will be randomized to receive usual care and eight weeks of preoperative BFRE or to follow usual care-only. Data will be collected before randomization, three-four days prior to TKR, six weeks, three months, and 12 months after TKR. Primary outcome will be the change in 30-second chair stand test from baseline to three- month follow-up. Key secondary outcomes will be Timed Up & Go, 40-meter fast-paced walk test, isometric knee extensor and flexor strength, patient-reported outcome, and selected myofiber properties.

Intention-to-treat principle and per protocol analyses will be conducted. A one-way analysis of variance model will be used to analyze between group mean changes. Between-intervention comparison will be analyzed using a mixed linear model. Also, paired student t-tests will be performed and regression analysis will be used for analyzation of associations between selected outcomes.

49

Ethical approval

The trial has been accepted by the Central Denmark Region Committee on Biomedical Research Ethics (Journal No 10-72-19-19) and the Danish Data Protection Agency (Journal No 652164). All results will be published in international peer-reviewed scientific journals regardless of positive, negative or inconclusive results.

Trial registration

The trial is registered at Clinical Trials (NCT04081493)

Article Summary**Strengths and limitations of this study**

- The trial is a multicenter, randomized controlled assessor blinded trial.
- This is the first clinical trial to investigate the effect of low-load ischemic resistance training as a preconditioning method prior to elective knee replacement surgery.
- Patients will not be blinded to their allocation into intervention groups (BFR vs. control)
- This is a protocol paper

Key words

Blood flow restricted exercise, knee osteoarthritis, total knee replacement surgery, preconditioning

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

69 **INTRODUCTION**

70 Knee OA is a degenerative joint disease associated with pain, reduced physical activity, and quality
71 of life and affects almost 40% of all individuals ≥ 60 years of age (1-5). Approaching end-stage knee
72 OA, total knee replacement (TKR) is often the preferred treatment choice to reduce pain and regain
73 functional capacity. That is, TKR is considered a highly successful treatment to improve quality of
74 life and long-term function (6). However, despite being considered highly successful,
75 approximately 20% of the patients undergoing TKR experience a suboptimal outcome (6), which
76 has often been suggested to be related to incomplete restoration of physical function (7). In
77 addition, TKR patients typically demonstrate long-lasting deficits in quadriceps strength and
78 functional performance (2, 4). This failure to return to “normal” strength levels has been suggested
79 to be associated with preoperatively lower limb muscle strength and function (2) .

80 Preconditioning exercise designed to prepare the musculoskeletal system to better tolerate
81 stressful events such as the impact of invasive surgery has been suggested to be applicable prior to
82 elective TKR (6). This is supported by the results of two randomized controlled trials indicating that
83 preoperative heavy resistance strength training (HRST) may enhance functional capacity and knee
84 extensor muscle strength three months postoperatively (7, 8). Joint pain resulting from the high
85 mechanical loads associated with HRST may represent a barrier to this type of training in some
86 patients suffering from severe knee OA (1, 9). Therefore, a more tolerable, yet effective, alternative
87 is needed for this population. Also, three recent systematic reviews investigating the topic of
88 preoperative physiotherapy-based exercise before TKR all warrant high quality, well-powered
89 evidence to investigate the efficacy of preoperative physiotherapy before TKR (10-12).

90 Resistance training with low exercise loads ($\sim 30\%$ 1 repetition maximum) performed with
91 concurrent partial blood flow restriction to the working limb (Blood flow restricted exercise: BFRE)
92 has received increasing clinical interest during the last decade (1, 13-32). The application of low

muscle/tendon/joint forces in BFRE has been documented to increase human skeletal muscle size and to cause substantial strength gain in healthy young and old individuals, as well as some patient populations, despite the low magnitude of mechanical stress imposed on the trained tissue (13, 25, 26). When applied in the clinical setting, BFRE has demonstrated positive effects on skeletal muscle hypertrophy, strength, and functional capacity in mild-degree knee OA patients (1, 9, 33, 34) although not observed in all studies (33). Importantly, BFRE appears to be feasible with a high training adherence in knee OA patients (1, 33, 34). The use of different restrictive pressures (absolute restrictive pressures: 160-200 mmHg and individualized pressure of 70%; the pressure needed to provide complete blood flow restriction (total limb occlusion pressure: LOP) has been applied without any adverse events in mild-degree knee OA (1, 33, 34). This is in line with Hughes et al. (13), who suggested that when BFRE is performed correctly, it has been demonstrated to be as safe as free-flow exercise methods (13). Currently, no consensus exists about the appropriate restrictive pressure to induce favorable muscle adaptation in patients suffering from knee OA. This might be due to the fact that the effective occlusion pressure seems to be dictated by the exercise load/intensity (35). Thus, the effective occlusion pressure varies between studies due to use of different exercises or differences in exercise load and intensity. Restrictive pressures ranging from 40%-80% of total arterial leg occlusion pressure (LOP) have been suggested to be sufficient to evoke muscular adaptation in healthy adults (14, 17, 18, 36). If the load is less than 30% 1RM, higher restrictive pressures seems required to evoke muscle hypertrophy, while lower pressures (40% LOP) requires training loads of 30% 1RM or above to be performed (36). Injury or joint pain (i.e. from the knee) might limit the amount of resistance applied during strength testing, and may thus compromise the ability to rely fully on a given 30% 1RM estimation. Therefore, higher pressures than 40% LOP are suggested to be used in clinical settings (36). On the other hand, higher pressures are associated with more discomfort during exercise and in between-set rest pauses (14),

1
2
3
4 117 which potentially can affect exercise motivation negatively in patients. Thus, an occlusion pressure
5
6 118 sufficiently high to evoke measurable muscle adaptation despite potentially exercising at loads
7
8
9 119 lower than 30% 1RM; yet tolerable to maintain a high adherence, seems a favorable choice for this
10
11 120 particular patient population.

12
13 121 The adaptive mechanisms evoked by BFRE seem to involve accumulation of metabolites,
14
15
16 122 ischemia (transient tissue hypoxia), which may increase recruitment of higher threshold (Type II)
17
18 123 fibers through stimulation of group III and IV afferent nerve fibers (37, 38), and also activation of
19
20 124 myogenic muscle stem cells (satellite cells: SC) (13, 26, 31). SC are cells positioned between the
21
22
23 125 sarcolemma and the myofiber basal lamina (31, 39). SC play an important role in human skeletal
24
25 126 muscle growth due to their ability to donate new myonuclei to the muscle fibers (31, 40-44). That
26
27 127 is, the human skeletal muscle fibers are multinucleated cells with each myonucleus controlling the
28
29
30 128 protein synthesis of a certain cytoplasmatic area in the muscle fiber (40-42, 45). Myonuclei
31
32 129 transcriptional activity can be fully maximized with exercise, hence requiring new myonuclei to
33
34 130 support further muscle tissue accretion (41, 42, 44). It has been suggested that exercise-related
35
36 131 addition of SC and myonuclei by means of BFRE might reduce the muscle atrophy related to
37
38
39 132 bedrest and/or prolonged inactivity (31, 46). Previous studies applying short term (10 days)
40
41 133 preoperative BFRE before an anterior cruciate ligament rupture-reconstruction found no atrophy
42
43 134 protective effect or higher postoperative muscle strength compared to performing a low-load
44
45
46 135 exercise without blood flow restriction (placebo). However, it might be questionable if the applied
47
48 136 training frequency, intensity and training period have been sufficient to promote SCs and myonuclei
49
50 137 addition. Thus, longer periods of intensive training might be necessary to promote the desired
51
52
53 138 muscle morphological adaptations (addition of myonuclei and increased SC content).

54
55 139
56
57 140 **Aim and hypothesis of the trial**
58
59
60

The primary aim of this trial is to investigate the efficacy of eight weeks of BFRE compared to receiving usual care prior to TKR on postoperative chair stand performance. We hypothesize that eight weeks of preoperative BFRE will lead to increased 30 second chair stand performance (30-second Chair Stand Test: 30-s CST) when assessed three months postoperatively. Secondary aims are to investigate the efficacy of preoperative BFRE on lower limb muscle strength three months after TKR and investigate the potential relationship to functional capacity and quality of life. Furthermore, it will be investigated to which extent eight weeks of BFRE induce myofiber hypertrophy and gain in satellite cell number and myonuclei content in the knee extensor musculature.

MATERIAL & METHODS

Design

The trial is designed as a multicenter (two sites), randomized, assessor blinded, controlled trial following the CONSORT guidelines (47). Primary endpoint will be three months after TKR. Additional and secondary endpoints will be evaluated during the week of TKR, six weeks after TKR (questionnaires only) and 12 months after TKR. Muscle biopsies will be obtained from all patients undergoing surgery at Horsens Regional Hospital at baseline, during surgery and three months after TKR.

Participants

Patients will be recruited from the Departments of Orthopedic Surgery at Horsens and Silkeborg Regional Hospitals in Denmark. Patient enrollment will start September 2nd 2019 at Horsens Regional Hospital and October 1st 2019 at Silkeborg Regional Hospital. Patient recruitment is expected to be completed in June 2021. All patients are expected to have completed baseline testing

1
2
3
4 165 ultimo September 2021 and have performed three-month follow-up ultimo April 2022. Thus, at the
5
6
7 166 end of September 2023 all patients are expected to have completed 12-month follow-up testing.
8
9 167
10
11 168 Inclusion criteria: 1) Patients ≥ 50 years scheduled for TKR due to knee OA at Horsens- or
12
13
14 169 Silkeborg Regional Hospital.
15
16 170
17
18 171 Exclusion criteria: 1) Severe cardiovascular diseases (New York Heart Association (NYHA) class
19
20 172 III and IV), previous stroke incident, thrombosis incident; 2) traumatic nerve injury in affected limb
21
22
23 173 3) unregulated hypertension (systolic ≥ 180 or diastolic ≥ 110 mmHg) 4) spinal cord injury; 5)
24
25 174 planned other lower limb surgery within 12 months; 6) cancer diagnosis and currently undergoing
26
27 175 chemo-, immuno-, or radiotherapy; 7) inadequacy in written and spoken Danish; 8) an existing
28
29
30 176 prosthesis in the index limb; 9) living more than 45 minutes from either Horsens Regional Hospital
31
32 177 or Silkeborg Regional Hospital; 10) pregnancy.
33
34 178
35
36
37 179 *Please insert figure 1 around here*
38
39 180
40
41 181 All patients will be screened for eligibility by four orthopedic chief physicians at Horsens Regional
42
43 182 Hospital and by three orthopedic chief physicians at Silkeborg Regional Hospital who will perform
44
45
46 183 the initial inclusion of study participants and hand out written project information. All patients
47
48 184 accepting to participate will be asked to complete a written informed consent allowing the
49
50 185 physiotherapist (at Horsens Regional Hospital and Silkeborg Regional Hospital) to contact the
51
52
53 186 patients by phone for a final eligibility and exclusion criteria-screening and book an appointment
54
55 187 for baseline testing. If the patient agrees to participate in the trial, he/she will sign a written
56
57 188 informed consent to participate in the project. Subsequently, the patient will be baseline-tested at
58
59
60

the hospital by a blinded (to group allocation) assessor. Patients declining to participate in the RCT will be offered the option of participating in a parallel observational cohort trial. All patients included in the project will be scheduled for a TKR. Two-three weeks before surgery all patients will be invited to a, preoperative information meeting where nurses, surgeons, and physiotherapists will provide detailed information on pain management, nutrition, the surgical procedure, physical activity, postoperative home-based rehabilitation (table 1a and 1b), load management, etc. (usual care) (48). On the day of surgery, patients will be hospitalized at Horsens Regional Hospital or Silkeborg Regional Hospital where an orthopedic chief physician will perform the TKR procedure. The day after surgery all patients will receive physiotherapy-supervised training once or twice per day by a physiotherapist in order to fulfill the discharge criteria (table 2a and 2b) (48). Patients will generally be discharged within ~one-two days after fulfilling all the discharge criteria listed above. After discharge, all patients will receive a standard home-based rehabilitation program focusing on improving knee joint mobility, increasing the tolerance for standing without assistive devices, and lower extremity muscle strength. Variations in the selection of exercises and exercise variables exist in the standard home-based rehabilitation programs between the respective hospitals; however, the purpose of the programs is identical. If the patients do not fulfill the discharge criteria, they will be offered supervised knee-specific exercise therapy at a municipal rehabilitation center or specialized hospital-based rehabilitation after discharge from the hospital.

Please insert table 1a and 1 b about here

Please insert table 2a and figure 2b around here

Randomization

1
2
3
4 213 After baseline assessment, patients will be randomized (1:1) using the Research Electronic Data
5
6 214 Capture (REDCap) randomization system to either the training (BFRE) group or the control (CON)
7
8
9 215 group. Prior to randomization, all patients will be booked for follow-up test sessions and surgery.
10
11 216 All randomization procedures will be performed by the physiotherapists in charge of the BFRE
12
13 217 training. Assessors performing the tests will be blinded to group allocation until completion of the
14
15
16 218 trial. A flow chart of the patient allocation procedures is depicted in Figure 1.
17
18 219
19
20 220 CON group: Participants in CON will receive usual care (see above) prior to TKR and be
21
22
23 221 encouraged to continue their usual lifestyle up until TKR.
24
25 222
26
27 223 BFRE group: In addition to receiving usual care (cf. above), participants in the BFRE group will
28
29 224 perform supervised BFRE sessions three times per week for eight weeks supervised by a
30
31 225 physiotherapist educated in administering BFRE. All BFRE training will be performed at Horsens
32
33 226 Regional Hospital and Silkeborg Regional Hospital.
34
35
36 227
37
38 228 **Intervention procedures**
39
40
41 229 BFRE
42
43 230 Each BFRE session will consist of a 10-minute warm up (ergometer cycling) followed by two
44
45 231 different unilateral lower-limb resistance training exercises: 1) leg press and 2) knee extension
46
47
48 232 performed on standard strength training machines. Each exercise will be performed with the
49
50 233 affected lower limb only and consist of four rounds interspaced by 30 seconds of rest (table 3). First
51
52 234 round: 30 repetitions (reps); second round: 15 reps; third round: 15 reps; fourth round: until
53
54 235 exhaustion (Table 1). If patients can perform more than 15 repetitions in the fourth exercise set, the
55
56
57 236 exercise load will be increased with the minimum extra load possible (30). Participants will be
58
59 237 instructed to perform both the eccentric and concentric contraction phases using a steady 2-second
60

pace duration. The fourth and final exercise set will be performed to the point of exhaustion defined as being unable to complete the final concentric contraction phase in 2 seconds. During the 30 second rest period, patients will rest in a standardized resting position while maintaining the initial cuff-pressure. Between each exercise, patients will have a 5-minute "free-flow" rest period. The 5 minutes rest period applied between exercises was chosen based on experiences from a previous pilot project (Jorgensen & Bohn 2019, unpublished data) and experience with applying BFRE in clinical practice. In both situations, we often experienced that patients stayed seated in the leg press machine for >2 minutes after the last (fatiguing) set to feel sufficiently rested and confident to walk from one exercise machine to another. The cuff will be released immediately after completion of the final exercise set.

The occlusion pressure during both exercises will be set at 60% of total limb occlusion pressure (LOP) and the starting load intensity will be 30% with 1 repetition maximum (1RM) in both exercises.

Individual LOP will be determined using a pneumatic, conically shaped, 12 cm wide, rigid cuff (Occlude Aps, Denmark) attached to the patient's most proximal area of the thigh on the affected side. While sitting on an examination table with the ankle and 1/3 of the lower limb off the table, a vascular Doppler probe (EDAN Instruments, inc., China) will be placed posterior to the medial malleolus over the posterior tibial artery to capture the auscultatory pulse. To determine the cuff pressure (mmHg) needed for total blood flow occlusion, the cuff will gradually be inflated in 20 mmHg steps until reaching the pressure where the auscultatory pulse is interrupted (LOP). The first time the auscultatory pulse is interrupted, the examiner releases 10-20 mmHg pressure from the cuff until the auscultatory pulse is present again. When the auscultatory pulse reappears, the cuff is inflated with 10 mmHg until the LOP is found again. If the second LOP is identical to the first, it

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

will be defined as the LOP for that specific patient. Otherwise, the procedure will be repeated until determining an identical LOP two consecutive times.

Please insert Table 3 about here

Outcome variables

Outcome assessments will be performed at baseline (before randomization), three-four days before surgery, six weeks after TKR, three months after TKR, and 12 months after TKR. To reduce the number of postoperative visits, only questionnaires; The Knee disability and Osteoarthritis Outcome Score (KOOS), EuroQol Group 5-dimensions (EQ-5D-L5) and reporting of adverse event or receiving supervised physiotherapy postoperatively will be sent via email six weeks after surgery. Two testers (two trained physiotherapists) blinded to group allocation will perform all baseline and follow-up measurements. Bergström needle muscle biopsies (49) will be taken from vastus lateralis of the quadriceps muscle in both lower limbs from patients included at Horsens Regional Hospital only at baseline, during surgery, and three months after TKR by doctors trained in performing the procedure. An overview of the data collection parameters is presented in Table 4.

Before starting the baseline testing, all assessors will be thoroughly trained in performing the tests according to the standardized test procedures for each test method. All assessors will be blinded to intervention allocation (pre surgery BFRE training or usual care). Further, assessors will be trained in how to communicate with the participants at follow-up test sessions to avoid break of blinding due to miscommunication. Also, all cases where blinding is being broken will be registered. Also, the physiotherapist in charge of LL-BFRE will be thoroughly trained in performing the exercise on healthy subjects before applying LL-BFRE on study-patients. At the last scheduled exercise session (i.e. 24th session), the physiotherapists in charge of LL-BFRE will

carefully remind the participants not to reveal their group allocation to any assessors at any time point during post testing.

The primary investigator will be in weekly contact with the physiotherapists supervising the LL-BFRE at Horsens Regional Hospitalet and Silkeborg Regional Hospital where day-to-day-retraining and supervision can be arranged. Furthermore, physiotherapists supervising the LL-BFRE will receive in-depth retraining every three months.

Outcomes

Please insert Table 4 about here

Primary outcome

The 30s-CST will be assessed using a 44 cm (seat height) chair with armrests. The 30s-CST measures the number of sit-to-stand repetitions completed within 30 seconds. The 30s-CST is considered a valid and sensitive measure of lower-extremity sit-to-stand function with good to excellent intra- and inter-observer reliability (50-52).

Secondary outcomes

The Timed Up & Go test (TUG) assesses the time required for patients to stand from a 44 cm (seat height) chair walk around a tape mark 3 meters away and sit into the chair at return. The patients will be instructed to walk as fast and safely as possible towards the tape mark (and touch the tape mark (with at least one foot), turn around and return to the chair and sit down. Use of armrests is allowed. The fastest of two trials will be used for further analysis. Up to one minute of

rest will be allowed between trials (53, 54). Good inter-rater reliability has been demonstrated with the TUG test (52).

4x10 meter walk test (40m-FWT) measures the total time it takes to walk 4 x 10 meters excluding turns (meter/sec) (52). Patients will be instructed to walk as quickly and as safely as possible without running to a visible mark 10 meters away, return and repeat for a total distance of 40 meters (52). Prior to the test, one practice trial will be provided to check understanding. The 40m-FWT is a valid and responsive measure for assessing short distance maximum walking speed with excellent inter-rater reliability (52).

1RM leg press strength will be estimated from a 5-8RM leg press test. Patients perform three low-load warm-up sets. The first and second warm-up sets consist of 12 repetitions, and the third warm-up set consists of eight repetitions. The load of each warm-up set will be increased with 10 kilos. After warm-up, the load will be increased to determine the 5RM. If the 5RM cannot be determined within three trials, a fourth all-out trial (as many repetitions as possible) will be performed. The 1RM will be calculated as $[1RM = \text{load (kg)} / 1.0278 - 0.0278 \cdot \text{number of repetitions}]$ (55).

1RM knee extension strength will be estimated from 5-8RM knee extension test as described above for the estimation of 1RM leg press test (55).

Maximal isometric voluntary contraction (MVC) of the knee will be measured using a handheld dynamometer (HHD). The patients will be seated on an examination table with knees and hips positioned at 90° flexion. The patients will be instructed to remain seated in an upright position and place both hands on the shoulder to avoid compensation. The HHD will be fixed with a rigid belt to the examination table. Adjustable straps will be used to allow MVCs of the knee extensors to be performed at 90° knee flexion in all patients. The HHD will be positioned 5 cm above the medial

malleolus (56). The patients will be instructed to produce as much force as possible into the HHD.

Good to excellent inter- and intra-rater reliability has previously been demonstrated on group-level in patients suffering from knee OA for maximum knee extensor muscle strength testing with HDD (56, 57). Patients will receive four trials. For analysis, the mean maximal strength of the second, third and fourth measures will be calculated and corrected for bodyweight (56)

MVC of the knee flexors will be measured and performed using HHD at 90° knee flexion with the patients seated identically as during MVC for the knee extensors (56). The HHD will be positioned posterior aspect of calcaneus (56) and patients will be instructed to produce as much force as possible into the HHD. Good to excellent inter- and intra-rater reliability has previously been demonstrated on group-level in patients suffering from knee OA for maximum knee flexor muscle strength testing with HDD (56). Patients will receive four trials. For analysis, the mean maximal strength of the second, third and fourth measures will be calculated and corrected for bodyweight (56)

Myofiber cross sectional area (CSA), muscle fiber type composition, satellite cell content, and myonuclei number will be assessed by obtaining needle biopsies (100-150 mg) from all patients enrolled at Horsens Regional Hospital. The biopsies will be obtained bilaterally from the middle portion of the vastus lateralis muscle utilizing the percutaneous needle biopsy technique of Bergström (49, 58, 59). Biopsies will be performed by two experienced orthopedic surgeons (chief physicians) trained in performing the needle muscle biopsy technique at Horsens Regional Hospital. Efforts will be made to extract tissue from the same region (2-3 cm apart) and depth (~1-2 cm.) (49). The tissue samples will be dissected of all visible blood, adipose tissue, and connective tissue and mounted in Tissue-Tec (4583, Sakura Finetek, Alphen aan den Rijn, The Netherlands), frozen

1
2
3
4 358 in isopenate pre-cooled with liquid nitrogen, and stored at -80°C (31, 49, 60). All muscle samples
5
6
7 359 will be analyzed as previously described by Nielsen et al. (31) using immunofluorescence
8
9 360 microscopy. Transverse serial sections (8 µm) of the embedded muscle biopsy specimen will be cut
10
11 361 at -22°C using a cryostat (HM560; Microm, Walldorf, Germany) and will be mounted on glass
12
13
14 362 slides for subsequent analysis as described in detail elsewhere (31). Myogenic stem cells (satellite
15
16 363 cells (SC)) will be visualized with an antibody against Pax7 (31). Type I (stained) and Type II
17
18 364 (unstained) myofibers will be differentiated, and muscle fiber area will be determined (31): MSC-
19
20
21 365 derived nuclei will stain positive for Pax7 and be within the basal lamina; nuclei (DAPI stained)
22
23 366 with a sublaminar placement will be considered myonuclei (31).
24

25 367
26
27 368 **Knee disability and Osteoarthritis Outcome Score (KOOS)** is a patient-administered knee
28
29
30 369 specific questionnaire comprising five subscales: Pain; Symptoms; Activities of daily living; Sport
31
32 370 & Recreation; and Knee-Related Quality of Life. Each item is scored from 0 to 4 (61). The raw
33
34 371 score for each of the five subscales is the total sum of the associated item scores. Scores can be
35
36
37 372 transformed to a 0 to 100 scale. The scores of the five subscales can be expressed as a composite
38
39 373 outcome profile, higher scores indicating fewer problems (62). The KOOS questionnaire is valid
40
41 374 and reliable in patients suffering from knee OA and patients on the waiting list for TKA for knee
42
43
44 375 OA (61, 63, 64).
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

EuroQol Group 5-dimension (EQ-5D-5L) is a self-completion questionnaire consisting of two parts; the first part of the EQ-5D-5L comprises five dimensions involving mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. All dimensions have five response categories (no problems, slight problems, moderate problems, severe problems, and extreme problems) resulting in a five digit descriptive health state (65), which will be converted into a summary index ranging from -0.624 (worst) to 1.000 (best), using a Danish value set (66). The second part, EQ-VAS rates the overall current health status from 0 (worst imaginable health) to 100 (best imaginable health) (65). The EQ-5D-5L is reliable and valid in patients with knee OA eligible for TKA (67, 68).

Adverse events will be defined as unpredicted or unintended events, signs, or disease occurring during the period from inclusion until the 3-month follow-up (primary end-point) resulting in contact with the healthcare system (hospital or general practitioner) independent of whether or not the event is related to the intervention or outcome assessments. Adverse events will be recorded and categorized in accordance with the definitions established by the United States Food and Drug Administration [88]. Continuous registration of adverse events will be performed and a short open-ended questionnaire will be administered at three months follow-up.

Other Outcome Measures

Blood pressure will be measured by the orthopedic chief physicians when patients are visiting the outpatient clinic. Blood pressure will be used to determine eligibility to participate in the project.

Exercise compliance and progression will be obtained by the physiotherapist in charge of the training sessions and entered directly into the REDCap-system. The progression will be monitored as the total load lifted by the patient for exercise session.

Numeric rating scale for pain is a segmented unidimensional 11-item measure of pain intensity in adults (69) that will be used to rate pain intensity during both testing and exercise sessions. (69). 0 represents no pain while 10 represents worst pain imaginable (69).

Declining to be operated will be measured at three month follow-up, where patients will be asked whether they decided to be operated or not. Patients who declined to be operated will be invited to participate in all prescheduled follow-up assessments.

Postoperative supervised physiotherapy will be measured at six week, three month, and 12 month follow-up by answering a questionnaire. If patients have participated in postoperative supervised physiotherapy, the patient must specify whether the treatment was related to the TKR or due to other circumstances.

Knee joint active range of motion will be measured with a 360° plastic goniometer (scale 1°) with 16.5 cm moveable arms at baseline in the week of surgery, three months, and 12 months after surgery. Laying supine on an examination table, the knee joint flexion and knee joint extension will be measured separately (70). The tester then identifies the most prominent part of the trochanter, the lateral epicondyle of the femur, the lateral head of fibula, and the lateral malleolus. When identified, the patient is asked to flex the knee as much as possible with the heel maintaining contact to the surface at all time (70). Secondly, the patients will be asked to extend the knee joint as much as

possible. To allow the knee to extend as much as possible, a firm quadratic box (height: 5 cm, width: 8 cm, length: 15 cm) will be placed under the heel of the patient. The procedure of measuring knee extension will be similar to knee flexion, as the patients increases the degree of knee extension maximally (70). The fulcrum of the goniometer will correspond visually to the trans-epicondylar axis of the knee joint. The moveable arms of the goniometer will be pointed towards the greater trochanter and the lateral malleolus (70).

Data management

All data from the physical function tests will be entered into RedCap by the assessors using double data entry to ensure data quality. All patient-reported outcome data (KOOS, NRS Pain, EQ-5D-5L) will be entered directly into RedCap by the patients, and usage of the “required fields” will ensure no missing items from the completed questionnaires. To reduce missing data, a reminder email will be sent automatically from the RedCap-system. All patient data will be anonymized by assigning study numbers to each patient (coding). Personal data about the patient will be located separately from the main dataset to protect confidentiality during all trial phases. The raw dataset will be maintained for ten years after completion of the trial with indefinite restricted access due to sensitive data. After publication of the trial, a fully anonymized patient-level dataset and corresponding statistical description will be made publicly available if required by the scientific journal, in which the results are published.

Sample size

The power and sample size calculation is based on the expected differences between the two subject groups from baseline to three-month follow-up (8). Due to lack of data on the primary outcome for

1
2
3
4 447 investigations applying LL-BFRE before a surgical procedure, we decided to base our sample size
5
6 448 calculation on Skoffler et al. (8) who investigated the efficacy of four weeks of preoperative and
7
8
9 449 four weeks postoperative HRST (intervention group) compared to four weeks of postoperative
10
11 450 HRST only (control group) on 30-s CST three months in patients receiving a TKR (8). The authors
12
13
14 451 found a between-group difference of 3-4 repetition difference (14.7 ± 4.7 repetitions versus $11.0 \pm$
15
16 452 4.4 repetitions) three months after TKR surgery (8).

17
18 453 To reduce the probability of type I errors and enable detection of a between-group difference
19
20
21 454 also, α -level is set at 0.05 ($p < 0.05$) and β -level is set at 0.20 (80% power). Expecting a 3-repetition
22
23 455 between-group difference three months postoperatively and assuming a SD of 4.7 in both groups,
24
25 456 39 patients are required in each group (yielding 78 patients in total). With an anticipated dropout
26
27
28 457 rate of 10%, 84 patients will be recruited for the trial.

29
30 458
31
32 459 **Statistical considerations**

33
34
35 460 The primary efficacy analysis will be an assessment of the between group difference in change in
36
37 461 the 30-S CST from baseline to three-month follow-up (primary endpoint).

38
39 462 All descriptive statistics and tests will be reported in accordance with the recommendations of
40
41 463 the “Enhancing the QUALity and Transparency Of health Research” (EQUATOR) network (71) and
42
43
44 464 the CONSORT statement (47). Intention-to-treat principle (i.e. all patients as randomized
45
46 465 independent of departures from allocation treatment, compliance and/or withdrawals) and per
47
48 466 protocol analysis will be conducted. A one-way analysis of variance (one-way ANOVA) model will
49
50
51 467 be used to analyze between group mean changes in continuous outcome measures (31). The model
52
53 468 includes changes from baseline to 12-month follow-up. Between-intervention comparison from
54
55 469 baseline to three months after surgery will be analyzed using a mixed linear model with patient ID
56
57
58 470 as a random effect and time and group as fixed effects (31, 72). Also, to gain insight into the

potential pre-to-post training differences within the respective training or control groups, paired student t-tests will be performed. Level of statistical significance is $P < 0.05$. *Secondary outcome variables:* Between-intervention comparison from baseline to the week of surgery, six weeks after surgery, three and 12 months after surgery will be analyzed as described for the primary outcome. Regression analysis will be used to analyze the potential associations between preoperative strength and postoperative lower extremity function and self-reported outcome as well as between preoperative functional capacity and postoperative functional capacity. Additionally, regression analysis will be used to analyze the association between preoperative number of satellite cells and myonuclei on postoperative isometric knee extensor muscle strength, muscle fiber cross sectional area, and functional capacity. All statistical analyses will be performed by the primary investigator using Stata.

Ethical aspects and dissemination

The trial has been accepted by the Central Denmark Region Committee on Biomedical Research Ethics (Journal No 10-72-19-19) and by the Danish Data Protection Agency (Journal No 652164). The trial is registered at Clinicaltrials.gov (NCT04081493). Before inclusion, all patients will provide their written informed consent in accordance with the Helsinki Declaration. All data and information collected in regard to this trial will be treated confidentially (blinded and encrypted) by the researchers and staff connected to the trial.

All results from the trial will be published in international peer-reviewed scientific journals regardless of the results being considered positive, negative or inconclusive.

Patient and public involvement

Before developing this clinical trial, a pilot project was performed to determine the feasibility and

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

efficacy of BFRE in patients suffering from lower limb injuries. The experiences with the training modality and the verbal feedback from patients on training duration, frequency, and intensity resulted in useful knowledge that certainly has improved the development of the present clinical trial.

DISCUSSION

To the best of our knowledge, this is the first trial to investigate the effect of preoperative BFRE on functional capacity, self-reported outcome, lower limb muscle strength and myofiber morphology/stem cell abundance in patients scheduled for TKR. Only few studies have investigated (short term (10 days)) preoperative BFRE without finding an atrophy protective effect or difference in muscle strength compared to a control group performing a placebo intervention (SHAM group) (73). However, patients performing short term preoperative BFRE before ACL-R demonstrated higher muscle endurance compared to a SHAM group (74). Therefore, results of this trial are expected to provide novel information on longer periods of BFRE that will enable researchers to design effective exercise-based preconditioning protocols for elective TKR patients. The LL-BFRE protocol applied in the present project is widely used and follows the recommendations from a recent position stand by Patterson et al. (75). The authors suggested that exercising 2-3 times per week at 20-40% of 1RM in 2-4 sets (e.g. 30-15-15-15 or sets to failure) using pressures between 40 to 80% of LOP has demonstrated to be effective when aiming at increasing muscle strength and promoting muscle hypertrophy (75).

The trial is designed as an assessor blinded randomized controlled trial, thus representing the highest evidence level. However, the nature of the trial does not allow blinding of the participants which is an inherent limitation of the trial. The trial is conducted at two hospitals that consistently perform a high number of TKR procedures annually (225 and 460, respectively), thus securing a

strong expertise in terms of surgery and infrastructure. Both hospitals have all equipment needed available for surgery, post-operative hospitalization, training, and testing. All outcome variables are considered valid and reliable measures and consist of both objective outcomes and self-reported patient outcomes.

No adverse health-related events have been reported in previous studies applying BFRE in patients' suffering from knee OA or in healthy older adults (1, 9, 13, 23, 33, 34). Further, in a recent review and meta-analysis it was stated that exercise with concurrent blood-flow restriction is a safe exercise modality when occlusion procedures are applied correctly (13). The inherent invasive procedure of muscle biopsies may cause adverse events in rare occasions. Therefore, all muscle biopsy samples will be collected by trained medical doctors and performed following administration of local anesthesia and in fully sterile conditions. The needle muscle biopsy protocol has been applied in a large number of previous investigations including very old frail subjects (97 years of age) without any reporting of adverse events besides occasional muscle soreness(31, 49, 58, 76, 77).

There are some limitations of the project that must be taken into account. First, our primary end point is three months postoperatively. The (uncontrolled) period discharge to three months postoperatively renders the project vulnerable to external variabilities. However, from a pragmatic point of view, this uncontrolled period from discharge to three-month follow-up reflects the reality that Danish patients face postoperatively. Thus, the results at three-month follow-up will, indeed, reflect the impact of performing preoperative LL-BFRE on the postoperative outcome regardless of the external variable that can hamper the results. Secondly, the discharge criteria at Horsens Regional Hospital and Silkeborg Regional Hospital withhold slight differences. That is, the acceptable knee joint ROM at discharge differs between the sites, thus it can be speculated that more patients from Silkeborg Regional Hospital will be offered a postoperative, supervised rehabilitation program. This might affect the number of patients receiving supervised physiotherapy

1
2
3
4 543 after discharge between sites. However, all patients included in the present project will report
5
6 544 whether they have received postoperative supervised physiotherapy at all follow-up assessments.
7
8
9 545 Thus, we will be able to determine (and normalize) a potential between-site difference in patients
10
11 546 receiving supervised physiotherapy after TKR.
12

13 547
14
15 **Author contributions**
16 548

17
18 549 SLJ, PAA, MBB, and IM were all part of designing the trial and approved the final version of the
19
20 550 protocol. Also, SLJ, PAA, MBB, and IM wrote and revised the protocol.
21

22 551
23
24
25 552 **Data statement**

26
27 553 All obtained data will be stored in anonymized form at the Danish National Archives and deleted
28
29 554 after 10 years.
30

31 555
32
33
34 556 **Funding**

35
36 557 This work trial is supported by Aase og Ejnar Danielsen's Foundation (100,000 dkk), Nis-Hanssen's
37
38 558 Mindeslegat (163,883 dkk) and the Health Research Foundation of Central Denmark Region
39
40
41 559 (99,658 dkk), Hede-Nielsen Foundation (8,000 dkk).
42

43 560
44
45 561 **Competing interest**

46
47 562 None to be declared
48
49

50 563
51
52 564 **Ethics approval**

53
54 565 The trial has been accepted by the Central Denmark Region Committee on Biomedical Research
55
56
57
58
59
60

566 Ethics (Journal No 10-72-19-19) and by the Danish Data Protection Agency (Reference No
567 652164).

569 **Word count**

570 5.770 words

571

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Ferraz RB, Gualano B, Rodrigues R, Kurimori CO, Fuller R, Lima FR, et al. Benefits of Resistance Training with Blood Flow Restriction in Knee Osteoarthritis. *Medicine and science in sports and exercise*. 2018.

2. Bade MJ, Kohrt WM, Stevens-Lapsley J. Outcomes before and after total knee arthroplasty compared to healthy adults. *The Journal of orthopaedic and sports physical therapy*. 2010.

3. Fransen M, McConnell S, Harmer AR, Van dE, Simic M, Bennell KL. Exercise for osteoarthritis of the knee. 2015.

4. Skoffler B, Dalgas U, Mechlenburg I. Progressive resistance training before and after total hip and knee arthroplasty: A systematic review. 2015.

5. Sundhedsstyrelsen. Knæartrose - nationale kliniske retningslinjer og faglige visitationsretningslinjer2012.

6. Franz A, Queitsch FP, Behringer M, Mayer C, Krauspe R, Zilkens C. Blood flow restriction training as a prehabilitation concept in total knee arthroplasty: A narrative review about current preoperative interventions and the potential impact of BFR. *Medical hypotheses*. 2018.

7. Calatayud J, Casaña J, Ezzatvar Y, Jakobsen MD, Sundstrup E, Andersen LL. High-intensity preoperative training improves physical and functional recovery in the early post-operative periods after total knee arthroplasty: a randomized controlled trial. *Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA*. 2016.

8. Skoffler B, Maribo T, Mechlenburg I, Hansen PM, Søballe K, Dalgas U. Efficacy of Preoperative Progressive Resistance Training on Postoperative Outcomes in Patients Undergoing Total Knee Arthroplasty. *Arthritis Care & Research*. 2016.

9. Bryk FF, dos Reis AC, Fingerhut D, Araujo T, Schutzer M, Cury RdPL, et al. Exercises with partial vascular occlusion in patients with knee osteoarthritis: a randomized clinical trial. *Knee Surgery, Sports Traumatology, Arthroscopy*. 2016;24(5):1580-6.

10. Wang L, Lee M, Zhang Z, Moodie J, Cheng D, Martin J. Does preoperative rehabilitation for patients planning to undergo joint replacement surgery improve outcomes? A systematic review and meta-analysis of randomised controlled trials. *BMJ open*. 2016;6(2):e009857-2015-.

11. Chesham RA, Shanmugam S. Does preoperative physiotherapy improve postoperative, patient-based outcomes in older adults who have undergone total knee arthroplasty? A systematic review. 2017.

12. Kwok IH, Paton B, Haddad FS. Does Pre-Operative Physiotherapy Improve Outcomes in Primary Total Knee Arthroplasty? - A Systematic Review. *The Journal of arthroplasty*. 2015;30(9):1657-63.

13. Hughes L, Paton B, Rosenblatt B, Gissane C, Patterson SD. Blood flow restriction training in clinical musculoskeletal rehabilitation: A systematic review and meta-analysis. 2017.

14. Counts BRDSJBBEKDGMJAKMTRSATBMGLJP. Influence of Relative Blood Flow Restriction Pressure on Muscle Activation and Muscle Adaptation. *Muscle & nerve*. 2016;53:438-45.

15. Kim D, Loenneke JP, Ye X, Bemben DA, Beck TW, Larson RD, et al. Low-load resistance training with low relative pressure produces muscular changes similar to high-load resistance training. *Muscle & nerve*. 2017;56(6):E126-E33.

16. Loenneke JP, Fahs CA, Rossow LM, Sherk VD, Thiebaud RS, Abe T, et al. Effects of cuff width on arterial occlusion: implications for blood flow restricted exercise. *European journal of applied physiology*. 2012;112(8):2903-12.

17. Loenneke JP, Kim D, Fahs CA, Thiebaud RS, Abe T, Larson RD, et al. The influence of exercise load with and without different levels of blood flow restriction on acute changes in muscle thickness and lactate. *Clinical Physiology and Functional Imaging*. 2017.

18. Loenneke JP, Kim D, Fahs CA, Thiebaud RS, Abe T, Larson RD, et al. Effects of exercise with and without different degrees of blood flow restriction on torque and muscle activation. *Muscle & nerve*. 2015.
19. Loenneke JP, Thrower AD, Balapur A, Barnes JT, Pujol TJ. Blood flow-restricted walking does not result in an accumulation of metabolites. *Clinical physiology and functional imaging*. 2012;32(1):80-2.
20. Loenneke JP, Wilson JM, Balapur A, Thrower AD, Barnes JT, Pujol TJ. Time under tension decreased with blood flow-restricted exercise. *Clinical physiology and functional imaging*. 2012;32(4):268-73.
21. Loenneke JP, Wilson JM, Wilson GJ, Pujol TJ, Bembien MG. Potential safety issues with blood flow restriction training. 2011. p. 510-8.
22. Loenneke JP, Young KC, Fahs CA, Rossow LM, Bembien DA, Bembien MG. Blood flow restriction: rationale for improving bone. *Medical hypotheses*. 2012;78(4):523-7.
23. Ozaki H, Loenneke JP, Abe T. Blood flow-restricted walking in older women: does the acute hormonal response associate with muscle hypertrophy? *Clinical physiology and functional imaging*. 2017;37(4):379-83.
24. Ozaki H, Loenneke JP, Thiebaud RS, Stager JM, Abe T. Possibility of leg muscle hypertrophy by ambulation in older adults: a brief review. *Clinical interventions in aging*. 2013;8:369-75.
25. Scott BR, Loenneke JP, Slattery KM, Dascombe BJ. Blood flow restricted exercise for athletes: A review of available evidence. *Journal of science and medicine in sport*. 2016;19(5):360-7.
26. Scott BR, Loenneke JP, Slattery KM, Dascombe BJ. Exercise with blood flow restriction: an updated evidence-based approach for enhanced muscular development. *Sports medicine (Auckland, NZ)*. 2015;45(3):313-25.
27. Takarada Y, Nakamura Y, Aruga S, Onda T, Miyazaki S, Ishii N. Rapid increase in plasma growth hormone after low-intensity resistance exercise with vascular occlusion. *Journal of applied physiology (Bethesda, Md: 1985)*. 2000;88(1):61-5.
28. Takarada Y, Sato Y, Ishii N. Effects of resistance exercise combined with vascular occlusion on muscle function in athletes. *European journal of applied physiology*. 2002;86:308-14.
29. Takarada Y, Takazawa H, Ishii N. Applications of vascular occlusion diminish disuse atrophy of knee extensor muscles. *Medicine and science in sports and exercise*. 2000;32(12):2035-9.
30. Jørgensen AN, Aagaard P, Nielsen JL, Frandsen U, Diederichsen LP. Effects of blood-flow-restricted resistance training on muscle function in a 74-year-old male with sporadic inclusion body myositis: a case report. *Clinical Physiology and Functional Imaging*. 2016;36(6):504-9.
31. Nielsen JL, Aagaard P, Bech RD, Nygaard T, Hvid LG, Wernbom M, et al. Proliferation of myogenic stem cells in human skeletal muscle in response to low-load resistance training with blood flow restriction. *The Journal of physiology*. 2012;590(17):4351-61.
32. Nielsen JL, Aagaard P, Prokhorova TA, Nygaard T, Bech RD, Suetta C, et al. Blood-flow restricted training leads to myocellular macrophage infiltration and upregulation of heat-shock proteins, but no apparent muscle damage. *The Journal of physiology*. 2017;14:4857-73.
33. Segal N, Davis MD, Mikesky AE. Efficacy of Blood Flow-Restricted Low-Load Resistance Training For Quadriceps Strengthening in Men at Risk of Symptomatic Knee Osteoarthritis. *Geriatric orthopaedic surgery & rehabilitation*. 2015;6(3):160-7.
34. Segal NA, Williams GN, Davis MC, Wallace RB, Mikesky AE. Efficacy of blood flow-restricted, low-load resistance training in women with risk factors for symptomatic knee osteoarthritis. *PM & R : the journal of injury, function, and rehabilitation*. 2015;7(4):376-84.
35. Jessee MB, Mattocks KT, Buckner SL, Dankel SJ, Mouser JG, Abe T, et al. Mechanisms of Blood Flow Restriction: The New Testament. *Techniques in Orthopaedics*. 2018;33(2):72-9.

1

2

3

4 680

5 681

6 682

7 683

8 684

9 685

10 686

11 687

12 688

13 689

14 690

15 691

16 692

17 693

18 694

19 695

20 696

21 697

22 698

23 699

24 700

25 701

26 702

27 703

28 704

29 705

30 706

31 707

32 708

33 709

34 710

35 711

36 712

37 713

38 714

39 715

40 716

41 717

42 718

43 719

44 720

45 721

46 722

47 723

48 724

49 725

50 726

51 727

52 728

53 729

54 730

55 731

56 732

57 733

58 734

59 735

60 736

36. Mattocks KT, Jessee MB, Mouser JG, Dankel SJ, Buckner SL, Bell ZW, et al. The Application of Blood Flow Restriction: Lessons From the Laboratory. *Current sports medicine reports*. 2018;17(4):129-34.

37. Wernbom M, Augustsson J, Raastad T. Ischemic strength training: a low-load alternative to heavy resistance exercise? *Scandinavian Journal of Medicine & Science in Sports*. 2008;18(4):401-16.

38. Wernbom M, Aagaard P. Muscle fibre activation and fatigue with low-load blood flow restricted resistance exercise-An integrative physiology review. *Acta physiologica (Oxford, England)*. 2019:e13302.

39. Mauro A. Satellite cell of skeletal muscle fibers. *The Journal of biophysical and biochemical cytology*. 1961.

40. Kadi F, Charifi N, Denis C, Lexell J. Satellite cells and myonuclei in young and elderly women and men. *Muscle and Nerve*. 2004.

41. Olsen S, Aagaard P, Kadi F, Tufekovic G, Verney J, Olesen JL, et al. Creatine supplementation augments the increase in satellite cell and myonuclei number in human skeletal muscle induced by strength training. *Journal of Physiology*. 2006.

42. Francaux M, Deldicque L. Exercise and the control of muscle mass in human. *Pflügers Archiv - European Journal of Physiology*. 2018.

43. Kadi F, Schjerling P, Andersen LL, Charifi N, Madsen J, Christensen LR, et al. The effects of heavy resistance training and detraining on satellite cells in human skeletal muscles. *The Journal of physiology*. 2004.

44. Bazgir B, Fathi R, Valojerdi MR, Mozdziak P, Asgari A. Satellite cells contribution to exercise mediated muscle hypertrophy and repair. 2016.

45. Covinsky KE, Lindquist K, Dunlop DD, Gill TM, Yelin E. Effect of arthritis in middle age on older-age functioning. *Journal of the American Geriatrics Society*. 2008;56(1):23-8.

46. Bruusgaard JC, Johansen IB, Egner IM, Rana ZA, Gundersen K. Myonuclei acquired by overload exercise precede hypertrophy and are not lost on detraining. *Proceedings of the National Academy of Sciences*. 2010.

47. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *International journal of surgery (London, England)*. 2012;10(1):28-55.

48. M B. Knæalloplastik - fysioterapeutisk instruks <https://e-dok.rm.dk/edok/admin/GUI.nsf/Desktop.html?Open&login>: e-dok; 2019 [updated 03.04.19. 4:[1].

49. Suetta C, Andersen JL, Dalgas U, Berget J, Koskinen S, Aagaard P, et al. Resistance training induces qualitative changes in muscle morphology, muscle architecture, and muscle function in elderly postoperative patients. *Journal of applied physiology (Bethesda, Md: 1985)*. 2008;105(1):180-6.

50. Gill S, McBurney H. Reliability of performance-based measures in people awaiting joint replacement surgery of the hip or knee. *Physiotherapy Research International : The Journal for Researchers and Clinicians in Physical Therapy*. 2008;13(3):141-52.

51. Jones CJ, Rikli RE, Beam WC. A 30-s chair-stand test as a measure of lower body strength in community-residing older adults. *Research quarterly for exercise and sport*. 1999;70(2):113-9.

52. Wright AA, Cook CE, Baxter GD, Dockerty JD, Abbott JH. A comparison of 3 methodological approaches to defining major clinically important improvement of 4 performance measures in patients with hip osteoarthritis. *The Journal of orthopaedic and sports physical therapy*. 2011;41(5):319-27.

53. Bloch ML, Jonsson LR, Kristensen MT. Introducing a Third Timed Up & Go Test Trial Improves Performances of Hospitalized and Community-Dwelling Older Individuals. *Journal of geriatric physical therapy (2001)*. 2017;40(3):121-6.

54. Kristensen MT, Ekdahl C, Kehlet H, Bandholm T. How many trials are needed to achieve performance stability of the Timed Up & Go test in patients with hip fracture? *Archives of Physical Medicine and Rehabilitation*. 2010;91(6):885-9.

55. Hansen H. RM-testmanal. Danish Physiotherapy Society: Danish Physiotherapy Society; 2012. p. 2.
56. Koblbauer IFH, Lambrecht Y, Van DH, Neeter C, Engelbert RHH, Poolman RW, et al. Reliability of maximal isometric knee strength testing with modified hand-held dynamometry in patients awaiting total knee arthroplasty: Useful in research and individual patient settings? A reliability study. *BMC Musculoskeletal Disorders*. 2011.
57. C N, V.A.B S, Y L, I K, M VDH, R.H.H E, et al. Reliability of hand-held dynamometry in patients awaiting total knee arthroplasty. *Physiotherapy (United Kingdom)*. 2011.
58. Ekblom B. The muscle biopsy technique. Historical and methodological considerations. *Scandinavian Journal of Medicine & Science in Sports*. 2017;27(5):458-61.
59. Bergstrom J. Muscle electrolytes in man determined by neutron activation analysis on needle biopsy specimens. *Scandinavian Journal of Clinical and Laboratory Investigation (England)*. 1962;14(Suppl 68).
60. Aagaard P, Andersen JL, Dyhre-Poulsen P, Leffers AM, Wagner A, Peter Magnusson S, et al. A mechanism for increased contractile strength of human pennate muscle in response to strength training: Changes in muscle architecture. *Journal of Physiology*. 2001;534(2):613-23.
61. Roos EM, Lohmander LS. The Knee injury and Osteoarthritis Outcome Score (KOOS): From joint injury to osteoarthritis. 2003.
62. Nilsson AK, Lohmander LS, Klassbo M, Roos EM. Hip disability and osteoarthritis outcome score (HOOS)--validity and responsiveness in total hip replacement. *BMC musculoskeletal disorders*. 2003;4:10-2474-4-10. Epub 003 May 30.
63. Lyman S, Lee YY, McLawhorn AS, Islam W, MacLean CH. What Are the Minimal and Substantial Improvements in the HOOS and KOOS and JR Versions After Total Joint Replacement? *Clinical orthopaedics and related research*. 2018;476(12):2432-41.
64. Collins NJ, Prinsen CA, Christensen R, Bartels EM, Terwee CB, Roos EM. Knee Injury and Osteoarthritis Outcome Score (KOOS): systematic review and meta-analysis of measurement properties. *Osteoarthritis and cartilage*. 2016;24(8):1317-29.
65. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation*. 2011;20(10):1727-36.
66. Wittrup-Jensen KU, Lauridsen J, Gudex C, Pedersen KM. Generation of a Danish TTO value set for EQ-5D health states. *Scandinavian Journal of Public Health*. 2009;37(5):459-66.
67. Bilbao A, Garcia-Perez L, Arenaza JC, Garcia I, Ariza-Cardiel G, Trujillo-Martin E, et al. Psychometric properties of the EQ-5D-5L in patients with hip or knee osteoarthritis: reliability, validity and responsiveness. *Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation*. 2018;27(11):2897-908.
68. Buchholz I, Janssen MF, Kohlmann T, Feng YS. A Systematic Review of Studies Comparing the Measurement Properties of the Three-Level and Five-Level Versions of the EQ-5D. *Pharmacoeconomics*. 2018;36(6):645-61.
69. Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). *Arthritis care & research*. 2011;63 Suppl 11:S240-52.
70. Jakobsen TL, Christensen M, Christensen SS, Olsen M, Bandholm T. Reliability of knee joint range of motion and circumference measurements after total knee arthroplasty: does tester experience matter? *Physiotherapy Research International*. 2010;15(3):126-34.
71. Christensen R, Bliddal H, Henriksen M. Enhancing the reporting and transparency of rheumatology research: a guide to reporting guidelines. *Arthritis research & therapy*. 2013;15(1):109.

1
2
3
4 788
5 789
6 790
7 791
8 792
9 793
10 794
11 795
12 796
13 797
14 798
15 799
16 800
17 801
18 802
19 803
20 804
21
22 805
23
24 806
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

72. Malcata RM, Hopkins WG, Pearson SN. Tracking career performance of successful triathletes. *Medicine and science in sports and exercise*. 2014;46(6):1227-34.

73. Grapar Zargi T, Drobnic M, Jkoder J, Strazar K, Kacin A. The effects of preconditioning with ischemic exercise on quadriceps femoris muscle atrophy following anterior cruciate ligament reconstruction: a quasi-randomized controlled trial. *European journal of physical and rehabilitation medicine*. 2016;52(3):310-20.

74. Zargi T, Drobnic M, Strazar K, Kacin A. Short-Term Preconditioning With Blood Flow Restricted Exercise Preserves Quadriceps Muscle Endurance in Patients After Anterior Cruciate Ligament Reconstruction. *Frontiers in physiology*. 2018;9:1150.

75. Patterson SD, Hughes L, Warmington S, Burr J, Scott BR, Owens J, et al. Blood Flow Restriction Exercise Position Stand: Considerations of Methodology, Application, and Safety. *Frontiers in physiology*. 2019;10:533.

76. Andersen J, Aagaard P. Myosin heavy chain IIX overshoot in human skeletal muscle. *Muscle & nerve*. 2000;23:1095-104.

77. Malm C, Nyberg P, Engstrom M, Sjodin B, Lenkei R, Ekblom B, et al. Immunological changes in human skeletal muscle and blood after eccentric exercise and multiple biopsies. *The Journal of physiology*. 2000;529 Pt 1:243-62.

807 *Table 1a. Postoperative rehabilitation program, Horsens Regional Hospital*

Week 0-3				
Step	Exercise	Repetitions	Sets	Resistance
Step 1 & 2	Supine peristaltic pump exercise with feet above heart level	20 minutes	3-4/day	-
Step 1	Supine knee extension mobilization	20 seconds	3 sets	-
Step 1	Supine unilateral knee and hip extension and flexion mobilization with slipper under the heel	5 repetitions	3 sets	Slipper minimizes floor friction
Step 2	Seated knee extension and flexion mobilization with slipper under the foot	5 repetitions	3 sets	Slipper minimizes floor friction
Step 2	Standing weight transfer exercise	15 repetitions each side	1 set	Bodyweight
Step 2	Sit to stand from a high chair or the edge of table	5 repetitions	3 sets	Bodyweight
Week 3 and onwards				
Step 1 & 2	Supine peristaltic pump exercise with feet above heart level	20 minutes	3-4/day	-
Step 1	Seated knee extension mobilization	20 seconds	4 rounds	Arms can be used to apply pressure onto the knee to help extend the knee
Step 1	Step up exercise	10-15 repetitions	2-3 sets	Bodyweight
Step 1	Standing knee isometric knee towel press	10-15 repetitions	2-3 sets	Ball/Towel rolled together
Step 1	Sit to stand from a chair	10-15 repetitions	2-3 sets	Bodyweight
Step 1	One leg standing	30 seconds	1 set	Bodyweight
Step 2	Standing hip flexion	Not informed	Not informed	Elastic band
Step 2	Standing hip abduction	Not informed	Not informed	Elastic band
Step 2	Partial frontal plane sliding lunge	10 repetitions	3 sets, 2-3/day	Bodyweight
Step 2	Partial back sliding lunge	10 repetitions	3 sets, 2-3/day	Bodyweight
Optional	Cycling	10-20 minutes	1 set	Light resistance can be added when it is possible to perform a full round with the operated limb.

Step 1 is performed in the morning and step 2 is performed in the afternoon. All exercises are performed once per day.

810 *Table 1b. Postoperative rehabilitation program, Silkeborg Regional Hospital*

Week 0-2				
Step	Exercise	Repetitions	Sets	Resistance
Optional	Cycling	5-10 minutes	2/day	
-	Supine peristaltic pump exercise	Not informed	Not informed	-
-	Rest with leg above heart level	30 minutes	4/day	-
-	Seated isometric knee extension	3 seconds	10 sets	Lower leg and the foot
-	Seated knee flexion mobilization	3 seconds	10 sets	-
-	Seated knee extension mobilization	30 seconds	3 sets	Apply pressure to the knee joint using the arms
-	Supine isometric knee extension	3 seconds	10 sets	Lower leg and the foot
-	Supine passive knee extension mobilization			Gravity will extend the knee joint
Week 2 and onwards				
-	Supine knee isometric knee towel press	3seconds hold	10sets	Lower leg and the foot

-	Sit to stand	10 repetitions	1 set	Body weight
-	Standing knee flexion mobilization	3 seconds	10 sets	Body weight
-	Step Up Exercise	10 repetitions	1 set	Body weight

Table 2a. Discharge criteria at Horsens Regional Hospital

Minimum knee flexion range of motion	60 degrees
Maximal knee extension deficit	15 degrees
In-and-out of bed	Independent
Sit-to-stand	Independent
Walking with/without assistive devices	Independent
Stair negotiation with/without assistive devices	Independent
Activities of daily living	Independent
Understanding of the home-based postoperative exercise program	Sufficient

Table 2b. Discharge criteria at Silkeborg Regional Hospital

Minimum knee flexion range of motion	90 degrees
Maximal knee extension deficit	5 degrees
In-and-out of bed	Independent
Sit-to-stand	Independent
Walking with/without assistive devices	Independent
Stair negotiation with/without assistive devices	Independent
Activities of daily living	Independent
Understanding of the home-based postoperative exercise program	Sufficient

Table 3. Exercise variables for the blood-flow restricted exercise (BFRE) protocol

Exercise variable	Week 1-8
Level of LOP	60% LOP
Sets	4
Load intensity	30% 1RM
Repetitions 1 st set	30
Repetitions 2 nd & 3 rd set	15
Repetitions 4 th set	To volitional failure
Contraction modes per repetition	
Concentric	2 seconds
Isometric	0 seconds
Eccentric	2 seconds
Rest between repetitions	0 seconds
Time under tension per repetition	4 seconds
Range of movement	maximum
Rest between sets	30 seconds
Rest between sessions	≥36 hours
Progression	The minimal possible load (5 kilo) is added when patients perform >15 repetitions in 4 th set

Table 4. Outcome measures to be collected.

Outcome measures	Data collection instrument	Time-points of assessment
Primary outcome		
Sit-to-stand function	30 seconds chair stand test	B, S, 3 and 12 months
Secondary outcomes		
Ambulatory capacity	Timed Up & Go	B, S, 3 and 12 months
Gait speed	4x10-meter walk test	B, S, 3 and 12 months
Isometric Knee extensor muscle strength	Handheld Dynamometer	B, S, 3 and 12 months
Isometric Knee flexion muscle strength	Handheld Dynamometer	B, S, 3 and 12 months
Myofiber morphology	Muscle Biopsies	B, S, 3 months
Myogenic stem cell content	Muscle Biopsies	B, S, 3 months
Pain	KOOS	B, S, 6 weeks, 3 and 12 months
Symptoms	KOOS	B, S, 6 weeks, 3 and 12 months
Activities of daily living	KOOS	B, S, 6 weeks, 3 and 12 months
Sports & Recreation	KOOS	B, S, 6 weeks, 3 and 12 months
Quality of life	KOOS	B, S, 6 weeks, 3 and 12 months
Socioeconomic costs	EQ-5D	B, S, 6 weeks, 3 and 12 months
Adverse Events	Questionnaire and medical records	3 months
Exercise compliance and progression	Physiotherapist records	BFRE
Pain during visits	NRS for pain	B, BFRE, S, 3 and 12 months
Declining to be operated	Questionnaire	3 months
Postoperative supervised physiotherapy	Questionnaire	6 weeks, 3 and 12 months
Knee joint range of motion	Goniometer	B, S, 3 and 12 months
Patient characteristics and related measurements	Questionnaire	B
Gender	Tape measure	B
Age	Electronic body mass scale	B
Height	Questionnaire	B
Body mass	Questionnaire	B
Civil Status	Questionnaire	B
Educational Level	Questionnaire	B
Employment Status	Questionnaire	B
Substance Use (alcohol, smoking)	Questionnaire	B
Duration of knee symptoms	Questionnaire	B
Pain medication during the last week	Questionnaire	B
Co-morbidities	Questionnaire	B

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table and figure legends

Table 1a. Step 1 is performed in the morning and step 2 is performed in the afternoon. All exercises are performed once per day.

Table 1b. All exercises are performed once per day. Cycling ergometer exercise is optional.

Table 3. LOP: Total limb occlusion pressure; RM: Repetition Maximum

Table 4. KOOS = Knee disability and Osteoarthritis Outcome Score; B = Baseline; S = 0-2 days before surgery; D = during surgery; 3 months = 3 months after TKR; 12 months = 12 after TKR; NRS = Numeric Ranking Scale of pain

Figure 1. Flow chart of the enrollment, treatment, and follow-up phases. TKR: Total Knee Replacement, BFRE: Low-load blood-flow restricted exercise

```
graph TD
    A[Patients scheduled for a TKR at Horsens Regional Hospital and Silkeborg Regional Hospital  
Assessed for eligibility (n)] --> B[Enrolment]
    A --> C[Excluded (n)  
- Not meeting inclusion criteria (n)  
- Declining to participate  
- Other reasons (n)]
    B --> D[Baseline assessments and randomization]
    D --> E[BFRE group (n=42)]
    D --> F[CON Group (n=42)]
    E --> G[Lost to follow-up (n)  
Did not complete the intervention (n)  
Declining TKA (n)]
    F --> H[Lost to follow-up (n)  
Declining TKA (n)]
    G --> I[Lost to follow-up (n)]
    H --> J[Lost to follow-up (n)]
    I --> K[Lost to follow-up (n)]
    J --> L[Lost to follow-up (n)]
    K --> M[Lost to follow-up (n)]
    L --> N[Lost to follow-up (n)]
    G --> O[Surgery follow-up]
    H --> O
    O --> I
    O --> J
    O --> L
    O --> N
    O --> P[12 months follow Up]
```

Flowchart illustrating the study design and patient progression:

- Enrolment:** Patients scheduled for a TKR at Horsens Regional Hospital and Silkeborg Regional Hospital, Assessed for eligibility (n).
- Exclusion:** Excluded (n) due to:
 - Not meeting inclusion criteria (n)
 - Declining to participate
 - Other reasons (n)
- Baseline assessments and randomization:** Patients are randomized into two groups:
 - BFRE group (n=42)**
 - CON Group (n=42)**
- Follow-up:** Patients are tracked at multiple time points:
 - Surgery follow-up:** Patients who did not complete the intervention or declined TKA are tracked.
 - 6 weeks follow-up:** Patients lost to follow-up at this time point.
 - 3 months primary Endpoint:** Patients lost to follow-up at this time point.
 - 12 months follow Up:** Patients lost to follow-up at this time point.



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description
Administrative information		
Title (p 1, I 1-3)	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry
A: p 2, I 56-57		
B:	2b	All items from the World Health Organization Trial Registration Data Set
Protocol version	3	Date and version identifier
P 1, I 22		
Funding	4	Sources and types of financial, material, and other support
P 21, I 494-496		
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors
A: P 1, I 5-11	5b	Name and contact information for the trial sponsor
B: P 1, I 15-20		
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)
Introduction		
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention
P 3, I 67-133		
P 3, I 70-76	6b	Explanation for choice of comparators
Objectives	7	Specific objectives or hypotheses
P 5, I 129-136		
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)
P 6, I 140-145		

Methods: Participants, interventions, and outcomes

Study setting P6, I 148-149	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained
Eligibility criteria P6, I 155-163	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)
Interventions A: p7, I 164-240 C: p12, 283-285	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)
Outcomes P 10, I 245-384	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial
	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)
Table 1		
Sample size P 17, I 391-401	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations
Recruitment P 6, I 148-151	15	Strategies for achieving adequate participant enrolment to reach target sample size

Methods: Assignment of interventions (for controlled trials)

Allocation:

Sequence generation P8, I 196-201	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions
--------------------------------------	-----	--

Allocation concealment mechanism P8, I 196-201	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned
Implementation P8, I 196-201	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions
Blinding (masking) P8, I 200	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how
	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial

Methods: Data collection, management, and analysis

Data collection methods P 10, I 245-420	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols
Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol
Statistical methods P 17, I 400-420	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)
P 17, I 400-420	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)

Methods: Monitoring

Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed
-----------------	-----	---

	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor

Ethics and dissemination

Research ethics approval P 18, I 423-424	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)
Consent or assent P 7, I 164-173	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable
Confidentiality P 11, I 265-275	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial
Declaration of interests P 22, I 514	28	Financial and other competing interests for principal investigators for the overall trial and each study site
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation
Dissemination policy P 18, 442-444	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions
P 21, I 501-502	31b	Authorship eligibility guidelines and any intended use of professional writers

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

31c Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code

Appendices

Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons “[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)” license.

BMJ Open

The efficacy of low-load blood flow restricted resistance EXercise in patients with Knee osteoarthritis scheduled for total knee replacement (EXKnee). Protocol for a multicenter randomized controlled trial.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-034376.R3
Article Type:	Protocol
Date Submitted by the Author:	13-Aug-2020
Complete List of Authors:	Jørgensen, Stian; Regional Hospital Horsens, Department of occupational and physical therapy; Horsens Sygehus, H-HIP Bohn, Marie; Horsens Sygehus, Department of Orthopedic Surgery Aagaard, Per; Institute for Sports Science and Clinical Biomechanics, University of Southern Denmark, Mechlenburg, Inger; Aarhus University Hospital, Department of Orthopedics; Aarhus University, Clinical Medicine
Primary Subject Heading:	Sports and exercise medicine
Secondary Subject Heading:	Rehabilitation medicine
Keywords:	blood flow restriction exercise, knee osteoarthritis, total knee replacement surgery, preconditioning, functional capacity

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

The efficacy of low-load blood flow restricted resistance EXercise in patients with Knee osteoarthritis scheduled for total knee replacement (EXKnee). Protocol for a multicenter randomized controlled trial.

Stian Langgård Jørgensen^{1,2,5}, Marie Bagger Bohn², Per Aagaard³, Inger Mechlenburg^{4,5}

¹Department of Occupational and Physical Therapy, Horsens Regional Hospital, Denmark

²H-HIP, Department of Orthopedic Surgery, Horsens Regional Hospital, Denmark

³Department of Sports Science and Clinical Biomechanics, University of Southern Denmark

⁴Department of Orthopedic Surgery, Aarhus University Hospital, Denmark

⁵Department of Clinical Medicine, Aarhus University, Denmark

Corresponding Author:

Name: PhD student Stian Langgård Jørgensen

Address: Horsens Regional Hospital, Sundvej 30C, DK-8700 Horsens

E-mail: stiajo@rm.dk

Phone: +45 22 71 17 82

Word count: 5.650

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction

Up to 20% of patients undergoing total knee replacement (TKR) surgery report no or suboptimal pain relief after TKR. Moreover, despite chances of recovering to preoperative functional levels, patients receiving TKR have demonstrated persistent deficits in quadriceps strength and functional performance compared to healthy aged-matched adults. We intend to examine if low-load blood flow restricted exercise (BFRE) is an effective preoperative method to increase functional capacity, lower limb muscle strength and self-reported outcomes after TKR. In addition, the study aims to investigate to which extent preoperative BFRE will protect against surgery-related atrophy three months after TKR.

Methods

In this multicenter, randomized controlled and assessor blinded trial, 84 patients scheduled for TKR will be randomized to receive usual care and eight weeks of preoperative BFRE or to follow usual care-only. Data will be collected before randomization, three-four days prior to TKR, six weeks, three months, and 12 months after TKR. Primary outcome will be the change in 30-second chair stand test from baseline to three- month follow-up. Key secondary outcomes will be Timed Up & Go, 40-meter fast-paced walk test, isometric knee extensor and flexor strength, patient-reported outcome, and selected myofiber properties.

Intention-to-treat principle and per protocol analyses will be conducted. A one-way analysis of variance model will be used to analyze between group mean changes. Pre-to-post intervention comparisons will be analyzed using a mixed linear model. Also, paired student t-tests will be performed to gain insight into the potential pre-to-post training differences within the respective

training or control groups and regression analysis will be used for analyzation of associations between selected outcomes.

Ethical approval

The trial has been accepted by the Central Denmark Region Committee on Biomedical Research Ethics (Journal No 10-72-19-19) and the Danish Data Protection Agency (Journal No 652164). All results will be published in international peer-reviewed scientific journals regardless of positive, negative or inconclusive results.

Trial registration

The trial is registered at Clinical Trials (NCT04081493)

Article Summary

Strengths and limitations of this study

- The trial is a multicenter, randomized controlled assessor blinded trial.
- This is the first clinical trial to investigate the effect of low-load ischemic resistance training as a preconditioning method prior to elective knee replacement surgery.
- Patients will not be blinded to their allocation into intervention groups (BFR vs. control)
- This is a protocol paper

Key words

Blood flow restricted exercise, knee osteoarthritis, total knee replacement surgery, preconditioning

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

70 **INTRODUCTION**

71 Knee OA is a degenerative joint disease associated with pain, reduced physical activity, and quality
72 of life and affects almost 40% of all individuals ≥ 60 years of age (1-5). Approaching end-stage knee
73 OA, total knee replacement (TKR) is often the preferred treatment choice to reduce pain and regain
74 functional capacity. That is, TKR is considered a highly successful treatment to improve quality of
75 life and long-term function (6). However, despite being considered highly successful,
76 approximately 20% of the patients undergoing TKR experience a suboptimal outcome (6), which
77 has often been suggested to be related to incomplete restoration of physical function (7). In
78 addition, TKR patients typically demonstrate long-lasting deficits in quadriceps strength and
79 functional performance (2, 4). This failure to return to “normal” strength levels has been suggested
80 to be associated with preoperatively lower limb muscle strength and function (2) .

81 Preconditioning exercise designed to prepare the musculoskeletal system to better tolerate
82 stressful events such as the impact of invasive surgery has been suggested to be applicable prior to
83 elective TKR (6). This is supported by the results of two randomized controlled trials indicating that
84 preoperative heavy resistance strength training (HRST) may enhance functional capacity and knee
85 extensor muscle strength three months postoperatively (7, 8). Joint pain resulting from the high
86 mechanical loads associated with HRST may represent a barrier to this type of training in some
87 patients suffering from severe knee OA (1, 9). Therefore, a more tolerable, yet effective, alternative
88 is needed for this population. Also, three recent systematic reviews investigating the topic of
89 preoperative physiotherapy-based exercise before TKR all warrant high quality, well-powered
90 evidence to investigate the efficacy of preoperative physiotherapy before TKR (10-12).

91 Resistance training with low exercise loads (~30% 1 repetition maximum) performed with
92 concurrent partial blood flow restriction to the working limb (Blood flow restricted exercise: BFRE)
93 has received increasing clinical interest during the last decade (1, 13-32). The application of low

muscle/tendon/joint forces in BFRE has been documented to increase human skeletal muscle size and to cause substantial strength gain in healthy young and old individuals, as well as some patient populations, despite the low magnitude of mechanical stress imposed on the trained tissue (13, 25, 26). When applied in the clinical setting, BFRE has demonstrated positive effects on skeletal muscle hypertrophy, strength, and functional capacity in mild-degree knee OA patients (1, 9, 33, 34) although not observed in all studies (33). Importantly, BFRE appears to be feasible with a high training adherence in knee OA patients (1, 33, 34). The use of different restrictive pressures (absolute restrictive pressures: 160-200 mmHg and individualized pressure of 70%; the pressure needed to provide complete blood flow restriction (total limb occlusion pressure: LOP) has been applied without any adverse events in mild-degree knee OA (1, 33, 34). This is in line with Hughes et al. (13), who suggested that when BFRE is performed correctly, it has been demonstrated to be as safe as free-flow exercise methods (13).

Currently, no consensus exists about the appropriate restrictive pressure to induce favorable muscle adaptation in patients suffering from knee OA. This might be due to the fact that the effective occlusion pressure seems to be dictated by the exercise load/intensity (35). Thus, the effective occlusion pressure varies between studies due to use of different exercises or differences in exercise load and intensity. Restrictive pressures ranging from 40%-80% of total arterial leg occlusion pressure (LOP) have been suggested to be sufficient to evoke muscular adaptation in healthy adults (14, 17, 18, 36). If the load is less than 30% 1RM, higher restrictive pressures seems required to evoke muscle hypertrophy, while lower pressures (40% LOP) requires training loads of 30% 1RM or above to be performed (36). Injury or joint pain (i.e. from the knee) might limit the amount of resistance applied during strength testing, and may thus compromise the ability to rely fully on a given 30% 1RM estimation. Therefore, higher pressures than 40% LOP are suggested to be used in clinical settings (36). On the other hand, higher pressures are associated with more

1
2
3
4 118 discomfort during exercise and in between-set rest pauses (14), which potentially can affect exercise
5
6 119 motivation negatively in patients. Thus, an occlusion pressure sufficiently high to evoke measurable
7
8
9 120 muscle adaptation despite potentially exercising at loads lower than 30% 1RM; yet tolerable to
10
11 121 maintain a high adherence, seems a favorable choice for this particular patient population.
12

13 122 The adaptive mechanisms evoked by BFRE seem to involve accumulation of metabolites,
14
15
16 123 ischemia (transient tissue hypoxia), which may increase recruitment of higher threshold (Type II)
17
18 124 fibers through stimulation of group III and IV afferent nerve fibers (37, 38), and also activation of
19
20 125 myogenic muscle stem cells (satellite cells: SC) (13, 26, 31). SC are cells positioned between the
21
22
23 126 sarcolemma and the myofiber basal lamina (31, 39). SC play an important role in human skeletal
24
25 127 muscle growth due to their ability to donate new myonuclei to the muscle fibers (31, 40-44). That
26
27 128 is, the human skeletal muscle fibers are multinucleated cells with each myonucleus controlling the
28
29
30 129 protein synthesis of a certain cytoplasmatic area in the muscle fiber (40-42, 45). Myonuclei
31
32 130 transcriptional activity can be fully maximized with exercise, hence requiring new myonuclei to
33
34 131 support further muscle tissue accretion (41, 42, 44). It has been suggested that exercise-related
35
36
37 132 addition of SC and myonuclei by means of BFRE might reduce the muscle atrophy related to
38
39 133 bedrest and/or prolonged inactivity (31, 46). Previous studies applying short term (10 days)
40
41 134 preoperative BFRE before an anterior cruciate ligament rupture-reconstruction found no atrophy
42
43 135 protective effect or higher postoperative muscle strength compared to performing a low-load
44
45
46 136 exercise without blood flow restriction (placebo). However, it might be questionable if the applied
47
48 137 training frequency, intensity and training period have been sufficient to promote SCs and myonuclei
49
50 138 addition. Thus, longer periods of intensive training might be necessary to promote the desired
51
52
53 139 muscle morphological adaptations (addition of myonuclei and increased SC content).
54

55 140
56
57 141 **Aim and hypothesis of the trial**
58
59
60

The primary aim of this trial is to investigate the efficacy of eight weeks of BFRE compared to receiving usual care prior to TKR on postoperative chair stand performance. We hypothesize that eight weeks of preoperative BFRE will lead to increased 30 second chair stand performance (30-second Chair Stand Test: 30-s CST) when assessed three months postoperatively. Secondary aims are to investigate the efficacy of preoperative BFRE on lower limb muscle strength three months after TKR and investigate the potential relationship to functional capacity and quality of life. Furthermore, it will be investigated to which extent eight weeks of BFRE induce myofiber hypertrophy and gain in satellite cell number and myonuclei content in the knee extensor musculature.

MATERIAL & METHODS

Design

The trial is designed as a multicenter (two sites), randomized, assessor blinded, controlled trial following the CONSORT guidelines (47). Primary endpoint will be three months after TKR. Additional and secondary endpoints will be evaluated during the week of TKR, six weeks after TKR (questionnaires only) and 12 months after TKR. Muscle biopsies will be obtained from all patients undergoing surgery at Horsens Regional Hospital at baseline, during surgery and three months after TKR.

Participants

Patients will be recruited from the Departments of Orthopedic Surgery at Horsens and Silkeborg Regional Hospitals in Denmark. Patient enrollment will start September 2nd 2019 at Horsens Regional Hospital and October 1st 2019 at Silkeborg Regional Hospital. Patient recruitment is expected to be completed in June 2021. All patients are expected to have completed baseline testing

1
2
3
4 166 in September 2021. To account for surgery and intervention, the three-month follow-up will be
5
6
7 167 concluded in April 2022. Thus, at the end of September 2022 all patients are expected to have
8
9 168 completed 12-month follow-up testing.

10
11 169
12
13
14 170 Inclusion criteria: 1) Patients ≥ 50 years scheduled for TKR due to knee OA at Horsens- or
15
16 171 Silkeborg Regional Hospital.

17
18 172
19
20 173 Exclusion criteria: 1) Severe cardiovascular diseases (New York Heart Association (NYHA) class
21
22
23 174 III and IV), previous stroke incident, thrombosis incident; 2) traumatic nerve injury in affected limb
24
25 175 3) unregulated hypertension (systolic ≥ 180 or diastolic ≥ 110 mmHg) 4) spinal cord injury; 5)
26
27 176 planned other lower limb surgery within 12 months; 6) cancer diagnosis and currently undergoing
28
29
30 177 chemo-, immuno-, or radiotherapy; 7) inadequacy in written and spoken Danish; 8) an existing
31
32 178 prosthesis in the index limb; 9) living more than 45 minutes from either Horsens Regional Hospital
33
34 179 or Silkeborg Regional Hospital; 10) pregnancy.

35
36 180
37
38
39 181 *Please insert figure 1 around here*

40
41 182
42
43 183 All patients will be screened for eligibility by four orthopedic chief physicians at Horsens Regional
44
45
46 184 Hospital and by three orthopedic chief physicians at Silkeborg Regional Hospital who will perform
47
48 185 the initial inclusion of study participants and hand out written project information. All patients
49
50 186 accepting to participate will be asked to complete a written informed consent allowing the
51
52
53 187 physiotherapist (at Horsens Regional Hospital and Silkeborg Regional Hospital) to contact the
54
55 188 patients by phone for a final eligibility and exclusion criteria-screening and book an appointment
56
57 189 for baseline testing. If the patient agrees to participate in the trial, he/she will sign a written

informed consent to participate in the project. Subsequently, the patient will be baseline-tested at the hospital by a blinded (to group allocation) assessor. Patients declining to participate in the RCT will be offered the option of participating in a parallel observational cohort trial. All patients included in the project will be scheduled for a TKR. Two-three weeks before surgery all patients will be invited to a, preoperative information meeting where nurses, surgeons, and physiotherapists will provide detailed information on pain management, nutrition, the surgical procedure, physical activity, postoperative home-based rehabilitation (table 1a and 1b), load management, etc. (usual care) (48). On the day of surgery, patients will be hospitalized at Horsens Regional Hospital or Silkeborg Regional Hospital where an orthopedic chief physician will perform the TKR procedure. The day after surgery all patients will receive physiotherapy-supervised training once or twice per day by a physiotherapist in order to fulfill the discharge criteria (table 2a and 2b) (48). Patients will generally be discharged within ~one-two days after fulfilling all the discharge criteria listed above. After discharge, all patients will receive a standard home-based rehabilitation program focusing on improving knee joint mobility, increasing the tolerance for standing without assistive devices, and lower extremity muscle strength. Variations in the selection of exercises and exercise variables exist in the standard home-based rehabilitation programs between the respective hospitals; however, the purpose of the programs is identical. If the patients do not fulfill the discharge criteria, they will be offered supervised knee-specific exercise therapy at a municipal rehabilitation center or specialized hospital-based rehabilitation after discharge from the hospital.

Please insert table 1a and 1 b about here

Please insert table 2a and table 2b around here

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Randomization

After baseline assessment, patients will be randomized (1:1) using the Research Electronic Data Capture (REDCap) randomization system to either the training (BFRE) group or the control (CON) group. Prior to randomization, all patients will be booked for follow-up test sessions and surgery. All randomization procedures will be performed by the physiotherapists in charge of the BFRE training. Assessors performing the tests will be blinded to group allocation until completion of the trial. A flow chart of the patient allocation procedures is depicted in Figure 1.

CON group: Participants in CON will receive usual care (see above) prior to TKR and be encouraged to continue their usual lifestyle up until TKR.

BFRE group: In addition to receiving usual care (cf. above), participants in the BFRE group will perform supervised BFRE sessions three times per week for eight weeks supervised by a physiotherapist educated in administering BFRE. All BFRE training will be performed at Horsens Regional Hospital and Silkeborg Regional Hospital.

Intervention procedures

BFRE

Each BFRE session will consist of a 10-minute warm up (ergometer cycling) followed by two different unilateral lower-limb resistance training exercises: 1) leg press and 2) knee extension performed on standard strength training machines. Each exercise will be performed with the affected lower limb only and consist of four rounds interspaced by 30 seconds of rest (table 3). First round: 30 repetitions (reps); second round: 15 reps; third round: 15 reps; fourth round: until exhaustion (Table 1). If patients can perform more than 15 repetitions in the fourth exercise set, the exercise load will be increased with the minimum extra load possible (30). Participants will be

instructed to perform both the eccentric and concentric contraction phases using a steady 2-second pace duration. The fourth and final exercise set will be performed to the point of exhaustion defined as being unable to complete the final concentric contraction phase in 2 seconds. During the 30 second rest period, patients will rest in a standardized resting position while maintaining the initial cuff-pressure. Between each exercise, patients will have a 5-minute "free-flow" rest period. The 5 minutes rest period applied between exercises was chosen based on experiences from a previous pilot project (Jorgensen & Bohn 2019, unpublished data) and experience with applying BFRE in clinical practice. In both situations, we often experienced that patients stayed seated in the leg press machine for >2 minutes after the last (fatiguing) set to feel sufficiently rested and confident to walk from one exercise machine to another. The cuff will be released immediately after completion of the final exercise set.

The occlusion pressure during both exercises will be set at 60% of total limb occlusion pressure (LOP) and the starting load intensity will be 30% with 1 repetition maximum (1RM) in both exercises.

Individual LOP will be determined using a pneumatic, conically shaped, 12 cm wide, rigid cuff (Occlude Aps, Denmark) attached to the patient's most proximal area of the thigh on the affected side. While sitting on an examination table with the ankle and 1/3 of the lower limb off the table, a vascular Doppler probe (EDAN Instruments, inc., China) will be placed posterior to the medial malleolus over the posterior tibial artery to capture the auscultatory pulse. To determine the cuff pressure (mmHg) needed for total blood flow occlusion, the cuff will gradually be inflated in 20 mmHg steps until reaching the pressure where the auscultatory pulse is interrupted (LOP). The first time the auscultatory pulse is interrupted, the examiner releases 10-20 mmHg pressure from the cuff until the auscultatory pulse is present again. When the auscultatory pulse reappears, the cuff is inflated with 10 mmHg until the LOP is found again. If the second LOP is identical to the first, it

1
2
3
4 263 will be defined as the LOP for that specific patient. Otherwise, the procedure will be repeated until
5
6 264 determining an identical LOP two consecutive times.
7
8

9 265
10 266 *Please insert Table 3 about here*
11 267
12

13 268 **Outcome variables**
14

15 269 Outcome assessments will be performed at baseline (before randomization), three-four days before
16
17 surgery, six weeks after TKR, three months after TKR, and 12 months after TKR. To reduce the
18 270
19 number of postoperative visits, only questionnaires; The Knee disability and Osteoarthritis Outcome
20 271
21 Score (KOOS), EuroQol Group 5-dimensions (EQ-5D-L5) and reporting of adverse event or
22 272
23 receiving supervised physiotherapy postoperatively will be sent via email six weeks after surgery.
24
25 273
26 Two testers (two trained physiotherapists) blinded to group allocation will perform all baseline and
27 274
28 follow-up measurements. Bergström needle muscle biopsies (49) will be taken from vastus lateralis
29 275
30 of the quadriceps muscle in both lower limbs from patients included at Horsens Regional Hospital
31
32 276
33 only at baseline, during surgery, and three months after TKR by doctors trained in performing the
34 277
35 procedure. An overview of the data collection parameters is presented in Table 4.
36 278
37

38 279 Before starting the baseline testing, all assessors will be thoroughly trained in performing
39
40 the tests according to the standardized test procedures for each test method. All assessors will be
41 280
42 blinded to intervention allocation (pre surgery BFRE training or usual care). Further, assessors will
43 281
44 be trained in how to communicate with the participants at follow-up test sessions to avoid break of
45 282
46 blinding due to miscommunication. Also, all cases where blinding is being broken will be
47
48 283
49 registered. Also, the physiotherapist in charge of LL-BFRE will be thoroughly trained in
50 284
51 performing the exercise on healthy subjects before applying LL-BFRE on study-patients. At the last
52 285
53 scheduled exercise session (i.e. 24th session), the physiotherapists in charge of LL-BFRE will
54
55 286
56
57
58
59
60

carefully remind the participants not to reveal their group allocation to any assessors at any time point during post testing.

The primary investigator will be in weekly contact with the physiotherapists supervising the LL-BFRE at Horsens Regional Hospitalet and Silkeborg Regional Hospital where day-to-day-retraining and supervision can be arranged. Furthermore, physiotherapists supervising the LL-BFRE will receive in-depth retraining every three months.

Outcomes

Please insert Table 4 about here

Primary outcome

The 30s-CST will be assessed using a 44 cm (seat height) chair with armrests. The 30s-CST measures the number of sit-to-stand repetitions completed within 30 seconds. The 30s-CST is considered a valid and sensitive measure of lower-extremity sit-to-stand function with good to excellent intra- and inter-observer reliability (50-52).

Secondary outcomes

The Timed Up & Go test (TUG) assesses the time required for patients to stand from a 44 cm (seat height) chair walk around a tape mark 3 meters away and sit into the chair at return. The patients will be instructed to walk as fast and safely as possible towards the tape mark (and touch the tape mark (with at least one foot), turn around and return to the chair and sit down. Use of armrests is allowed. The fastest of two trials will be used for further analysis. Up to one minute of

rest will be allowed between trials (53, 54). Good inter-rater reliability has been demonstrated with the TUG test (52).

4x10 meter walk test (40m-FWT) measures the total time it takes to walk 4 x 10 meters excluding turns (meter/sec) (52). Patients will be instructed to walk as quickly and as safely as possible without running to a visible mark 10 meters away, return and repeat for a total distance of 40 meters (52). Prior to the test, one practice trial will be provided to check understanding. The 40m-FWT is a valid and responsive measure for assessing short distance maximum walking speed with excellent inter-rater reliability (52).

1RM leg press strength will be estimated from a 5-8RM leg press test. Patients perform three low-load warm-up sets. The first and second warm-up sets consist of 12 repetitions, and the third warm-up set consists of eight repetitions. The load of each warm-up set will be increased with 10 kilos. After warm-up, the load will be increased to determine the 5RM. If the 5RM cannot be determined within three trials, a fourth all-out trial (as many repetitions as possible) will be performed. The 1RM will be calculated as $[1RM = \text{load (kg)} / 1.0278 - 0.0278 \cdot \text{number of repetitions}]$ (55).

1RM knee extension strength will be estimated from 5-8RM knee extension test as described above for the estimation of 1RM leg press test (55).

Maximal isometric voluntary contraction (MVC) of the knee will be measured using a handheld dynamometer (HHD). The patients will be seated on an examination table with knees and hips positioned at 90° flexion. The patients will be instructed to remain seated in an upright position and place both hands on the shoulder to avoid compensation. The HHD will be fixed with a rigid belt to the examination table. Adjustable straps will be used to allow MVCs of the knee extensors to be performed at 90° knee flexion in all patients. The HHD will be positioned 5 cm above the medial

malleolus (56). The patients will be instructed to produce as much force as possible into the HHD.

Good to excellent inter- and intra-rater reliability has previously been demonstrated on group-level in patients suffering from knee OA for maximum knee extensor muscle strength testing with HDD (56, 57). Patients will receive four trials. For analysis, the mean maximal strength of the second, third and fourth measures will be calculated and corrected for bodyweight (56)

MVC of the knee flexors will be measured and performed using HHD at 90° knee flexion with the patients seated identically as during MVC for the knee extensors (56). The HHD will be positioned posterior aspect of calcaneus (56) and patients will be instructed to produce as much force as possible into the HHD. Good to excellent inter- and intra-rater reliability has previously been demonstrated on group-level in patients suffering from knee OA for maximum knee flexor muscle strength testing with HDD (56). Patients will receive four trials. For analysis, the mean maximal strength of the second, third and fourth measures will be calculated and corrected for bodyweight (56)

Myofiber cross sectional area (CSA), muscle fiber type composition, satellite cell content, and myonuclei number will be assessed by obtaining needle biopsies (100-150 mg) from all patients enrolled at Horsens Regional Hospital. The biopsies will be obtained bilaterally from the middle portion of the vastus lateralis muscle utilizing the percutaneous needle biopsy technique of Bergström (49, 58, 59). Biopsies will be performed by two experienced orthopedic surgeons (chief physicians) trained in performing the needle muscle biopsy technique at Horsens Regional Hospital. Efforts will be made to extract tissue from the same region (2-3 cm apart) and depth (~1-2 cm.) (49). The tissue samples will be dissected of all visible blood, adipose tissue, and connective tissue and mounted in Tissue-Tec (4583, Sakura Finetek, Alphen aan den Rijn, The Netherlands), frozen

1
2
3
4 360 in isopenate pre-cooled with liquid nitrogen, and stored at -80°C (31, 49, 60). All muscle samples
5
6
7 361 will be analyzed as previously described by Nielsen et al. (31) using immunofluorescence
8
9 362 microscopy. Transverse serial sections (8 µm) of the embedded muscle biopsy specimen will be cut
10
11 363 at -22°C using a cryostat (HM560; Microm, Walldorf, Germany) and will be mounted on glass
12
13
14 364 slides for subsequent analysis as described in detail elsewhere (31). Myogenic stem cells (satellite
15
16 365 cells (SC)) will be visualized with an antibody against Pax7 (31). Type I (stained) and Type II
17
18 366 (unstained) myofibers will be differentiated, and muscle fiber area will be determined (31): MSC-
19
20
21 367 derived nuclei will stain positive for Pax7 and be within the basal lamina; nuclei (DAPI stained)
22
23 368 with a sublaminar placement will be considered myonuclei (31).
24

25 369
26
27 370 **Knee disability and Osteoarthritis Outcome Score (KOOS)** is a patient-administered knee
28
29
30 371 specific questionnaire comprising five subscales: Pain; Symptoms; Activities of daily living; Sport
31
32 372 & Recreation; and Knee-Related Quality of Life. Each item is scored from 0 to 4 (61). The raw
33
34 373 score for each of the five subscales is the total sum of the associated item scores. Scores can be
35
36
37 374 transformed to a 0 to 100 scale. The scores of the five subscales can be expressed as a composite
38
39 375 outcome profile, higher scores indicating fewer problems (62). The KOOS questionnaire is valid
40
41 376 and reliable in patients suffering from knee OA and patients on the waiting list for TKA for knee
42
43
44 377 OA (61, 63, 64).
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

EuroQol Group 5-dimension (EQ-5D-5L) is a self-completion questionnaire consisting of two parts; the first part of the EQ-5D-5L comprises five dimensions involving mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. All dimensions have five response categories (no problems, slight problems, moderate problems, severe problems, and extreme problems) resulting in a five digit descriptive health state (65), which will be converted into a summary index ranging from -0.624 (worst) to 1.000 (best), using a Danish value set (66). The second part, EQ-VAS rates the overall current health status from 0 (worst imaginable health) to 100 (best imaginable health) (65). The EQ-5D-5L is reliable and valid in patients with knee OA eligible for TKA (67, 68).

Adverse events will be defined as unpredicted or unintended events, signs, or disease occurring during the period from inclusion until the 3-month follow-up (primary end-point) resulting in contact with the healthcare system (hospital or general practitioner) independent of whether or not the event is related to the intervention or outcome assessments. Adverse events will be recorded and categorized in accordance with the definitions established by the United States Food and Drug Administration [88]. Continuous registration of adverse events will be performed and a short open-ended questionnaire will be administered at three months follow-up.

Other Outcome Measures

Blood pressure will be measured by the orthopedic chief physicians when patients are visiting the outpatient clinic. Blood pressure will be used to determine eligibility to participate in the project.

Exercise compliance and progression will be obtained by the physiotherapist in charge of the training sessions and entered directly into the REDCap-system. The progression will be monitored as the total load lifted by the patient for exercise session.

Numeric rating scale for pain is a segmented unidimensional 11-item measure of pain intensity in adults (69) that will be used to rate pain intensity during both testing and exercise sessions. (69). 0 represents no pain while 10 represents worst pain imaginable (69).

Declining to be operated will be measured at three month follow-up, where patients will be asked whether they decided to be operated or not. Patients who declined to be operated will be invited to participate in all prescheduled follow-up assessments.

Postoperative supervised physiotherapy will be measured at six week, three month, and 12 month follow-up by answering a questionnaire. If patients have participated in postoperative supervised physiotherapy, the patient must specify whether the treatment was related to the TKR or due to other circumstances.

Knee joint active range of motion will be measured with a 360° plastic goniometer (scale 1°) with 16.5 cm moveable arms at baseline in the week of surgery, three months, and 12 months after surgery. Laying supine on an examination table, the knee joint flexion and knee joint extension will be measured separately (70). The tester then identifies the most prominent part of the trochanter, the lateral epicondyle of the femur, the lateral head of fibula, and the lateral malleolus. When identified, the patient is asked to flex the knee as much as possible with the heel maintaining contact to the surface at all time (70). Secondly, the patients will be asked to extend the knee joint as much as

possible. To allow the knee to extend as much as possible, a firm quadratic box (height: 5 cm, width: 8 cm, length: 15 cm) will be placed under the heel of the patient. The procedure of measuring knee extension will be similar to knee flexion, as the patients increases the degree of knee extension maximally (70). The fulcrum of the goniometer will correspond visually to the trans-epicondylar axis of the knee joint. The moveable arms of the goniometer will be pointed towards the greater trochanter and the lateral malleolus (70).

Data management

All data from the physical function tests will be entered into RedCap by the assessors using double data entry to ensure data quality. All patient-reported outcome data (KOOS, NRS Pain, EQ-5D-5L) will be entered directly into RedCap by the patients, and usage of the “required fields” will ensure no missing items from the completed questionnaires. To reduce missing data, a reminder email will be sent automatically from the RedCap-system. All patient data will be anonymized by assigning study numbers to each patient (coding). Personal data about the patient will be located separately from the main dataset to protect confidentiality during all trial phases. The raw dataset will be maintained for ten years after completion of the trial with indefinite restricted access due to sensitive data. After publication of the trial, a fully anonymized patient-level dataset and corresponding statistical description will be made publicly available if required by the scientific journal, in which the results are published.

Sample size

The power and sample size calculation is based on the expected differences between the two subject groups from baseline to three-month follow-up (8). Due to lack of data on the primary outcome for

1
2
3
4 449 investigations applying LL-BFRE before a surgical procedure, we decided to base our sample size
5
6
7 450 calculation on Skoffler et al. (8) who investigated the efficacy of four weeks of preoperative and
8
9 451 four weeks postoperative HRST (intervention group) compared to four weeks of postoperative
10
11 452 HRST only (control group) on 30-s CST three months in patients receiving a TKR (8). The authors
12
13
14 453 found a between-group difference of 3-4 repetition difference (14.7 ± 4.7 repetitions versus $11.0 \pm$
15
16 454 4.4 repetitions) three months after TKR surgery (8).

17
18 455 To reduce the probability of type I errors and enable detection of a between-group difference
19
20
21 456 also, α -level is set at 0.05 ($p < 0.05$) and β -level is set at 0.20 (80% power). Expecting a 3-repetition
22
23 457 between-group difference three months postoperatively and assuming a SD of 4.7 in both groups,
24
25 458 39 patients are required in each group (yielding 78 patients in total). With an anticipated dropout
26
27
28 459 rate of 10%, 84 patients will be recruited for the trial.

29
30 460
31
32 461 **Statistical considerations**

33
34
35 462 The primary efficacy analysis will be an assessment of the between group difference in change in
36
37 463 the 30-S CST from baseline to three-month follow-up (primary endpoint).

38
39 464 All descriptive statistics and tests will be reported in accordance with the recommendations of
40
41 465 the “Enhancing the QUALity and Transparency Of health Research” (EQUATOR) network (71) and
42
43
44 466 the CONSORT statement (47). Intention-to-treat principle (i.e. all patients as randomized
45
46 467 independent of departures from allocation treatment, compliance and/or withdrawals) and per
47
48 468 protocol analysis will be conducted. A one-way analysis of variance (one-way ANOVA) model will
49
50
51 469 be used to analyze between group mean changes in continuous outcome measures (31). The model
52
53 470 includes changes from baseline to 12-month follow-up. Between-intervention comparison from
54
55 471 baseline to three months after surgery will be analyzed using a mixed linear model with patient ID
56
57
58 472 as a random effect and time, group and hospital as fixed effects (31, 72). Also, to gain insight into
59
60

the potential pre-to-post training differences within the respective training or control groups, paired student t-tests will be performed. Level of statistical significance is $P < 0.05$. *Secondary outcome variables:* Between-intervention comparison from baseline to the week of surgery, six weeks after surgery, three and 12 months after surgery will be analyzed as described for the primary outcome. Regression analysis will be used to analyze the potential associations between preoperative strength and postoperative lower extremity function and self-reported outcome as well as between preoperative functional capacity and postoperative functional capacity. Additionally, regression analysis will be used to analyze the association between preoperative number of satellite cells and myonuclei on postoperative isometric knee extensor muscle strength, muscle fiber cross sectional area, and functional capacity. All statistical analyses will be performed by the primary investigator using Stata.

Ethical aspects and dissemination

The trial has been accepted by the Central Denmark Region Committee on Biomedical Research Ethics (Journal No 10-72-19-19) and by the Danish Data Protection Agency (Journal No 652164). The trial is registered at Clinicaltrials.gov (NCT04081493). Before inclusion, all patients will provide their written informed consent in accordance with the Helsinki Declaration. All data and information collected in regard to this trial will be treated confidentially (blinded and encrypted) by the researchers and staff connected to the trial.

All results from the trial will be published in international peer-reviewed scientific journals regardless of the results being considered positive, negative or inconclusive.

Patient and public involvement

Before developing this clinical trial, a pilot project was performed to determine the feasibility and

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

efficacy of BFRE in patients suffering from lower limb injuries. The experiences with the training modality and the verbal feedback from patients on training duration, frequency, and intensity resulted in useful knowledge that certainly has improved the development of the present clinical trial.

DISCUSSION

To the best of our knowledge, this is the first trial to investigate the effect of preoperative BFRE on functional capacity, self-reported outcome, lower limb muscle strength and myofiber morphology/stem cell abundance in patients scheduled for TKR. Only few studies have investigated (short term (10 days)) preoperative BFRE without finding an atrophy protective effect or difference in muscle strength compared to a control group performing a placebo intervention (SHAM group) (73). However, patients performing short term preoperative BFRE before ACL-R demonstrated higher muscle endurance compared to a SHAM group (74). Therefore, results of this trial are expected to provide novel information on longer periods of BFRE that will enable researchers to design effective exercise-based preconditioning protocols for elective TKR patients. The LL-BFRE protocol applied in the present project is widely used and follows the recommendations from a recent position stand by Patterson et al. (75). The authors suggested that exercising 2-3 times per week at 20-40% of 1RM in 2-4 sets (e.g. 30-15-15-15 or sets to failure) using pressures between 40 to 80% of LOP has demonstrated to be effective when aiming at increasing muscle strength and promoting muscle hypertrophy (75).

The trial is designed as an assessor blinded randomized controlled trial, thus representing the highest evidence level. However, the nature of the trial does not allow blinding of the participants which is an inherent limitation of the trial. The trial is conducted at two hospitals that consistently perform a high number of TKR procedures annually (225 and 460, respectively), thus securing a

strong expertise in terms of surgery and infrastructure. Both hospitals have all equipment needed available for surgery, post-operative hospitalization, training, and testing. All outcome variables are considered valid and reliable measures and consist of both objective outcomes and self-reported patient outcomes.

No adverse health-related events have been reported in previous studies applying BFRE in patients' suffering from knee OA or in healthy older adults (1, 9, 13, 23, 33, 34). Further, in a recent review and meta-analysis it was stated that exercise with concurrent blood-flow restriction is a safe exercise modality when occlusion procedures are applied correctly (13). The inherent invasive procedure of muscle biopsies may cause adverse events in rare occasions. Therefore, all muscle biopsy samples will be collected by trained medical doctors and performed following administration of local anesthesia and in fully sterile conditions. The needle muscle biopsy protocol has been applied in a large number of previous investigations including very old frail subjects (97 years of age) without any reporting of adverse events besides occasional muscle soreness(31, 49, 58, 76, 77).

There are some limitations of the project that must be taken into account. First, our primary end point is three months postoperatively. The (uncontrolled) period discharge to three months postoperatively renders the project vulnerable to external variabilities. However, from a pragmatic point of view, this uncontrolled period from discharge to three-month follow-up reflects the reality that Danish patients face postoperatively. Thus, the results at three-month follow-up will, indeed, reflect the impact of performing preoperative LL-BFRE on the postoperative outcome regardless of the external variable that can hamper the results. Secondly, the discharge criteria at Horsens Regional Hospital and Silkeborg Regional Hospital withhold slight differences. That is, the acceptable knee joint ROM at discharge differs between the sites, thus it can be speculated that more patients from Silkeborg Regional Hospital will be offered a postoperative, supervised rehabilitation program. This might affect the number of patients receiving supervised physiotherapy

1
2
3
4 545 after discharge between sites. However, all patients included in the present project will report
5
6 546 whether they have received postoperative supervised physiotherapy at all follow-up assessments.
7
8
9 547 Thus, we will be able to determine (and normalize) a potential between-site difference in patients
10
11 548 receiving supervised physiotherapy after TKR. Also, site-specific differences in the postoperative
12
13 549 rehabilitation protocols (Tables 1a and 1b) may be considered a limitation. That is, the protocols
14
15
16 550 contain both identical but also different exercises and progression steps. However, a recent review
17
18 551 and meta-analysis found no difference in effectiveness between clinic-based or inpatient programs
19
20 552 compared with home-based rehabilitation programs in the early subacute period after TKA (27) and
21
22
23 553 studies in other knee patient populations have also been unable to observe differences in main
24
25 554 outcome variables when comparing home-based postoperative rehabilitation to supervised
26
27 555 postoperative rehabilitation (28, 29). We feel confident therefore that the apparent differences
28
29
30 556 between the postoperative rehabilitation protocols are not highly likely to affect the results of the
31
32 557 present study. Nonetheless, to verify this notion we will introduce site allocation (Horsens Hospital
33
34 558 vs. Silkeborg Hospital) as a separate independent variable in the mixed linear model used for the
35
36 559 statistical analysis.
37
38
39 560
40
41 561
42

43 562 **Author contributions**

44
45 563 SLJ, PAA, MBB, and IM were all part of designing the trial and approved the final version of the
46
47
48 564 protocol. Also, SLJ, PAA, MBB, and IM wrote and revised the protocol.
49
50 565

51
52 566 **Data statement**

53
54
55 567 All obtained data will be stored in anonymized form at the Danish National Archives and deleted
56
57 568 after 10 years.
58
59
60

569

Funding

This work trial is supported by Aase og Ejnar Danielsen's Foundation (100,000 dkk), Nis-Hanssen's Mindeslegat (163,883 dkk) and the Health Research Foundation of Central Denmark Region (99,658 dkk), Hede-Nielsen Foundation (8,000 dkk).

574

Competing interest

None to be declared

577

Ethics approval

The trial has been accepted by the Central Denmark Region Committee on Biomedical Research Ethics (Journal No 10-72-19-19) and by the Danish Data Protection Agency (Reference No 652164).

582

Word count

5.770 words

585

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Ferraz RB, Gualano B, Rodrigues R, Kurimori CO, Fuller R, Lima FR, et al. Benefits of Resistance Training with Blood Flow Restriction in Knee Osteoarthritis. *Medicine and science in sports and exercise*. 2018.

2. Bade MJ, Kohrt WM, Stevens-Lapsley J. Outcomes before and after total knee arthroplasty compared to healthy adults. *The Journal of orthopaedic and sports physical therapy*. 2010.

3. Fransen M, McConnell S, Harmer AR, Van dE, Simic M, Bennell KL. Exercise for osteoarthritis of the knee. 2015.

4. Skoffler B, Dalgas U, Mechlenburg I. Progressive resistance training before and after total hip and knee arthroplasty: A systematic review. 2015.

5. Sundhedsstyrelsen. Knæartrose - nationale kliniske retningslinjer og faglige visitationsretningslinjer2012.

6. Franz A, Queitsch FP, Behringer M, Mayer C, Krauspe R, Zilkens C. Blood flow restriction training as a prehabilitation concept in total knee arthroplasty: A narrative review about current preoperative interventions and the potential impact of BFR. *Medical hypotheses*. 2018.

7. Calatayud J, Casaña J, Ezzatvar Y, Jakobsen MD, Sundstrup E, Andersen LL. High-intensity preoperative training improves physical and functional recovery in the early post-operative periods after total knee arthroplasty: a randomized controlled trial. *Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA*. 2016.

8. Skoffler B, Maribo T, Mechlenburg I, Hansen PM, Søballe K, Dalgas U. Efficacy of Preoperative Progressive Resistance Training on Postoperative Outcomes in Patients Undergoing Total Knee Arthroplasty. *Arthritis Care & Research*. 2016.

9. Bryk FF, dos Reis AC, Fingerhut D, Araujo T, Schutzer M, Cury RdPL, et al. Exercises with partial vascular occlusion in patients with knee osteoarthritis: a randomized clinical trial. *Knee Surgery, Sports Traumatology, Arthroscopy*. 2016;24(5):1580-6.

10. Wang L, Lee M, Zhang Z, Moodie J, Cheng D, Martin J. Does preoperative rehabilitation for patients planning to undergo joint replacement surgery improve outcomes? A systematic review and meta-analysis of randomised controlled trials. *BMJ open*. 2016;6(2):e009857-2015-.

11. Chesham RA, Shanmugam S. Does preoperative physiotherapy improve postoperative, patient-based outcomes in older adults who have undergone total knee arthroplasty? A systematic review. 2017.

12. Kwok IH, Paton B, Haddad FS. Does Pre-Operative Physiotherapy Improve Outcomes in Primary Total Knee Arthroplasty? - A Systematic Review. *The Journal of arthroplasty*. 2015;30(9):1657-63.

13. Hughes L, Paton B, Rosenblatt B, Gissane C, Patterson SD. Blood flow restriction training in clinical musculoskeletal rehabilitation: A systematic review and meta-analysis. 2017.

14. Counts BRDSJBBEKDGMJAKMTRSATBMGLJP. Influence of Relative Blood Flow Restriction Pressure on Muscle Activation and Muscle Adaptation. *Muscle & nerve*. 2016;53:438-45.

15. Kim D, Loenneke JP, Ye X, Bemben DA, Beck TW, Larson RD, et al. Low-load resistance training with low relative pressure produces muscular changes similar to high-load resistance training. *Muscle & nerve*. 2017;56(6):E126-E33.

16. Loenneke JP, Fahs CA, Rossow LM, Sherk VD, Thiebaud RS, Abe T, et al. Effects of cuff width on arterial occlusion: implications for blood flow restricted exercise. *European journal of applied physiology*. 2012;112(8):2903-12.

17. Loenneke JP, Kim D, Fahs CA, Thiebaud RS, Abe T, Larson RD, et al. The influence of exercise load with and without different levels of blood flow restriction on acute changes in muscle thickness and lactate. *Clinical Physiology and Functional Imaging*. 2017.

18. Loenneke JP, Kim D, Fahs CA, Thiebaud RS, Abe T, Larson RD, et al. Effects of exercise with and without different degrees of blood flow restriction on torque and muscle activation. *Muscle & nerve*. 2015.
19. Loenneke JP, Thrower AD, Balapur A, Barnes JT, Pujol TJ. Blood flow-restricted walking does not result in an accumulation of metabolites. *Clinical physiology and functional imaging*. 2012;32(1):80-2.
20. Loenneke JP, Wilson JM, Balapur A, Thrower AD, Barnes JT, Pujol TJ. Time under tension decreased with blood flow-restricted exercise. *Clinical physiology and functional imaging*. 2012;32(4):268-73.
21. Loenneke JP, Wilson JM, Wilson GJ, Pujol TJ, Bembien MG. Potential safety issues with blood flow restriction training. 2011. p. 510-8.
22. Loenneke JP, Young KC, Fahs CA, Rossow LM, Bembien DA, Bembien MG. Blood flow restriction: rationale for improving bone. *Medical hypotheses*. 2012;78(4):523-7.
23. Ozaki H, Loenneke JP, Abe T. Blood flow-restricted walking in older women: does the acute hormonal response associate with muscle hypertrophy? *Clinical physiology and functional imaging*. 2017;37(4):379-83.
24. Ozaki H, Loenneke JP, Thiebaud RS, Stager JM, Abe T. Possibility of leg muscle hypertrophy by ambulation in older adults: a brief review. *Clinical interventions in aging*. 2013;8:369-75.
25. Scott BR, Loenneke JP, Slattery KM, Dascombe BJ. Blood flow restricted exercise for athletes: A review of available evidence. *Journal of science and medicine in sport*. 2016;19(5):360-7.
26. Scott BR, Loenneke JP, Slattery KM, Dascombe BJ. Exercise with blood flow restriction: an updated evidence-based approach for enhanced muscular development. *Sports medicine (Auckland, NZ)*. 2015;45(3):313-25.
27. Takarada Y, Nakamura Y, Aruga S, Onda T, Miyazaki S, Ishii N. Rapid increase in plasma growth hormone after low-intensity resistance exercise with vascular occlusion. *Journal of applied physiology (Bethesda, Md: 1985)*. 2000;88(1):61-5.
28. Takarada Y, Sato Y, Ishii N. Effects of resistance exercise combined with vascular occlusion on muscle function in athletes. *European journal of applied physiology*. 2002;86:308-14.
29. Takarada Y, Takazawa H, Ishii N. Applications of vascular occlusion diminish disuse atrophy of knee extensor muscles. *Medicine and science in sports and exercise*. 2000;32(12):2035-9.
30. Jørgensen AN, Aagaard P, Nielsen JL, Frandsen U, Diederichsen LP. Effects of blood-flow-restricted resistance training on muscle function in a 74-year-old male with sporadic inclusion body myositis: a case report. *Clinical Physiology and Functional Imaging*. 2016;36(6):504-9.
31. Nielsen JL, Aagaard P, Bech RD, Nygaard T, Hvid LG, Wernbom M, et al. Proliferation of myogenic stem cells in human skeletal muscle in response to low-load resistance training with blood flow restriction. *The Journal of physiology*. 2012;590(17):4351-61.
32. Nielsen JL, Aagaard P, Prokhorova TA, Nygaard T, Bech RD, Suetta C, et al. Blood-flow restricted training leads to myocellular macrophage infiltration and upregulation of heat-shock proteins, but no apparent muscle damage. *The Journal of physiology*. 2017;14:4857-73.
33. Segal N, Davis MD, Mikesky AE. Efficacy of Blood Flow-Restricted Low-Load Resistance Training For Quadriceps Strengthening in Men at Risk of Symptomatic Knee Osteoarthritis. *Geriatric orthopaedic surgery & rehabilitation*. 2015;6(3):160-7.
34. Segal NA, Williams GN, Davis MC, Wallace RB, Mikesky AE. Efficacy of blood flow-restricted, low-load resistance training in women with risk factors for symptomatic knee osteoarthritis. *PM & R : the journal of injury, function, and rehabilitation*. 2015;7(4):376-84.
35. Jessee MB, Mattocks KT, Buckner SL, Dankel SJ, Mouser JG, Abe T, et al. Mechanisms of Blood Flow Restriction: The New Testament. *Techniques in Orthopaedics*. 2018;33(2):72-9.

36. Mattocks KT, Jessee MB, Mouser JG, Dankel SJ, Buckner SL, Bell ZW, et al. The Application of Blood Flow Restriction: Lessons From the Laboratory. *Current sports medicine reports*. 2018;17(4):129-34.
37. Wernbom M, Augustsson J, Raastad T. Ischemic strength training: a low-load alternative to heavy resistance exercise? *Scandinavian Journal of Medicine & Science in Sports*. 2008;18(4):401-16.
38. Wernbom M, Aagaard P. Muscle fibre activation and fatigue with low-load blood flow restricted resistance exercise-An integrative physiology review. *Acta physiologica (Oxford, England)*. 2019:e13302.
39. Mauro A. Satellite cell of skeletal muscle fibers. *The Journal of biophysical and biochemical cytology*. 1961.
40. Kadi F, Charifi N, Denis C, Lexell J. Satellite cells and myonuclei in young and elderly women and men. *Muscle and Nerve*. 2004.
41. Olsen S, Aagaard P, Kadi F, Tufekovic G, Verney J, Olesen JL, et al. Creatine supplementation augments the increase in satellite cell and myonuclei number in human skeletal muscle induced by strength training. *Journal of Physiology*. 2006.
42. Francaux M, Deldicque L. Exercise and the control of muscle mass in human. *Pflügers Archiv - European Journal of Physiology*. 2018.
43. Kadi F, Schjerling P, Andersen LL, Charifi N, Madsen J, Christensen LR, et al. The effects of heavy resistance training and detraining on satellite cells in human skeletal muscles. *The Journal of physiology*. 2004.
44. Bazgir B, Fathi R, Valojerdi MR, Mozdziak P, Asgari A. Satellite cells contribution to exercise mediated muscle hypertrophy and repair. 2016.
45. Covinsky KE, Lindquist K, Dunlop DD, Gill TM, Yelin E. Effect of arthritis in middle age on older-age functioning. *Journal of the American Geriatrics Society*. 2008;56(1):23-8.
46. Bruusgaard JC, Johansen IB, Egner IM, Rana ZA, Gundersen K. Myonuclei acquired by overload exercise precede hypertrophy and are not lost on detraining. *Proceedings of the National Academy of Sciences*. 2010.
47. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *International journal of surgery (London, England)*. 2012;10(1):28-55.
48. M B. Knæalloplastik - fysioterapeutisk instruks <https://e-dok.rm.dk/edok/admin/GUI.nsf/Desktop.html?Open&login>: e-dok; 2019 [updated 03.04.19. 4:[1].
49. Suetta C, Andersen JL, Dalgas U, Berget J, Koskinen S, Aagaard P, et al. Resistance training induces qualitative changes in muscle morphology, muscle architecture, and muscle function in elderly postoperative patients. *Journal of applied physiology (Bethesda, Md: 1985)*. 2008;105(1):180-6.
50. Gill S, McBurney H. Reliability of performance-based measures in people awaiting joint replacement surgery of the hip or knee. *Physiotherapy Research International : The Journal for Researchers and Clinicians in Physical Therapy*. 2008;13(3):141-52.
51. Jones CJ, Rikli RE, Beam WC. A 30-s chair-stand test as a measure of lower body strength in community-residing older adults. *Research quarterly for exercise and sport*. 1999;70(2):113-9.
52. Wright AA, Cook CE, Baxter GD, Dockerty JD, Abbott JH. A comparison of 3 methodological approaches to defining major clinically important improvement of 4 performance measures in patients with hip osteoarthritis. *The Journal of orthopaedic and sports physical therapy*. 2011;41(5):319-27.
53. Bloch ML, Jonsson LR, Kristensen MT. Introducing a Third Timed Up & Go Test Trial Improves Performances of Hospitalized and Community-Dwelling Older Individuals. *Journal of geriatric physical therapy (2001)*. 2017;40(3):121-6.
54. Kristensen MT, Ekdahl C, Kehlet H, Bandholm T. How many trials are needed to achieve performance stability of the Timed Up & Go test in patients with hip fracture? *Archives of Physical Medicine and Rehabilitation*. 2010;91(6):885-9.

55. Hansen H. RM-testmanal. Danish Physiotherapy Society: Danish Physiotherapy Society; 2012. p. 2.
56. Koblbauer IFH, Lambrecht Y, Van DH, Neeter C, Engelbert RHH, Poolman RW, et al. Reliability of maximal isometric knee strength testing with modified hand-held dynamometry in patients awaiting total knee arthroplasty: Useful in research and individual patient settings? A reliability study. *BMC Musculoskeletal Disorders*. 2011.
57. C N, V.A.B S, Y L, I K, M VDH, R.H.H E, et al. Reliability of hand-held dynamometry in patients awaiting total knee arthroplasty. *Physiotherapy (United Kingdom)*. 2011.
58. Ekblom B. The muscle biopsy technique. Historical and methodological considerations. *Scandinavian Journal of Medicine & Science in Sports*. 2017;27(5):458-61.
59. Bergstrom J. Muscle electrolytes in man determined by neutron activation analysis on needle biopsy specimens. *Scandinavian Journal of Clinical and Laboratory Investigation (England)*. 1962;14(Suppl 68).
60. Aagaard P, Andersen JL, Dyhre-Poulsen P, Leffers AM, Wagner A, Peter Magnusson S, et al. A mechanism for increased contractile strength of human pennate muscle in response to strength training: Changes in muscle architecture. *Journal of Physiology*. 2001;534(2):613-23.
61. Roos EM, Lohmander LS. The Knee injury and Osteoarthritis Outcome Score (KOOS): From joint injury to osteoarthritis. 2003.
62. Nilsson AK, Lohmander LS, Klassbo M, Roos EM. Hip disability and osteoarthritis outcome score (HOOS)--validity and responsiveness in total hip replacement. *BMC musculoskeletal disorders*. 2003;4:10-2474-4-10. Epub 003 May 30.
63. Lyman S, Lee YY, McLawhorn AS, Islam W, MacLean CH. What Are the Minimal and Substantial Improvements in the HOOS and KOOS and JR Versions After Total Joint Replacement? *Clinical orthopaedics and related research*. 2018;476(12):2432-41.
64. Collins NJ, Prinsen CA, Christensen R, Bartels EM, Terwee CB, Roos EM. Knee Injury and Osteoarthritis Outcome Score (KOOS): systematic review and meta-analysis of measurement properties. *Osteoarthritis and cartilage*. 2016;24(8):1317-29.
65. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation*. 2011;20(10):1727-36.
66. Wittrup-Jensen KU, Lauridsen J, Gudex C, Pedersen KM. Generation of a Danish TTO value set for EQ-5D health states. *Scandinavian Journal of Public Health*. 2009;37(5):459-66.
67. Bilbao A, Garcia-Perez L, Arenaza JC, Garcia I, Ariza-Cardiel G, Trujillo-Martin E, et al. Psychometric properties of the EQ-5D-5L in patients with hip or knee osteoarthritis: reliability, validity and responsiveness. *Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation*. 2018;27(11):2897-908.
68. Buchholz I, Janssen MF, Kohlmann T, Feng YS. A Systematic Review of Studies Comparing the Measurement Properties of the Three-Level and Five-Level Versions of the EQ-5D. *PharmacoEconomics*. 2018;36(6):645-61.
69. Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). *Arthritis care & research*. 2011;63 Suppl 11:S240-52.
70. Jakobsen TL, Christensen M, Christensen SS, Olsen M, Bandholm T. Reliability of knee joint range of motion and circumference measurements after total knee arthroplasty: does tester experience matter? *Physiotherapy Research International*. 2010;15(3):126-34.
71. Christensen R, Bliddal H, Henriksen M. Enhancing the reporting and transparency of rheumatology research: a guide to reporting guidelines. *Arthritis research & therapy*. 2013;15(1):109.

1
2
3
4 802
5 803
6 804
7 805
8 806
9 807
10 808
11 809
12 810
13 811
14 812
15 813
16 814
17 815
18 816
19 817
20 818
21 819
22
23
24 820
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

72. Malcata RM, Hopkins WG, Pearson SN. Tracking career performance of successful triathletes. *Medicine and science in sports and exercise*. 2014;46(6):1227-34.

73. Grapar Zargi T, Drobnic M, Jkoder J, Strazar K, Kacin A. The effects of preconditioning with ischemic exercise on quadriceps femoris muscle atrophy following anterior cruciate ligament reconstruction: a quasi-randomized controlled trial. *European journal of physical and rehabilitation medicine*. 2016;52(3):310-20.

74. Zargi T, Drobnic M, Strazar K, Kacin A. Short-Term Preconditioning With Blood Flow Restricted Exercise Preserves Quadriceps Muscle Endurance in Patients After Anterior Cruciate Ligament Reconstruction. *Frontiers in physiology*. 2018;9:1150.

75. Patterson SD, Hughes L, Warmington S, Burr J, Scott BR, Owens J, et al. Blood Flow Restriction Exercise Position Stand: Considerations of Methodology, Application, and Safety. *Frontiers in physiology*. 2019;10:533.

76. Andersen J, Aagaard P. Myosin heavy chain IIX overshoot in human skeletal muscle. *Muscle & nerve*. 2000;23:1095-104.

77. Malm C, Nyberg P, Engstrom M, Sjodin B, Lenkei R, Ekblom B, et al. Immunological changes in human skeletal muscle and blood after eccentric exercise and multiple biopsies. *The Journal of physiology*. 2000;529 Pt 1:243-62.

821 *Table 1a. Postoperative rehabilitation program, Horsens Regional Hospital*

Week 0-3				
Step	Exercise	Repetitions	Sets	Resistance
Step 1 & 2	Supine peristaltic pump exercise with feet above heart level	20 minutes	3-4/day	-
Step 1	Supine knee extension mobilization	20 seconds	3 sets	-
Step 1	Supine unilateral knee and hip extension and flexion mobilization with slipper under the heel	5 repetitions	3 sets	Slipper minimizes floor friction
Step 2	Seated knee extension and flexion mobilization with slipper under the foot	5 repetitions	3 sets	Slipper minimizes floor friction
Step 2	Standing weight transfer exercise	15 repetitions each side	1 set	Bodyweight
Step 2	Sit to stand from a high chair or the edge of table	5 repetitions	3 sets	Bodyweight
Week 3 and onwards				
Step 1 & 2	Supine peristaltic pump exercise with feet above heart level	20 minutes	3-4/day	-
Step 1	Seated knee extension mobilization	20 seconds	4 rounds	Arms can be used to apply pressure onto the knee to help extend the knee
Step 1	Step up exercise	10-15 repetitions	2-3 sets	Bodyweight
Step 1	Standing knee isometric knee towel press	10-15 repetitions	2-3 sets	Ball/Towel rolled together
Step 1	Sit to stand from a chair	10-15 repetitions	2-3 sets	Bodyweight
Step 1	One leg standing	30 seconds	1 set	Bodyweight
Step 2	Standing hip flexion	Not informed	Not informed	Elastic band
Step 2	Standing hip abduction	Not informed	Not informed	Elastic band
Step 2	Partial frontal plane sliding lunge	10 repetitions	3 sets, 2-3/day	Bodyweight
Step 2	Partial back sliding lunge	10 repetitions	3 sets, 2-3/day	Bodyweight
Optional	Cycling	10-20 minutes	1 set	Light resistance can be added when it is possible to perform a full round with the operated limb.

Step 1 is performed in the morning and step 2 is performed in the afternoon. All exercises are performed once per day.

824 *Table 1b. Postoperative rehabilitation program, Silkeborg Regional Hospital*

Week 0-2				
Step	Exercise	Repetitions	Sets	Resistance
Optional	Cycling	5-10 minutes	2/day	
-	Supine peristaltic pump exercise	Not informed	Not informed	-
-	Rest with leg above heart level	30 minutes	4/day	-
-	Seated isometric knee extension	3 seconds	10 sets	Lower leg and the foot
-	Seated knee flexion mobilization	3 seconds	10 sets	-
-	Seated knee extension mobilization	30 seconds	3 sets	Apply pressure to the knee joint using the arms
-	Supine isometric knee extension	3 seconds	10 sets	Lower leg and the foot
-	Supine passive knee extension mobilization			Gravity will extend the knee joint
Week 2 and onwards				
-	Supine knee isometric knee towel press	3seconds hold	10sets	Lower leg and the foot

1					
2					
3					
4	-	Sit to stand	10 repetitions	1 set	Body weight
5	-	Standing knee flexion mobilization	3 seconds	10 sets	Body weight
6	-	Step Up Exercise	10 repetitions	1 set	Body weight
7	826	All exercises are performed twice per day.			

827

828

829 *Table 2. Discharge criteria at Horsens Regional Hospital and Silkeborg Regional Hospital*

Outcome	Horsens Regional Hospital	Silkeborg Regional Hospital
Minimum knee flexion range of motion	60 degrees	90 degrees
Maximal knee extension deficit	15 degrees	5 degrees
In-and-out of bed	Independent	Independent
Sit-to-stand	Independent	Independent
Walking with/without assistive devices	Independent	Independent
Stair negotiation with/without assistive devices	Independent	Independent
Activities of daily living	Independent	Independent
Understanding of the home-based postoperative exercise program	Sufficient	Sufficient

830

831

832 *Table 3. Exercise variables for the blood-flow restricted exercise (BFRE) protocol*

Exercise variable	Week 1-8
Level of LOP	60% LOP
Sets	4
Load intensity	30% 1RM
Repetitions 1 st set	30
Repetitions 2 nd & 3 rd set	15
Repetitions 4 th set	To volitional failure
Contraction modes per repetition	
Concentric	2 seconds
Isometric	0 seconds
Eccentric	2 seconds
Rest between repetitions	0 seconds
Time under tension per repetition	4 seconds
Range of movement	maximum
Rest between sets	30 seconds
Rest between sessions	≥36 hours
Progression	The minimal possible load (5 kilo) is added when patients perform >15 repetitions in 4 th set

833

834

835

836

837

838 *Table 4. Outcome measures to be collected.*

Outcome measures	Data collection instrument	Time-points of assessment
------------------	----------------------------	---------------------------

839

Primary outcome		
Sit-to-stand function	30 seconds chair stand test	B, S, 3 and 12 months
Secondary outcomes		
Ambulatory capacity	Timed Up & Go	B, S, 3 and 12 months
Gait speed	4x10-meter walk test	B, S, 3 and 12 months
1RM Leg press strength	Leg press machine	B, S, 3, and 12 months
1RM Knee extension strength	Knee extension machine	B, S, 3, and 12 months
Isometric Knee extensor muscle strength	Handheld Dynamometer	B, S, 3 and 12 months
Isometric Knee flexion muscle strength	Handheld Dynamometer	B, S, 3 and 12 months
Myofiber morphology	Muscle Biopsies	B, S, 3 months
Myogenic stem cell content	Muscle Biopsies	B, S, 3 months
Pain	KOOS	B, S, 6 weeks, 3 and 12 months
Symptoms	KOOS	B, S, 6 weeks, 3 and 12 months
Activities of daily living	KOOS	B, S, 6 weeks, 3 and 12 months
Sports & Recreation	KOOS	B, S, 6 weeks, 3 and 12 months
Quality of life	KOOS	B, S, 6 weeks, 3 and 12 months
Socioeconomic costs	EQ-5D	B, S, 6 weeks, 3 and 12 months
Adverse Events	Questionnaire and medical records	3 months
Exercise compliance and progression	Physiotherapist records	BFRE
Pain during visits	NRS for pain	B, BFRE, S, 3 and 12 months
Declining to be operated	Questionnaire	3 months
Postoperative supervised physiotherapy	Questionnaire	6 weeks, 3 and 12 months
Knee joint range of motion	Goniometer	B, S, 3 and 12 months
Patient characteristics and related measurements	Questionnaire	B
Gender	Tape measure	B
Age	Electronic body mass scale	B
Height	Questionnaire	B
Body mass	Questionnaire	B
Civil Status	Questionnaire	B
Educational Level	Questionnaire	B
Employment Status	Questionnaire	B
Substance Use (alcohol, smoking)	Questionnaire	B
Duration of knee symptoms	Questionnaire	B
Pain medication during the last week	Questionnaire	B
Co-morbidities	Questionnaire	B

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table and figure legends

Table 1a. Step 1 is performed in the morning and step 2 is performed in the afternoon. All exercises are performed once per day.

Table 1b. All exercises are performed once per day. Cycling ergometer exercise is optional.

Table 3. LOP: Total limb occlusion pressure; RM: Repetition Maximum

Table 4. KOOS = Knee disability and Osteoarthritis Outcome Score; B = Baseline; S = 0-2 days before surgery; D = during surgery; 3 months = 3 months after TKR; 12 months = 12 after TKR; NRS = Numeric Ranking Scale of pain

Figure 1. Flow chart of the enrollment, treatment, and follow-up phases. TKR: Total Knee Replacement, BFRE: Low-load blood-flow restricted exercise


```
graph TD
    A[Patients scheduled for a TKR at Horsens Regional Hospital and Silkeborg Regional Hospital  
Assessed for eligibility (n)] --> B[Enrolment]
    A --> C[Excluded (n)  
- Not meeting inclusion criteria (n)  
- Declining to participate  
- Other reasons (n)]
    B --> D[Baseline assessments and randomization]
    D --> E[BFRE group (n=42)]
    D --> F[CON Group (n=42)]
    E --> G[Lost to follow-up (n)  
Did not complete the intervention (n)  
Declining TKA (n)]
    F --> H[Lost to follow-up (n)  
Declining TKA (n)]
    G --> I[Lost to follow-up (n)]
    H --> J[Lost to follow-up (n)]
    I --> K[Lost to follow-up (n)]
    J --> L[Lost to follow-up (n)]
    K --> M[Lost to follow-up (n)]
    L --> N[Lost to follow-up (n)]
    G --> O[Surgery follow-up]
    H --> O
    O --> I
    O --> J
    O --> L
    O --> N
    O --> P[12 months follow Up]
```

Flowchart illustrating the study design and patient progression:

- Enrolment:** Patients scheduled for a TKR at Horsens Regional Hospital and Silkeborg Regional Hospital, Assessed for eligibility (n).
- Exclusion:** Excluded (n) due to:
 - Not meeting inclusion criteria (n)
 - Declining to participate
 - Other reasons (n)
- Baseline assessments and randomization:** Patients are randomized into two groups:
 - BFRE group (n=42)**
 - CON Group (n=42)**
- Follow-up:** Patients are tracked at various time points:
 - Surgery follow-up:** Patients who did not complete the intervention or declined TKA are tracked.
 - 6 weeks follow-up:** Patients who were lost to follow-up at this point.
 - 3 months primary Endpoint:** Patients who were lost to follow-up at this point.
 - 12 months follow Up:** Patients who were lost to follow-up at this point.



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description
Administrative information		
Title (p 1, I 1-3)	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry
A: p 2, I 56-57		
B:	2b	All items from the World Health Organization Trial Registration Data Set
Protocol version	3	Date and version identifier
P 1, I 22		
Funding	4	Sources and types of financial, material, and other support
P 21, I 494-496		
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors
A: P 1, I 5-11	5b	Name and contact information for the trial sponsor
B: P 1, I 15-20		
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)
Introduction		
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention
P 3, I 67-133		
P 3, I 70-76	6b	Explanation for choice of comparators
Objectives	7	Specific objectives or hypotheses
P 5, I 129-136		
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)
P 6, I 140-145		

Methods: Participants, interventions, and outcomes

Study setting P6, I 148-149	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained
Eligibility criteria P6, I 155-163	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)
Interventions A: p7, I 164-240 C: p12, 283-285	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)
Outcomes P 10, I 245-384	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial
	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)
Table 1		
Sample size P 17, I 391-401	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations
Recruitment P 6, I 148-151	15	Strategies for achieving adequate participant enrolment to reach target sample size

Methods: Assignment of interventions (for controlled trials)

Allocation:

Sequence generation P8, I 196-201	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions
--------------------------------------	-----	--

1			
2	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central
3	concealment		telephone; sequentially numbered, opaque, sealed envelopes),
4	mechanism		describing any steps to conceal the sequence until interventions are
5	P8, I 196-201		assigned
6			
7	Implementation	16c	Who will generate the allocation sequence, who will enrol participants,
8	P8, I 196-201		and who will assign participants to interventions
9			
10	Blinding	17a	Who will be blinded after assignment to interventions (eg, trial
11	(masking)		participants, care providers, outcome assessors, data analysts), and
12	P8, I 200		how
13		17b	If blinded, circumstances under which unblinding is permissible, and
14			procedure for revealing a participant's allocated intervention during
15			the trial
16			
17			
18			

19 **Methods: Data collection, management, and analysis**

20	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other
21	methods		trial data, including any related processes to promote data quality (eg,
22	P 10, I 245-420		duplicate measurements, training of assessors) and a description of
23			study instruments (eg, questionnaires, laboratory tests) along with
24			their reliability and validity, if known. Reference to where data
25			collection forms can be found, if not in the protocol
26		18b	Plans to promote participant retention and complete follow-up,
27			including list of any outcome data to be collected for participants who
28			discontinue or deviate from intervention protocols
29			
30	Data	19	Plans for data entry, coding, security, and storage, including any
31	management		related processes to promote data quality (eg, double data entry;
32			range checks for data values). Reference to where details of data
33			management procedures can be found, if not in the protocol
34			
35	Statistical	20a	Statistical methods for analysing primary and secondary outcomes.
36	methods		Reference to where other details of the statistical analysis plan can be
37	P 17, I 400-420		found, if not in the protocol
38		20b	Methods for any additional analyses (eg, subgroup and adjusted
39			analyses)
40		20c	Definition of analysis population relating to protocol non-adherence
41	P 17, I 400-420		(eg, as randomised analysis), and any statistical methods to handle
42			missing data (eg, multiple imputation)
43			
44			
45			
46			
47			

48 **Methods: Monitoring**

49	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role
50			and reporting structure; statement of whether it is independent from
51			the sponsor and competing interests; and reference to where further
52			details about its charter can be found, if not in the protocol.
53			Alternatively, an explanation of why a DMC is not needed
54			
55			
56			
57			
58			
59			
60			

	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor

Ethics and dissemination

Research ethics approval P 18, I 423-424	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)
Consent or assent P 7, I 164-173	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable
Confidentiality P 11, I 265-275	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial
Declaration of interests P 22, I 514	28	Financial and other competing interests for principal investigators for the overall trial and each study site
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation
Dissemination policy P 18, 442-444	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions
P 21, I 501-502	31b	Authorship eligibility guidelines and any intended use of professional writers

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

31c Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code

Appendices

Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons “[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)” license.